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The background of the thesis is based on the conflicting results between bench and 
bedside regarding the susceptibility to myocardial infarction with old age and diabetes. 
In  laboratories  all  over  the  world,  strategies  have  been  developed  to  protect  the 
myocardium from this insult, including the use of ischaemic conditioning (short periods 
of ischaemia and reperfusion prior to or following lethal ischaemia) or the use of a 
variety of pharmacological agents. 
However,  surprisingly,  translating  these  effective  cardioprotective  treatments 
into the clinic has proved problematic. The main issue seems to be the fact that the 
experimental investigations have mainly used young, healthy animals while the human 
patients present often with a number of other risk factors, or comorbidities, such as 
type 2 diabetes and old age. 
Therefore  the  aim  of  this  thesis  was  to  investigate  the  susceptibility  to 
ischaemia-reperfusion  injury  and  the  proficiency  of  cardioprotective  strategies  to 
protect the heart in the setting of ageing and type 2 diabetes. 
Utilizing  a  model  of  type  2  diabetes,  the  Goto-Kakizaki  rat  and  its 
normoglycaemic  control Wistar  rat,  within  the range  of 3  to  18  months  of  age,  the 
Langendorff isolated heart model and in vivo coronary artery occlusion and reperfusion 
were  employed  to  investigate  the  susceptibility  to  ischaemia-reperfusion  injury.  
Mechanical  or  pharmacological  cardioprotective  strategies  were  also  investigated  in 
this setting and the mechanisms of the failed cardioprotection were examined further 
using in vitro techniques focusing on known pro survival signalling pathways within the 
myocardium. 
The ageing diabetic heart demonstrated an increased vulnerability to injury and 
was less amenable to protection by ischaemic conditioning. Pharmacological agents 
namely, metformin and sitagliptin appear to differentially protect the diabetic and non-
diabetic heart, and this could be due to the underlying intracellular changes associated 
with ageing and diabetes. 
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-/- - dipeptidyl peptidase-4 knock out  
DRP-1 - dynamin-related protein 1 
ECG - electrocardiogram 
ECL - enhanced chemiluminescence 
EM - electron microscope/microscopy 
eNOS - endothelial nitric oxide synthase 
EPO - erythropoietin 
ER - endoplasmic reticulum  
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ERK1/2 - extracellular signal related kinases 1 and 2 
ERRs - estrogen-related receptors 
ERR-α - estrogen-related receptor-alpha 
ERR-γ - estrogen-related receptor-gamma 
ETC - electron transport chain 
F0F1ATP synthase - complex V of the electron transport chain 
FAD
+ - flavin adenine dinucleotide (oxidised form) 
FADH/FADH2 - flavin adenine dinucleotide (reduced form) 
FAO- fatty acid oxidation 
FAT/CD36 - fatty acid translocase/transporters 
FoxO1 - forkhead box class-O1 
FOXO3a - forkhead box class-O3a 
g - grams 
GABA - gamma-aminobutyric acid 
GABAA R - gamma-aminobutyric acidA receptor 
GCN5 - histone acetyltransferase KAT2A 
GFAT - glutamine:fructose 6-phosphate amidotransferase 
GIP - glucose-dependent insulinotropic polypeptide 
GK - Goto-Kakizaki 
GLP-1 - glucagon-like peptide-1 
GLP-1 (7-36) - isoform of glucagon-like peptide-1 
GLP-1 (9-36) - metabolite of GLP-1 (7-36) 
GLP-1(7-37) - isoform of glucagon-like peptide-1 
GLUT-1 - glucose transporter-1 
GLUT-1 TG - glucose transporter-1 transgenic mice 
GLUT-2 - glucose transporter 2 
GLUT-4 - glucose transporter 4 
GPCR - G protein coupled receptor 
GPx - gluthathione peroxidase 
GSH - gluthathione 
GSK-3 - glycogen synthase kinase 3 
GSK-3β - glycogen synthase kinase-3β 
GTP - guanosine triphosphate 
h - hours 
H
+ - hydrogen ion/proton 
H2O - water 
H2O2 - hydrogen peroxide 
HAT - histone acetyletransferase  
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HbA1c - glycated haemoglobin A 
HDAC - class II histone deactylases 
HDL - high density lipoprotein 
HFD - high-fat diet induced insulin resistance syndrome rat 
hfis1 - human mitochondrial fission protein 1 
HIF-1α - hypoxic inducible factor-1α 
HK - hexokinase 
HMG-CoA  - 3-hydroxy-3-methylglutaryl-coenzyme A 
HR - heart rate 
HRP - horse radish peroxidase 
HW/BW% - heart weight to body weight percentage 
I.P. - intraperitoneal 
I/R% - infarct to risk zone ratio 
IFM - interfibrillar mitochondria 
IGF-1 - insulin-like growth factor 1 
IHD - ischaemic heart disease 
IL-6 - interleukin-6 
IMAC - inner membrane anion channel 
IMM - inner mitochondrial membrane 
IP - immunoprecipitation 
IPC - ischaemic preconditioning 
IPost - ischaemic post conditioning 
IR - ischaemia-reperfusion 
IRI - ischaemia-reperfusion injury 
IRS - insulin receptors 
IU - international units 
JAK - janus kinase  
K
+ - potassium channel 
KATP channel - ATP-sensitive K+ channel 
KC - Krebs cycle 
KCa - calcium gated potassium channel 
kg - kilograms 
KHB - Krebs Henseleit Buffer 
L - litre 
LAD - left anterior descending coronary artery 
LDL - low density lipoprotein 
LKB-1 - tumour repressor protein (also known as STK11) 
LVDP - left ventricular developed pressure  
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LVEDP - left ventricular end diastolic pressure 
LVEF - left ventricular ejection fraction 
LVH - left ventricular hypertrophy 
M - molar 
MAPK - mitogen-activated protein kinase 
MCP-1 - monocyte chemoattractant protein-1 
MEF-2 - myocyte enhancing factor-2  
MEK1/2 - mitogen-activated protein kinase 1/2 
Mfn1/2 - mitofusin 1/2 
Mg - milligrams 
Mg
2+ - magnesium 
MHC - myosin heavy chain 
MI - myocardial infarction 
Min - minute 
mM - millimolar 
mm/Hg - millimeter of mercury 
mmol/L - millimole per litre 
mmol/mol - millimole per mole 
MnSOD - manganese superoxide dismutase 
MOA - monoamine oxidase 
MOMP - mitochondrial outer membrane permeabilisation  
MPG - N-2-mercaptopropionyl glycine 
mPTP - mitochondrial permeability transition pore 
mtDNA - mitochondrial DNA 
MVO - microvascular obstruction 
n - number of subjects/samples 
Na
+/HCO3 - symporter- sodium/hydrogen carbonate symporter  
Na
+/K
+-ATPase - sodium/potassium ATPase 
Na
+ - sodium ion 
NAD
+ - nicotinamide adenine nucleotide (oxidised form) 
NADH - nicotinamide adenine nucleotide (reduced form) 
NADPH - nicotinamide adenine dinucleotide phosphate 
NAM - Nicotinamide 
Nampt - nicotinamide phosphoribosyltransferase 
NCX - sodium/calcium exchanger 
NFκB - nuclear factor κ B 
NO - nitric oxide 
NOD - non-obese diabetic mice  
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NPY - neuropeptide Y 
NR - nuclear receptor 
Nrfs - nuclear respiratory factors 
NS - non significant 
NTFs - nuclear transcription factors 
O2 - Oxygen 
O-GlcNAcylation - O-linked N-acetyl-glucosamine glycosylation 
OGT - O-linked N-acetylglucosamine 
OLETF - Otsuka Long Evans Tokushima Fatty rat 
OMM - outer mitochondrial membrane 
ONOO
- - peroxynitrite 
Opa1 - optic atrophy protein 1 
P - phosphate 
P160MBP - p160 myb binding protein 
p47
phox - subunit of NAPDH oxidase 
p53 - protein 53/tumour protein 53 
p66
shc - 66kDa isoform of the growth factor adapter Shc 
p85 - protein 85 
PBS - phosphate buffered saline 
PCI - percutaneous coronary intervention 
PDK-1 - phosphoinositide-dependent protein kinase-1 
PGC-1 – PPARγ coactivator-1 
PGC-1α - peroxisome proliferator –activated receptor γ co-activator 1 α 
PGC-1β - peroxisome proliferator –activated receptor γ co-activator 1 β 
Pi - inorganic phosphate 
PI3K - phosphatidylinositol-3-kinase 
PIP2 - phosphatidylinositol-3,4-biphosphate 
PIP3 - phosphatidylinositol-3,4,5-triphosphate 
PKA - protein kinase A 
PKC - protein kinase C 
PKC-β - protein kinase C –β isoform 
PKCε - protein kinase C epsilon 
PKG - protein kinase G 
PPARα - peroxisome proliferator-activated receptor alpha 
PPARβ - peroxisome proliferator-activated receptor beta 
PPARγ - peroxisome proliferator-activated receptor gamma 
PPIase - prolyl isomerase 
PRC - PGC-1-related coactivator  
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PRMT-1 - protein arginine N-methyltransferase 1 
PTEN - Protein phosphatase and tensin homolog deleted on chromosome 10 
PVDF - polyvinylidene fluoride 
RIC - remote ischaemic conditioning 
RIPA - RadioImmunoPrecipitation Assay 
RISK - reperfusion injury salvage kinase 
RNS - reactive nitrogen species 
ROS - reactive oxygen species 
Rpm - revolutions per minute 
RPP - rate pressure product 
RTKs - receptor tyrosine kinases 
SA Node - Sinoatrial node 
SAFE - survival activating factor enhancement 
SD - Sprague dawley rat 
SDF-1α - stromal cell-derived factor 1α 
SDS-PAGE - sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM - standard error of the mean 
SERCA - Calcium sarcoplasmic reticulum pump 
SIRT-1 - silence information regulator of transcription -type 1  
SOD - superoxide dismutase 
SR - sarcoplasmic reticulum 
SRC-1 - steroid receptor co-activator-1 
SSM - subsarcolemmal mitochondria 
STAT3 - signal transducer and activator of transcription 3 
STZ - streptozotocin 
SWOP - second window of cardioprotection 
T2D - type 2 diabetes 
Tfam - mitochondrial transcription factor A 
TNF - tumor necrosis factor 
TRAIL - TNF-related apoptosis-inducing ligands 
TRAP/DRIP  -  thyroid  hormone  receptor-associated  protein/vitamin  D  receptor-
interacting protein 
TSPO - translocator protein 
TTC - triphenyltetrazolium chloride 
UCP - uncoupling protein 
UKPDS - United Kingdom Prospective Diabetes Study 
VDAC - voltage-dependent anion channel 
VEGF - vascular endothelial growth factor  
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ZDF - zucker diabetic fatty 
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1.1  Myocardial ischaemia-reperfusion injury 
1.1.1  Overview of the cardiovascular system 
The cardiovascular (CV) system is highly adapted to efficiently transport vital nutrients 
and remove metabolic waste in order to ensure the viability of tissues.  Hence, any 
disruption  to  this  process  can  lead  to  detrimental  outcomes.    The  heart  is  a  very 
specialized muscle, with high energy demands necessary for its continuous activity.  To 
appreciate the consequences of a malfunctioned cardiovascular system, it is important 
to highlight some crucial aspects of the intricate regulation required for an accurate 
cardiovascular physiology. 
1.1.1.1  The control of myocardial contraction 
Specialised cells within cardiac muscle initiate an electrical signal in the Sinoatrial (SA) 
node  located  in  the  intra-atrial  septum,  which  propagates  through  the  atrial  walls 
triggering synchronous atrial contraction. Subsequently, electrical activity diffuses to 
the Atrio-Ventricular (AV) node, through the bundle of HIS and Purkinje fibres, causing 
simultaneous  ventricular  contraction  and  cardiac  systole.  Contraction  of  the  right 
ventricle propels deoxygenated blood under low pressure via the pulmonary circulation 
to  the  lungs. Whereas,  concurrent  contraction  of  the  left  ventricle  promotes  a  high 
pressure movement of oxygenated blood through the systemic circulation to peripheral 
tissues. Following ventricular contraction, both the atrial and ventricular chambers relax 
and  enter  cardiac  diastole,  whereby  venous  blood  enters  the  right  atrium  via  the 
superior and inferior  vena cava and flows through the tricuspid valve  into  the right 
ventricle.  Blood entering the left atrium via the pulmonary veins, passes through the 
mitral valve into the left ventricle 
1.    
The electrical activity of the heart is visualised by healthcare professionals by 
an electrocardiogram (ECG) and a typical ECG is shown in Figure 1.1. Many clinical 




Figure  1.1:  Typical  ECG  trace  with  accompanying  changes  in  the  electrical  activity  and  ventricular 
movements with the heart during contraction   
A complex vascular system ensures that the heart’s very high energy demands 
are met. Coronary arteries provide oxygenated blood to, and coronary veins remove 
deoxygenated from, the myocardium. The major vessels of the coronary circulation 
include  the  left  main  coronary  artery  that  divides  into  the  left  anterior  descending 
coronary artery (LAD) and circumflex branch, and the right main coronary artery. Both 
vessels originate at the coronary ostia located at the base of the aorta behind the aortic 
valve leaflets. Blood flow is  distributed via these vessels to different regions of the 
heart, with the left main coronary artery and subsequently the LAD providing blood to 
the  left  ventricle  (Figure  1.2).    The  specialised  anatomy  of  the  coronary  circulation 
means that each region of the heart is only supplied by one artery, therefore blockade 
of an artery and subsequent ischaemia can be extremely detrimental.  The cardiac 
veins redistribute deoxygenated blood to the right atrium through the coronary sinus 
and contain valves to ensure the unidirectional flow of blood.  The main coronary veins 
are the coronary sinus, the anterior interventricular veins, left marginal veins, posterior 
veins of the left ventricle, and the posterior interventricular veins 




Figure 1.2: Diagrammatic representation of the main vessels that constitute the coronary circulation 
within the heart.  The left anterior descending coronary artery (LAD) supplies the left ventricle with blood.  
1.1.1.2  Cardiac energy metabolism 
Production  and  utilization  of  adenosine  triphosphate  (ATP)  is  obligatory  for  ion 
homeostasis, contraction of sarcomeres, and to maintain basal metabolic processes 
within the heart
2.  The ratio between production and utilization is exquisitely regulated 
to ensure myocardial metabolism is modulated to meet the demand of ATP required.  
The majority of ATP, approximately 95% is produced via oxidative phosphorylation in 
the mitochondria, with the remaining 5% derived from glycolysis and ATP formation 
from the Krebs cycle. These processes are described in more detail later.  
Energy  metabolism  is  intricately  controlled.  The  conversion  of  glucose  into 
pyruvate via a set of cytosolic enzymes constitutes the glycolytic pathway (Figure 1.3). 
The eventual fate of pyruvate is dependent on the availability of O2. In the absence of 
O2, one glucose molecule is converted into two pyruvate molecules yielding 2 ATP 
molecules and lactic acid.  However, in the presence of O2, the pyruvate formed in 
glycolysis can be transferred into the mitochondria and interact with coenzyme A (CoA) 




Figure 1.3: The glycolytic pathway. One molecule of glucose is converted to two molecules of pyruvate 
via a 10 enzyme catalysed steps. Two molecules of ATP are produced per glucose molecule. 
Fatty acids released into the blood stream from triacylglycerol fat stores are 
taken up and utilized by the heart as the main source of ATP. Fatty acids enter a cell 
via  fatty  acid  protein  transporters  on  the  cell  surface  namely  fatty  acid  translocase 
(FAT/CD36). Once inside the cytosol, a CoA group is added to the free fatty acid by 
fatty acyl-CoA synthase to form a fatty acyl CoA molecule. Fatty acyl CoA molecules 
cannot pass through the inner mitochondrial membrane so it is transformed by carnitine 
palmitoyl  transferase  1  (CPT-1)  to  acylcarnitine.  An  exchange  transporter  protein 
located  on  the  inner  mitochondrial  membrane  exchanges  cartinine  for  acylcarnitine 
allowing  entry  into  the  mitochondria.  Acylcarnitine  reacts  with  CoA  via  carnitine 
palmitoyl  transferase  2  (CPT-2),  reforming  as  a  fatty  acyl  CoA  molecule  in  the 
mitochondria
3.    Each  molecule  of  fatty  acyl  CoA  enters  the  fatty  acid  β-oxidation 
pathway to form acetyl CoA and a shortened acyl CoA molecule. Oxidation of a fatty 
acyl CoA molecule is repeated until an even number of carbon atoms are completely 
converted to acetyl CoA. For example, an 18-carbon free fatty acid would yield nine 
molecules of acetyl CoA (Figure 1.5).  
Acetyl CoA derived from either a carbohydrate or fatty acid source enter the 
Krebs cycle and generate electrons for entry into the electron transport chain (ETC), 
stimulating  oxidative  phosphorylation  within  the  mitochondria.    The  structure  and 
importance of energy production from within the mitochondria is discussed in further 




Figure 1.4: The fate of glucose is dependent on the availability of oxygen. One molecule of glucose is 
converted into two molecules of pyruvate via glycolysis in the cytosol. In the absence of oxygen, pyruvate 
is converted into lactate. In the presence of oxygen, pyruvate enters the mitochondria and is converted by 
pyruvate dehydrogenase and reacts with Coenzyme A to form acetyl CoA. Acetyl CoA can enter the Krebs 
cycle and provides the substrates for oxidative phosphorylation. 
 
 
Figure 1.5: Fatty acids as a substrate for energy production. Circulating free fatty acids enter the cytosol 
via fatty acid transporters on the cell surface. Fatty acids are converted to fatty acyl-CoA and transformed 
into acyl-carnitine by carnitine palmitoyl transferase 1 (CPT-1), transferred across the membrane and 
converted into fatty acyl-CoA by carnitine palmitoyl transferase 2 (CPT-2). Each fatty acyl-CoA molecule 
undergoes  β-oxidation  forming  acetyl  CoA.  Acetyl  CoA  can  enter  the  Krebs  cycle  and  provides  the 
substrates for oxidative phosphorylation. 
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1.1.1.3  Cardiovascular disease 
The term cardiovascular disease (CVD) spans all diseases of the heart and circulatory 
system.  There are four main types of atherosclerotic CVD: coronary heart disease, 
stroke, peripheral arterial disease and aortic disease. All four have a general common 
phenotype  whereby  blood  flow  is  reduced  to  the  heart,  brain  or  peripheral  organs 
usually via an obstruction in the vasculature. This obstruction can be caused by the 
formation  of  a  blood  clot  within  a  blood  vessel  known  as  thrombosis  or  the 
accumulation of fatty deposits inside an artery, causing narrowing and hardening of 
that vessel, known as atherosclerosis. Other CVDs include congenital heart disease, 
rheumatic heart disease, cardiomyopathies and cardiac arrhythmias
4.  
Coronary heart disease (CHD) also known as ischaemic heart disease (IHD), is 
a debilitating and life threatening illness, that has become one of the leading causes of 
death  in  the  UK.  IHD  is  characterized  by  a  reduction  in  blood  supply  to  the  heart 
muscle  leading  to  a  decreased  delivery  of  vital  components  such  as  oxygen  and 
nutrients to the tissue.  This reduction in blood flow is attributed to a blockade in the 
coronary arteries of the heart, which carry oxygen-rich blood to the muscle.  These 
blockages are plaques that have built up inside coronary arteries and can consist of 
numerous factors including fat and cholesterol along with other substances present in 
the blood. Without sufficient oxygen delivered to the heart, the muscle cells become 
ischaemic, eventually leading to cell death. This phenomenon is known as myocardial 
infarction (MI)
4. The inability of the myocardium, which is an irreversibly differentiated 
tissue, to repair itself leads to an infiltration of inflammatory mediators. Lymphocytes, 
neutrophils and macrophages remove and replace dead cardiomyocytes with collagen 
deposits  which  lead  to  scar  formation.    Cardiac  muscle  efficiency  is  therefore 
compromised and can progress into heart failure
5.  
Atherosclerotic  plaques  can  take  numerous  years  to  develop  and  often  go 
unnoticed until it is too late. The rate at which they develop often depend on lifestyle 
choices (smoking, exercise) but also can be influenced by a person’s inherited genetic 
background. There are many so called risk factors that have been shown to increase a 
person’s  susceptibility  to  IHD,  these  include:  obesity,  hypertension  and  diabetes. 
Patients that present in the clinic with either acute or chronic myocardial infarction (MI) 
often have a plethora of these risk factors. My PhD thesis focuses on two associated 
risk factors: ageing and type 2 diabetes.   Introduction   
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1.1.1.3.1  Myocardial infarction: contribution of ischaemia-reperfusion injury 
As described, MI is caused by the prevention of blood flow to an area of the heart, 
therefore the best treatment strategy is to remove the impediment so that the blood 
flow is restored to the ischaemic area.  In clinical settings, after an acute MI (AMI), 
reperfusion  of  the  myocardium  is  performed  using  thrombolytic  therapy  or  primary 
percutaneous coronary intervention (PCI). Complete reperfusion of the myocardium is 
likely to be achieved, however death rates and incidence of cardiac heart failure after 
an AMI remain at 10% and 25% 
6, respectively.  These data suggest that paradoxically, 
the  return  in  blood  flow  could  cause  damage
7.  This  phenomenon  is  known  as 
ischaemia-reperfusion injury (IRI). 
  Since first being described by Jennings et al, 1960 
8 there has been vast efforts 
in targeting cellular damage caused by ischaemia-reperfusion injury.  There are four 
different  types  of  injury  caused  to  the  heart  by  reperfusion  leading  to  cardiac 
dysfunction:  myocardial  stunning,  microvascular  obstruction,  arrhythmias  and  lethal 
myocardial reperfusion injury
7.   
Myocardial stunning refers to the mechanical dysfunction following acute non-
lethal ischaemia-reperfusion, with no irreversible damage and eventual full functional 
recovery 
9.  Interestingly,  even  though  stunning  is  a  form  of  reperfusion  injury,  the 
intensity of ischaemia is thought to prime the myocardium for the development of such 
injury. In this regard, reduction in the severity of ischaemia would be effective in limiting 
post-ischaemic dysfunction.  Two interacting pathways have been described regarding 
the mechanism of reperfusion induced myocardial stunning: the oxyradical hypothesis 
and the calcium hypothesis 
9. These hypotheses combine to form a central concept 
that  reperfusion  of  the  myocardium  initiates  a  generation  of  oxygen-derived  free 
radicals and Ca
2+ overload causing detrimental effects to the contractile apparatus of 
the  cardiomyocyte.  The  generation  of  ROS  can  also  simultaneously  escalate  Ca
2+ 
overload  by  impairing  the  activity  of  the  Ca
2+  regulated  ATPase  and  subsequently 
hindering  Ca
2+  transport  in  the  sarcoplasmic  reticulum.  This  results  in  a  reduced 
sequestration  of  Ca
2+  and  increased  cytosolic  Ca
2+.  Furthermore,  ROS-induced 
sarcolemmal  damage  promotes  a  non-selective  permeability  of  the  membrane  and 
successively results in injurious Ca
2+ and Na
+ overload
9. Numerous investigations have 
uniformly demonstrated a protective effect of antioxidants against reperfusion induced 
myocardial stunning
9.  
Obstruction in the coronary microvasculature can lead to little or no blood flow 




10. It was first described by Krug et al, 1966 as the ‘inability to 
reperfuse  a  previously  ischaemic  region’
11.  Microvascular  obstruction  (MVO)  (also 
known as the no reflow phenomenon) can result from the deposit or accumulation of 
fatty materials within the microvasculature.   Micro-embolization of  constituents from 
atherosclerotic plaques or platelet micro-thrombi and also neutrophil plugging can form 
blockages preventing the return of blood flow to an ischaemic area
12.  Endothelial cell 
and  cardiomyocyte  swelling  can  also  cause  compression  on  external  capillaries 
resulting in impaired vasodilation and contribute to MVO. 
 Reperfusion arrhythmias occur upon revascularization of the acutely ischaemic 
myocardium 
13, these arrhythmias occur only in salvaged myocardium and cannot arise 
from  dead  cells.  Upon  restoration  of  blood  flow  there  is  a  reinstatement  of  ATP, 
generation of free radicals and an adjustment in the resting membrane potential due to 
alterations of the inward and outward ion flux. These changes have been suggested to 
contribute  to  these  rhythm  disturbances.  Interestingly,  it  has  been  shown  using 
experimental animal models that as the duration of ischaemia increases, so does the 
incidence  of  reperfusion  arrhythmias
13.  However,  the  occurrence  of  reperfusion 
arrhythmias  follows  a  bell-shaped  curve,  with  the  peak  incidence  arising  when  the 
myocardium is subjected to approximately 10 minutes of ischaemia
13. Arrhythmias that 
develop within 30 minutes of experimental coronary artery occlusion follow a bimodal 
distribution and can be classed into (1) immediate or phase 1a ventricular arrhythmias 
or (2) delayed or phase 1b arrhythmias.  The most common are ventricular premature 
beats, non-sustained ventricular tachycardia, non-sustained ventricular fibrillation and 
an accelerated idioventricular rhythm. These type of arrhythmias usually self-terminate 
or can be easily treated
14. However, sustained ventricular tachycardia or fibrillation that 
is  not  effectively  managed  by  anti-arrhythmic  drugs  or  ended  by  a  defibrillator  can 
result in sudden cardiac death
15.  
Lethal ischaemia-reperfusion injury can add to the demise of cardiomyocytes 
during ischaemia-reperfusion, both processes can contribute to eventual infarction of 
the  myocardium.  The  following  section  focusses  on  this  phenomenon,  the  cellular 
mechanisms that contribute to myocardial infarction and how these can be targeted to 
limit the damage caused by ischaemia-reperfusion injury.   Introduction   
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1.1.2  Myocardial Infarction   
1.1.2.1  Infarction and ischaemic injury 
The heart is a highly energetic organ, dependent on substrate utilization to produce 
and  use  adenosine  triphosphate  (ATP).  As  previously  mentioned,  under  normal 
conditions,  about  95%  of  ATP  is  produced  via  oxidative  phosphorylation  in  the 
mitochondria using fatty acids as the main energy substrate, with the remaining 5% 
originating from glycolysis.  For ATP to be produced, cells require oxygen. Coronary 
artery blockade or occlusion during ischaemia prevents the delivery of oxygen to the 
cells, leading to impairment of energy metabolism. Under ischaemic conditions, energy 
metabolism is shifted to anaerobic glycolysis to provide ATP. This causes the reduction 
of pyruvate to lactate increasing the release of protons (H
+) and inorganic phosphate, 
creating an acidic intracellular environment.  
A reduced production of ATP leads to numerous downstream effects within the 
myocardium, including deleterious accumulation of ions. Sarcoplasmic reticulum (SR) 
Ca
2+  uptake  mechanisms  are  impaired,  resulting  in  an  increased  intracellular 
accumulation  of  Ca
2+.  Prolonged  ischaemia  also  reduces  intracellular  Mg
2+,  an 
essential  cofactor  needed  to  activate  the  Na
+/K
+-ATPase  system.      A  combined 
reduction  of  both  ATP  and  Mg
2+  alter  the  activity  of  the  Na
+/K
+-ATPase  of  the 
sarcolemma resulting in an accumulation of Na
+ in the cytosol. Increased H
+ ions also 
contribute to the accumulation of Na




overload is exacerbated by inhibition of the Na
+ pump caused by ATP depletion. The 
cell attempts to counteract the accumulation of Na
+ by reversing the usual movement of 
ions through the Na
+/Ca
2+ exchanger to remove Na
+ from the cell at the consequence 
of accumulating more cytosolic Ca
2+.  Excess cytosolic Ca
2+  is transported into the 
mitochondria by the mitochondrial Ca
2+ uniporter causing an increase in the activation 
of Ca
2+-dependent dehydrogenase enzymes.  A subsequent decline in the generation 
of NADH results in a reduced availability of electrons to enter the electron transport 
chain (ETC). As a consequence, mitochondrial membrane potential subsides due to 
the limitation of the proton gradient. The proton-translocating F0F1ATP synthase, which 
normally produces ATP, becomes an F0F1ATPase, consuming ATP to pump H
+ from 
the matrix into the intermembrane space
16, 17.  
As  the  severity  of  the  ischaemic  insult  progresses,  the  accumulation  of 
intracellular of solutes causes osmotic swelling. This eventually results in sarcolemmal 
disruption and will trigger necrotic cell death pathways (Figure 1.6).     Introduction   
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The ultrastructural changes which occur in the myocardium can be rectified with 
reperfusion of the ischaemic region if reperfusion is rapidly reinstated. Ischaemic times 
of greater than 20 min produce more pronounced tissue injury, and ultimately if not 
prevented end in cardiomyocyte death. Area at risk of the myocardium
18, 19, ischaemic 
duration
18,  19, volume of collateral blood flow
18 and temperature
20 are all factors that 
have been suggested to contribute to myocardial infarction in experimental models. 
 
 
Figure 1.6: Ischaemic injury. Cessation of blood flow during ischaemia decreases the delivery of oxygen to 
the  ischaemic  area.  The  decrease  in  the  availability  of  oxygen  results  in  the  reliance  on  anaerobic 
metabolism yielding in a decreased production of ATP. Consequently, the cellular environment becomes 
acidic and ion transport is affected. These changes lead to an increase in cytosolic calcium and sodium 
driving osmotic swelling and necrotic cell death.  
 
1.1.2.2  Infarction and reperfusion injury 
Upon  reperfusion  of  the  ischaemic  myocardium,  restoration  of  oxygen  and  hence 
increased  ATP  production  lead  to  a  metabolic  and  biochemical  shift  to  counteract 
aforementioned  ischaemia-induced  changes.    Paradoxically,  reperfusion  salvages 
myocardium  but  also  induces  some  cell  death  due  to  rapid  metabolic  changes. 
Numerous endogenous factors contribute to lethal reperfusion injury.  These include an 
increase  in  oxidative  stress  via  the  production  of  reactive  oxygen  species  (ROS), 
restoration of intracellular calcium and pH and triggering of inflammatory mechanisms; 
all  of  which  interact  with  each  other  to  mediate  opening  of  the  mitochondrial 
permeability  transition  pore  (PTP),  leading  to  eventual  cardiomyocyte  death, 




Figure  1.7:  Reperfusion  injury..  Upon  reperfusion  of  the  ischaemic  myocardium  there  is  a  rapid 
restoration of oxygen and subsequently the production of ATP is restored. These changes result in an 
increase in reactive oxygen and nitrogen species (ROS/RNS), inflammatory mediators, intracellular calcium 
and the restoration of pH.  Subsequently, the mitochondrial permeability transition pore (mPTP) opens 
allowing the entry of solutes into the mitochondrial matrix, resulting in mitochondrial swelling. Cytosolic 
Ca2+ overload can also lead to the rupture of the sarcolemmal membrane. These processes initiate cell 
death pathways.  
1.1.2.2.1  Oxygen paradox 
On rapid re-oxygenation  of the ischaemic myocardium  an ‘oxygen paradox’ occurs, 
whereby    oxidative  stress  caused  by  an  imbalance  of  pro-oxidative  enzymes  and 
anti-oxidative enzymes, leads to further deleterious effects on the myocardium than 
that caused by ischaemia alone 
21. Hearse et al, demonstrated in the isolated rat heart 
that  hypoxia  followed  by  re-oxygenation  elicited  more  damage  than  hypoxia  alone, 
causing  myofibrillar  hypercontracture  and  sarcolemmal  disruption 
21.    As  aerobic 
metabolism  is  restored  upon  re-oxygenation,  reactive  oxygen  species  (ROS)  are 
generated  from  within  the  mitochondria 
22  and  from  endothelial  cells  via  xanthine 
oxidase 
23.  As  reperfusion  persists,  neutrophils  can  also  produce  ROS  via  NADPH 
oxidases 
23.  Experimental  investigations  have  highlighted  such  a  vital  role  for  the 
oxygen paradox in the damage produced by reperfusion, numerous studies utilizing 
antioxidant agents at the onset of reperfusion have noted a reduction in infarct size. 
However,  development  of  clinical  strategies  to  target  oxidative  stress  within  the 
myocardium  has  been  disappointing 
24.  Vitally,  oxidative  stress  reduces  the   Introduction   
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bioavailability  of  nitric  oxide  (NO) 
25,  an  intracellular  signalling  molecule  that  has 
important  innate  cardioprotective  interactions  such  as  inhibition  of  neutrophil 
accumulation, inactivation of superoxide’s and improvement of coronary blood flow 
26. 
1.1.2.2.2  Intracellular calcium overload 
An increase in oxygen availability and restoration of aerobic glycolysis promote a rapid 
increase in intracellular Ca
2+, together causing re-energization of the cell. The return of 
ATP  levels  promote  activation  of  ATP-controlled  ion  pumps,  the  Na
+/K
+  pump  is 
reactivated  generating  a  Na
+  gradient  that  favours  the  forward  movement  of  the 
Na
+/Ca
2+  exchanger,  decreasing  cytoplasmic  Ca
2+  concentration.    The 
Ca
2+-sarcoplasmic  reticulum  pump  (SERCA)  sequesters  Ca
2+  in  the  sarcoplasmic 
reticulum (SR) leading to overload and subsequent release of Ca
2+. This continuous 
cycling  of  Ca
2+  uptake  and  release  by  the  SR,  and  the  preceding  oxidative 
stress-induced dysfunction of the SR and sarcolemma membrane damage, contributes 
to cytosolic Ca
2+ overload initiating myofibrillar activation and hypercontracture.  
1.1.2.2.3  Restoration of physiological pH  
Rapid normalization of cellular pH upon reperfusion can also contribute to further Ca
2+ 
overload  within  the  cell.  The  ischaemia-induced  acidic  pH  of  the  cell  reduces  its 
contractility; upon reperfusion there is a rapid normalisation of pH within the interstitial 
space with the cytoplasm remaining acidic.  This creates a proton gradient to extrude 
H
+ ions from the cell via the Na
+/H
+ exchanger and the Na
+/HCO3
- symporter. These 
actions promote hypercontracture via a net influx of Na
+ driving further over load of 
cellular Ca
2+. Interestingly, in vitro studies have shown that maintenance of an acidic 
extracellular  environment  during  the  first  few  minutes  of  reperfusion  elicits 
cardioprotective effects on the myocardium, however this effect was lost if the acidosis 
persisted beyond 3 minutes 
27.  Lactate produced during anaerobic glycolysis and other 
cellular debris’ are washed-out upon reperfusion creating an osmotic gradient between 
the  intracellular  and  extracellular  space  favouring  water  to  enter  the  cell.  The 
accumulation of water and cytosolic overload of Na
+ activating the Na
+/H
+ exchanger 
leads  to  intracellular  pressure  increases  and  stretch  in  the  sarcolemma.  This 
mechanical  stretch  and  hence  hypercontracture  of  the  cell  leads  to  eventual  cell 
rupture.    Introduction   
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1.2  Mitochondria and ischaemia-reperfusion injury 
1.2.1  Mitochondria 
1.2.1.1  Mitochondrial morphology 
Mitochondria are dynamic organelles that can interact with other mitochondria, alter 
their appearance and change their morphology. They can undergo a process called 
fission to generate fragmented mitochondria or alternatively endure a fusion process 
creating an interconnected, elongated phenotype. Efficient regulation of both fission 
and fusion of mitochondria by specific proteins have been implicated in a number of 
biological processes. These processes include cell division, autophagy, apoptosis and 
metabolism
28.   
The  aforementioned  deleterious  effects  of  reperfusion  can  impact  on  the 
mitochondria not only via signalling to the mPTP, but can also lead to morphological 
changes 
29. These changes are determined by the redistribution of mitochondrial DNA 
and  other  constituents  that  maintain  mitochondrial  structure  and  function  forming 
networks of elongated or fragmented mitochondria. The  equilibrium between  fission 
and fusion is a dynamic, cycling process that is controlled by distinct proteins. Fission 
is  controlled  by  the  GTPase  molecule,  dynamin-related  protein  1  (Drp-1)  that  is 
recruited  from  the  cytosol  to  the  mitochondria  and  interacts  with  the  OMM  protein 
human mitochondrial fission protein 1 (hFis1) 
30, 31.  Mitochondrial fusion is controlled 
by 3 dynamin-related GTPases, mitofusin (Mfn) 1 and 2  within the OMM and optic 
atrophy protein 1 (Opa1) within the IMM
32,  33.  Alongside the involvement of Mfn2 in 
promoting mitochondrial fusion, Mfn2 can tether the mitochondria to the endoplasmic 
reticulum (ER) 
34. This results in an increased mitochondrial accumulation of cytotoxic 
Ca
2+  that  is  released  from  the  ER  which  may  influence  mPTP  opening 
34.    The 
relationship  between  cell  death  and  mitochondrial  dynamics  is  still  not  completely 
understood.  Ong  et  al,  2010  demonstrated  that  inhibiting  mitochondrial  fission 
decreased cardiomyocyte death following ischaemia/reperfusion  and that  HL-1  cells 
overexpressing mitofusin proteins were protected against this insult 
35. However, it has 
been suggested that fused mitochondria are more sensitive to cell death increasing 
mPTP opening 
36, Mfn-2 deficient mice are protected against reperfusion injury 
37 and 
Mfn1 deficient mice are protected against ROS-induced mitochondrial dysfunction 
38. 
1.2.1.2  Mitochondrial biogenesis 
Mitochondrial biogenesis can be defined as the process that leads to the growth and 
division  of  pre-existing  mitochondria
39.  Compromised  mitochondrial  biogenesis  and   Introduction   
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hence function can be influenced by environmental stresses and has been linked to 
numerous diseases
40, especially between metabolic and cardiovascular diseases.  It is 
also suggested that the transcriptional control of mitochondrial biogenesis coordinates 
with fission and fusion mechanisms within the mitochondria
39 (Figure 1.8). 
 
Figure  1.8:  The  control  of  mitochondrial  biogenesis.  The  co-activator  PGC-1α  binds  to  transcription 
factors to drive the transcription of genes involved in the regulation of mitochondrial biogenesis. PGC-1α 
increases the transcription of mitochondrial transcription factor A (Tfam) which results in mitochondrial 
DNA  transcription  and  replication.  These  newly  formed  mitochondria  can  fuse  together  forming  an 
extended  network  of  mitochondrion,  this  process  of  elongation  is  coordinated  by  fusion  proteins: 
mitofusin-1 (Mfn-1), mitofusin-2 (Mfn-2) and optic atrophy protein 1 (OPA-1). Damaged sections of fused 
mitochondria  can  be  removed  by  fission  proteins  (h-fis  and  DRP-1)  ensuring  correctly  functioning 
mitochondria remain.  
At  the  nuclear  level,  there  are  numerous  transcriptional  proteins  that  are 
involved  in  regulating  mitochondrial  biogenesis  including  mitochondrial  transcription 
factor A (Tfam), nuclear respiratory factors (Nrfs) and peroxisome proliferator-activated 
receptor gamma co-activator (PGC-1α) 
41, 42. Since its original discovery
43, PGC-1α has 
emerged as a master regulator of mitochondrial biogenesis implemented in maintaining 
optimum metabolic equilibrium
44. 
1.2.1.3  The physiological role of cardiac mitochondria 
Mitochondria are specialized, dynamic organelles located in the cytoplasm of the cell; 
they play an essential role in cell life and death. They are considered the ‘biochemical 
powerhouse’ of the cell, playing a crucial role in many metabolic processes leading to 
ATP  production.  They  also  contribute  to  cellular  stress  responses 
45,  cell  death 









1.2.1.4  Cardiac energy metabolism in the mitochondria 
Glucose and fatty acids are sequentially oxidised to form a common intermediate acetyl 
CoA in the mitochondria. The β-oxidation of fatty acids generates the electron carriers 
NADH  and  FADH.  Upon  entry  into  the  Krebs  cycle,  acetyl  CoA  is  further  oxidised 
producing  more  NADH  and  FADH2.  Cytosolic  NADH  generated  during  glycolysis 
cannot enter the mitochondria directly. The malate-aspartate shuttle indirectly transfers 
electrons  from  NADH  in  the  cytosol  across  the  impermeable  inner  mitochondrial 
membrane  (IMM)  to  NADH  in  the  mitochondrial  matrix.  Generation  of 
NADH/FADH/FADH2 is summarised in Figure 1.9.   
 
Figure 1.9: The Krebs cycle.  Glycolytic and β-oxidation pathways lead to the production of acetyl CoA for 
entry into the Krebs cycle. The electron carrier, NADH that is generated in the cytosol is shuttled into the 
mitochondrial  matrix,  with  the  remaining  NADH  generated  within  the  mitochondria  throughout 
β-oxidation  and  at  several  points  of  the  Krebs  cycle.  An  alternative  electron  carrier  FADH2  is  also 
generated as a result of the conversion of succinate to fumarate.   
NADH  initiates  the  electron  transport  chain  (ETC)  by  feeding  electrons  to 
complex  I  (NADH-ubiquinone  oxidoreductase/dehydrogenase)  and  subsequently 
transferring electrons to ubiquinone (coenzyme Q). Ubiquinone is a lipid-soluble mobile 
electron carrier that transfers electrons from complex I to complex III (cytochrome bc1).    Introduction   
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In  the  terminal  redox  reaction,  complex  III  reduces  an  associated  electron  carrier, 
cytochrome c and electrons are transferred into complex IV (cytochrome c oxidase).  
These step-wise redox reactions at complexes I, III and IV are coupled to the active 
pumping  of  hydrogen  ions  out  of  the  mitochondrial  matrix  into  the  intermembrane 
space.  This  establishes  a  large  proton-motive  force  across  the  inner  membrane. 
Membrane  bound  complex  II  (succinate  dehydrogenase)  of  the  ETC  does  not 
contribute  to  this  proton-motive  force.  Complex  II  directly  reduces  succinate  to 
fumarate, as part of the Krebs cycle, generating the electron donor FADH2. Complex II 
donates the electrons generated from FADH2 directly to Ubiquinone promoting direct 
passage of electrons through complex’s III and IV. The proton-motive force created by 
the  accumulation  of  H
+  produces  a  large  driving  force  consisting  of  a  membrane 
potential (Δψm ~ -200mV ) and a proton gradient (ΔpH) which is used by ATP synthase 
(F1−F0 ATPase) to phosphorylate ADP to ATP 
50. ATP is exported to the cytosol via 
adenine nucleotide translocase (ANT) and used for numerous cellular processes. An 
overview of oxidative phosphorylation is summarised in Figure 1.10. 
 
Figure 1.10: Oxidative Phosphorylation. Electron carriers generated during glycolysis, β-oxidation and the 
Krebs cycle feed electrons to complex I of the electron transport chain (ETC). Electrons (e
-) are shuttled 
from complex I to complex III through ubiquinone (coenzyme Q) and then via cytochrome c to complex IV. 
The movement of e
- generate a proton (H
+) gradient across the membrane resulting in activation of the 
ATP synthase and generation of ATP. Complex II of the ETC does not contribute directly to the proton 
gradient. However, the conversion of succinate to fumarate during the Krebs cycle can directly provide 
the electrons to the ETC via FADH2. 
     Introduction   
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Alternatively, movement of electrons and proton influx into  the mitochondrial 
matrix  can  occur  independently  of  phosphorylating  ADP.  This  process  is  called 
uncoupled oxidative phosphorylation. This results from damage to the ATP-synthase or 
an increased permeability to the IMM allowing passive movement of protons.  This 
‘proton  leak’  is  facilitated  by  IMM  proteins  such  as  uncoupling  proteins  (UCPs)
51, 
adenine  nucleotide  translocases  (ANTs)
52and  also  cytochrome  c
53.  Energy  derived 
from proton leak is dissipated as heat.  
1.2.1.5  Mitochondrial ion transport 
Mitochondria possess a smooth outer mitochondrial membrane and a convoluted inner 
membrane forming tubular  structures  called  cristae.   These membranes  define  two 
distinct spaces in the mitochondrion, the intermembrane space between the inner and 
outer membrane, and the mitochondrial matrix within the inner membrane. The outer 
mitochondrial  membrane  (OMM)  is  a  phospholipid  bilayer  containing  numerous 
proteins called porins and channels that allow movement of molecules up to 10KDa 
between the mitochondria and the cytosol. An extensively studied outer mitochondrial 
membrane channel is the voltage-dependent anion channel (VDAC). VDAC is located 
between the outer and inner mitochondrial membrane. It provides the principal route of 
entry and exit of ions and metabolites across the outer membrane
54.  
The  inner  mitochondrial  membrane  (IMM)  is  the  major  permeability  barrier 
between the cytosol and the mitochondrial matrix, this membrane is freely permeable 
to only O2, CO2 and H2O. The diverse permeable nature of the IMM and OMM enable 
the  complexes  of  the  ETC  to  promote  a  proton  gradient  across  the  IMM.  This 
electrochemical gradient forms the basis of the mitochondrial membrane potential (ψm) 
and is a crucial determinant of ion transport across the IMM. 
Various  transport  proteins  including  ion  channels  are  located  in  the  highly 
complex  cristae-containing  membrane  allowing  passage  to  otherwise  impermeable 
molecules. These channels compromise approximately 80% of the IMM. The IMM also 
hosts complexes of the respiratory chain, ATP synthase and various enzymes
55.  
There are several modes of ion transport present in the IMM, these include 
symporters,  uniporters  and  antiporters
54.  Symporters  can  simultaneously  transport 
multiple ions or metabolites in the same direction across the membrane. Antiporters 
exchange  ions  across  different  sides  of  the  membrane,  with  or  without  an 
electrochemical gradient and uniporters allow the flow of ions electrophoretically down 
their  electrochemical  gradient
54.  The  IMM  has  numerous  well-characterised  cation-  Introduction   
43 
 
permeable channels. These include  the mitochondrial Ca
2+  uniporter  and ryanodine 
receptors and also potassium channels, the mitochondrial KATP and KCa channels. Ca
2+ 
can freely pass through the OMM but in order to enter the mitochondrial matrix, it must 
pass through the mitochondrial Ca
2+ uniporter located on the IMM. This highly Ca
2+-
selective, low conductance ion channel
56 provides the primary route for Ca
2+ uptake 
into the mitochondrial matrix. An increased uptake of Ca
2+ into the matrix is important 
for maintained production of ATP during oxidative phosphorylation
57.  Efficient control 
of mitochondrial K
+ flux
 is important to counterbalance the activity of the mitochondrial 
uniporter
58.  
However,  less  information  is  known  about  the  existence  and  expression  of 
anion  permeable  IMM  ion  channels.  Early  studies  provided  evidence  for  an  inner 
membrane  anion channel  (IMAC). These  channels  are  controlled  by  protons,  Mg
2+, 
temperature and pH but their exact physiological role is still largely unknown
59.  
Tightly regulated mitochondrial ion flux limits unnecessary energy wastage and 
prevents mitochondrial swelling and eventual rupture of the OMM
58. Rupture of the 
OMM can result in non-functional and deleterious mitochondria. Channel opening in 
response  to  energy  dissipation  will  increase  flux  through  the  ETC.  If  this  is  not 
efficiently compensated for by an increased production of substrates, oxidation status 
and  subsequent  changes  in  levels  of  reactive  oxygen  species  occur.  Hence, 
mitochondrial  ion  channels  can  also  act  as  redox  regulators  which  will  impact  on 
intracellular signalling cascades such as the transcription and translation of proteins 
and also cell death pathways
60. 
During  normal  physiological  conditions,  maintaining  mitochondrial  function, 
metabolism,  structure  and  ion  transport  are  crucial  for  numerous  critical  cellular 
functions. The recovery of pH, oxidative stress and Ca
2+ overload already described 
during  reperfusion,  can  impact  on  the  functional  capacity  and  activity  of  the 
mitochondria.  Reperfusion  increases  the  open  probability  of  the  mitochondrial 
permeability transition pore (mPTP). The mPTP is the major end-effector of ischaemia-
reperfusion injury, contributing to cardiomyocyte hypercontracture and cell death.  
1.2.1.6  Mitochondria permeability transition pore (mPTP) 
It was originally thought that mitochondrial swelling in response to high levels of Ca
2+ 
was  the  result  of  non-specific  permeabilisation  of  the  inner  membrane  of  the 
mitochondria. Work throughout the late 1970s proved otherwise, with the identification 




2+ 61. This was explored further into the late 1980s, whereby Crompton et al 
demonstrated that  both  Ca
2+  and  oxidative  stress  synergistically  promote  reversible 
opening  of  an  inner  membrane  pore  in  isolated  rat  heart  mitochondria
62.  This 
non-selective  membrane  channel,  is  now  commonly  known  as  mitochondrial 
permeability transition pore (mPTP) 
63.  The mPTP is a responsive channel, which 
opens and closes according to the cellular environment for example pH. 
The structure of the mPTP is still not completely defined and is a matter of 
intense debate
64. It became generally accepted that the mPTP comprised of a complex 
of proteins spanning the inner and outer mitochondrial membranes 
63. It was originally 
defined as an outer mitochondrial membrane protein voltage-dependent anion channel 
(VDAC),  mitochondrial  adenine  nucleotide  translocator  (ANT)  and  hexokinase.  This 
was  extended  to  include  outer  membrane  TSPO  and  Bcl-2  family  members.  In 
response to cellular stress such as high Ca
2+, cyclophillin D (CypD) was proposed to 
bind ANT initiating a tunnel-like structure, allowing passage of water and solutes from 
the cytosol into the mitochondria
65. Activation of the mPTP was strongly inhibited by 
CypD  receptor  blocker  cyclosporine  A  (CsA)
60.    However,  Kokoszka  et  al,  2004 
questioned this notion. They demonstrated that mitochondria lacking ANT protein still 
contained  a  Ca
2+-dependent  pore.  Moreover,  this  pore  could  be  triggered  by  thiol 
oxidants and inhibited by CsA. These findings suggested that ANT therefore was not 
an  obligatory  binding  partner  of  CypD  or  the  site  of  contact  for  oxidants
66.  The 
existence of VDAC as a component of the mPTP was also scrutinised, Krauskopf et al, 
2006 performed a detailed comparison of the mPTP in mitochondria from wild type and 
VDAC1
-/- mice and demonstrated VDAC1 was fully dispensable for mPTP regulation 
and  opening.  In  further  support  of  this,  Baines  et  al,  2007  demonstrated  all  three 
isoforms of VDAC were not components of the mPTP 
67. The outer membrane protein 
translocator protein (TSPO) also appears dispensable,  TSPO ligands did not affect 
activity of the large conductance mPTP
68. Based on the genetic and pharmacological 
evidence available it seems likely none of the original channel-forming proteins are in 
fact necessary for the formation of the mPTP.  
CypD is located in the mitochondria and possesses prolyl isomerase (PPIase) 
activity. Genetic ablation studies firmly support a modulatory role for this protein in the 
control  of  mPTP  opening
69.  Post  translational  modifications  of  CypD  such  as 
phosphorylation,  acetylation and nitrosylation also affect the open probability of the 
mPTP
70.  Interestingly,  CypD  can  intereact  with  numerous  proteins,  raising  the 




73  and  also  the  F0F1  ATP  synthase
74.  A  very  recent   Introduction   
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publication by Giorgio et al, 2013 has defined the binding site of CypD on the F0F1-ATP 
synthase as the OSCP subunit.  Inhibition of the F0F1 ATPase with benzodiazepine 
(Bz)-423, sensitised the mPTP to Ca
2+ and this effect was blunted by Pi induced CypD 
binding. They further suggest that the F0F1 ATP synthase dimerises to form the mPTP, 
which is sensitive to classical triggers and inhibitors of the previously defined large 
conductance channel. Interestingly, they find F0F1 ATP synthase monomers lack any 
channel activity
75. Interestingly, in this proposed model of the mPTP, pore opening was 
sensitive to Ca
2+ and Pi in the absence of CypD. The authors suggest that the binding 
of CypD to this dimerised channel sensitises the opening of the mPTP thereby opening 
in response to lower Ca
2+ concentrations. Further investigations are required to fully 
define the mPTP and the interaction with the outer mitochondrial membrane
76. Figure 
1.11 shows the classical and newly hypothesised structure of the mPTP. 
Upon  reperfusion  of  the  ischaemic  myocardium,  the  generation  of  ROS, 
overload of Ca
2+ and restoration of pH influence the open probability of the  mPTP. 
Opening of the mPTP immediately depolarizes the membrane potential (Δψm),  causing 
dissipation  of  the  proton  motive  force  required  to  maintain  successful  oxidative 
phosphorylation  and  hence  ATP  production,  leading  to  bioenergetic  failure  of  the 
cardiomyocyte 
63. Not only does a cessation of ATP production occur but the reverse 
mode of the ATPase synthase is activated to try and restore the proton gradient by 
consuming  ATP 
50.  Secondly,  small  molecules  pass  through  the  pore  leading  to 
accumulation of ions and cofactors within the mitochondria. This causes a metabolic 
imbalance  between  the  cytosol  and  the  membrane  favouring  the  release  of 
accumulated Ca
2+ and eventual mitochondrial swelling. Swelling of the mitochondria 
can  occur  with  or  without  rupture  of  the  inner  mitochondrial  membrane.  Pressure 
mounts  within  the  mitochondria  leading  to  eventual  rupture  of  the  outer  membrane 
causing the  release  of pro  apoptotic  proteins  and  hence  the  initiation of  cell  death 
pathways




Figure  1.11:  Structure  of  the  mitochondrial  permeability  transition  pore  (mPTP).    Structure  of  the 
mitochondrial permeability transition pore (mPTP). The structure of the mPTP was classically defined as 
shown  in  A.  This  model  proposed  a  complex  of  inner  and  outer  mitochondrial  membrane  proteins 
including mitochondrial adenine nucleotide translocator (ANT), voltage-dependent anion channel (VDAC), 
hexokinase (HK), Bcl-2 and translocator protein (TSPO). In response to reperfusion, the redox and Ca
2+ 
sensitive  pore,  is  modulated  by  cyclophillin  D  (CypD),  allowing  the  passage  of  solutes  into  the 
mitochondrial  matrix.  The  current  opinion  of  the  structure  of  the  mPTP  is  shown  in  B.  This  model 
proposes that the ATP synthase of the electron transport chain (ETC) forms dimers to allow the passage of 
water/solutes into the mitochondrial matrix in a redox and Ca
2+-dependent manner. This model suggests 
CypD is not an absolute requirement for pore opening but instead acts as a pore sensitiser. The outer 
membrane component of the mPTP in this model is not yet defined.   
 
1.2.2  PGC-1α 
1.2.2.1  PGC-1 family and PGC-1α structure and function 
The  group  of  transcriptional  coactivators,  peroxisome  proliferator-activated  receptor 
gamma  (PPARγ)  coactivator-1  (PGC-1),  are  inducible  factors that can  bind  to  both 
nuclear receptors (NR) and non NRs to drive gene transcription. PGC-1α was originally 
identified as a cold-inducible coactivator, following observation of its functional capacity 
to  respond  to  and  interact  with  peroxisome  proliferator-activated  receptor  gamma 
(PPARγ) in mitochondrial-rich brown adipose tissue in response to cold exposure
43. 
Other family members  include PGC-1β
78,  79  and  (PRC)
80. PGC-1β and PGC-1α are 
highly expressed in muscles and tissues with high oxidative capacities such as heart, 




80.  Interestingly,  these  coactivators  cannot  bind  DNA  directly.  However,  in 
response to activation signals such as changes in metabolism, exercise or cold, these 
transcriptional coactivators bind to receptors to provide a platform for protein interaction 
resulting in coactivator complexes. In turn, these complexes are capable of triggering 
the transcription of certain target genes.  
PGC-1α’s N amino terminal region provides the platform for proteins containing 
histone  acetyltransferase  (HAT)  activity  including  p300/  cAMP  response  element 
binding protein (CREB)-binding protein and steroid receptor coactivator-1 (SRC-1)
43. 
The carboxy terminal region allows for the interaction with a second activating complex, 
the thyroid hormone receptor-associated protein/vitamin D receptor-interacting protein 
(TRAP/DRIP) complex
81.  To initiate gene transcription, the transcription factor binds to 
the DNA response element in the promoter region of the target gene. Recruitment of 
PGC-1α allows association of the p300/CREB-binding protein and causes chromatin 
remodelling  by  histone  acetylation.    The  subsequent  and  direct  interaction  with 
TRAP/DRIP provides a molecular bridge between the coactivator complex and RNA 
polymerase  II.  Remodelling  of  chromatin  increases  the  accessibility  of  this 
transcriptional machinery and aids gene transcription. PGC-1α alone does not possess 
this ability but it acts as a scaffold for recruiting these proteins
81. Of note, PGC-1α also 
possesses an RNA processing domain at the Carboxy terminus that may contribute to 
further transcriptional regulation
82.  A generalised scheme demonstrating the docking of 
protein regulatory complexes to PGC-1α and subsequent gene transcription is shown 




Figure 1.12: PGC-1α coactivation of transcription factors.  Transcription factors (TF) bind to the DNA 
response element of their respective target gene (1), with subsequent recruitment of PGC-1α to the 
TF/DNA  response  element  complex  (2).  PGC-1α  interacts  with  p300/cAMP  response  element  binding 
protein (CREB)-binding protein and steroid receptor coactivator-1 (SRC-1) causing histone acetylation and 
chromatin remodelling (3 &4). This process allows the direct interaction with a second activating complex, 
the thyroid hormone receptor-associated protein/vitamin D receptor-interacting protein (TRAP/DRIP) (5). 
The TRAP/DRIP complex provides a molecular bridge for the association of RNA polymerase II (6) which 
drives gene transcription (7). 
1.2.2.2  Transcriptional control of PGC-1α  
The diverse actions of PGC-1α led to the consensus that this coactivator is able to 
interact with numerous transcription factors.  Within the heart, there are numerous NR 
and  non-NR  targets  of  PGC-1α;  NRs  include  PPARα,  PPARβ,  estrogen-related 
receptors-α and γ (ERRs). The non NR targets include, forkhead box class-O (FoxO1), 
myocyte enhancing factor-2 (MEF-2) and nuclear respiratory factor-1 and -2 (NRF-1 
and -2)
42.  The key functional domains involved in the interaction of PGC-1α with the 
aforementioned  transcription  factors  are  shown  in  Figure  1.13.    The  capacity  of 
PGC-1α to interact with these transcription factors serves to coordinate a plethora of 
effects on the mitochondria such as the control of mitochondrial biogenesis, energy 
substrate utilisation and cellular respiration




Figure 1.13: The key functional domains involved in the interaction of PGC-1α with transcription factors 
The activity of PGC-1α can be modulated by gene transcription. PGC-1α gene 
transcription  and  protein  expression  can  be  regulated  by  numerous  proteins  in 
response  to  certain  physiological  stimuli  such  as  changes  in  metabolic  demand, 
exercise  and  nerve  innervation.  Depending  on  the  upstream  activator  eliciting  an 
increased requirement for PGC-1α activity, the appropriate transcription factor can be 
co-activated  by  PGC-1α  to  meet  the  demands  of  the  cell 
84-86.  These  effects  are 
summarised in Figure 1.14.  
 
Figure  1.14:  Transcriptional  targets  of  PGC-1α.  PGC-1α  responds  to  changes  in  the  intracellular 
environment driving gene transcription depending on the requirement of the cell.   Introduction   
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AMPK is a crucial signalling molecule that acts as an energy sensor within the 
cell. In response to an increased AMP to ATP ratio, a range of catabolic pathways are 
initiated, including a rise in mitochondrial biogenesis and function which drives ATP 
production
87.    Treatment  of  muscle  cells  with  a  specific  AMPK  activator  such  as 
5-aminoimidazole-4-carboxamide-1-b-d-ribofuranoside  (AICAR)  led  to  an  increase  in 
PGC-1α transcription
88, 89. Moreover, PGC-1α activity has been shown to be essential 
for  AMPK-mediated  mitochondrial  activation
90.  The  signalling  events  leading  to  an 
AMPK  associated  increase  in  PGC-1α  expression  remain  unclear;  however  data 
obtained in human skeletal muscle suggest potential transcription targets that need 
further investigation
91.   The transcription factors FoxO1, CREB and MEF2 can bind to 
specific promoter regions of PGC-1α to drive transcription; moreover, inhibition of MEF2 
activity  by  class  II  histone  deacetylases  (HDACs)  suppresses  this  activity
84,  92.  
Interestingly, insulin a key signalling molecule which is involved in energy storage and 
control  of  catabolic  pathways  has  also  been  suggested  to  impact  on  PGC-1α 
transcription in muscle. Insulin responsive elements exist within the binding domain of 
the promoter region of the PGC-1α gene. These elements can be activated by FoxO1 
driving the transcription of PGC-1α. Insulin signalling phosphorylates Akt which in turn 
can phosphorylate and inhibit FoxO1 thereby reducing the transcription of PGC-1α
93. 
The defective insulin signalling exhibited in diabetes could impact on the regulatory role 
of PGC-1α. 
1.2.2.3  Post translational modifications of PGC-1α 
Post  translational  modifications  of  PGC-1α  include  acetylation,  phosphorylation, 
methylation, GlcNAcylation
94 and most recently SUMOylation 
95. Phosphorylation and 
acetylation  of  PGC-1α  have  been  the  most  extensively  studied  modifications. 
Numerous proteins can target and phosphorylate PGC-1α at numerous sites; AMPK 
alongside  its  direct  transcriptional  activity  can  also  activate  PGC-1α  through 
phosphorylation at threonine-177 and serine-538 and hence enhance its transcriptional 
coactivity
90.  Cytokine  activation  of  kinase  p38  MAPK  phosphorylates  PGC-1α, 
increasing its stability and potentiating its transcriptional activity
96.  This kinase can also 
indirectly  potentiate  PGC-1α  activity  by  inhibiting  co-repressor  p160MBP  in 
myoblasts
97. Akt phosphorylates PGC-1α directly
98 and indirectly
99 thereby reducing its 
activity.  Phosphorylation of Akt induced by insulin, can directly phosphorylate PGC-1α 
at  serine-570 alternatively this axis has been shown to phosphorylate  and stabilize 
protein  kinase  Clk2.  Clk2  can  phosphorylate  PGC-1α  resulting  in  specific  down 
regulation of PGC-1α/FoxO1 related activity consequently repressing gluconeogenesis 
and inhibiting the production of glucose
99.  Interestingly, proteasomal degradation of   Introduction   
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PGC-1α in the nucleus can be enhanced by GSK-3β mediated phosphorylation during 
acute  oxidative  stress
100,  moreover  this  inhibitory  phosphorylation  limits  silence 
information regulator 2-type 1 (SIRT1)-activation of PGC-1α, thereby further reducing 
its  activity  and  transcription.  Sustained  oxidative  stress  favours  SIRT-1  activity  and 
overcomes the inhibitory nuclear accumulation of PGC-1α and drives the transcription 
and cytoplasmic translation of PGC-1α
94.  
De/acetylation  is  another  key  regulatory  mechanism  of  PGC-1α  function; 
SIRT-1  deacetylates  and  increases  the  coactivation  of  PGC-1α  to  its  transcription 
targets,  whereas  acetylation  by  histone  acetyltransferase  KAT2A  (GCN5)  has  the 
opposing effect. The activity of SIRT-1 is dependent on the energy status of the cell. In 
times  of  energy  demand,  for  example  during  exercise  or  oxidative  stress,  SIRT-1 
substrate coenzyme nicotinamide adenine dinucleotide (NAD
+) and subsequently the 
NAD
+/NADH ratio are increased as energy stores are being depleted. This triggers 
SIRT-1 mediated deaceytlation of PGC-1α, promoting mitochondrial metabolism and 
increasing energy within the cell.  Interestingly, AMPK plays another vital role in the 
regulation of PGC-1α activity; AMPK increases the level of NAD
+ by enhancing FAO
101 
or the activity of nicotinamide phosphoribosyltransferase (Nampt)
102 thereby promoting 
the  deacetylation  action  of  SIRT1
101.    Moreover,  it  appears  the  phosphorylation  of 
PGC-1α by AMPK is required for SIRT-1 to target and deacetylate PGC-1α
101. Post 
translational modifications are summarised in Figure 1.15.  
 
Figure 1.15: Post translational modifications of PGC-1α   Introduction   
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1.2.2.4  PGC-1α signalling in the heart 
PGC-1α  is  abundantly  expressed  in  the  heart;  after  birth  PGC-1α  expression  is 
increased as the heart switches to favour mitochondrial FAO as the main source of 
energy
42,  103.  In  other  physiological  modifications  such  as  fasting,  the  heart  also 
increasingly relies on FAO for the production of ATP and therefore an increase in the 
expression  of  PGC-1α  is  observed  with  a  subsequently  increased  coactivation  of 
PPARα  and  ERRα
42,  103.    Gain-of-function  and  knock-down  studies  using  PGC-1α 
transgenic  mice  have  demonstrated  many  biological  functions  of  PGC-1α  in  vivo 
hearts. Enhanced activation of cardiomyocyte mitochondrial biogenesis was seen in 
mice that constitutively overexpress cardiac PGC-1α by control of the cardiac α-myosin 
heavy chain promoter (MHC-PGC-1α mice), moreover this enhanced activation led to 
eventual  death  by  heart  failure
103  suggesting  that  a  tight  control  of  mitochondrial 
biogenesis  is  extremely  important.    A  subsequent,  tetracycline-inducible  PGC-1α 
mouse (cs-tet-on PGC-1α mouse) further demonstrated the exquisite control PGC-1α 
has on mitochondrial biogenesis and function during development into adulthood
104. 
Acute  overactivation  of PGC-1α  during the  neonatal  period  caused mitochondria  to 
become dramatically oversized within the heart whereas ultrastructural changes within 
mitochondria only developed following chronic up regulation of PGC-1α expression
104.  
Interestingly,  PGC1α
  -/-  mice  produced  by  the  Spiegelman  group  demonstrate  a 
moderate decline in cardiac function with age associated with diminished expression of 
genes  associated  with  mitochondrial  FAO,  oxidative  phosphorylation  and  the  Krebs 
cycle which led to a modest impairment of ATP maintenance
105. In support of the first 
knock down model created, mitochondrial proteins and enzymes involved in FAO are 
down  regulated  in  the  failing  heart
106,  107.    Whereas,  the  PGC-1α 
-/-  mouse  model 
created and used by Leone et al, fail to observe the deviations in gene expression 
recorded in the mouse generated by Spiegelman lab
108.  
PGC-1α has also been implicated in the oxidative stress response by regulating 
the  expression  of  ROS  scavengers.  In  cultured  cells,  PGC-1α  and  –β  induce  the 
expression of antioxidant scavenger’s catalase, glutathione peroxidase and SOD-1/2 in 
response  to  hydrogen  peroxide  induced  oxidative  stress
109.  Moreover,  PGC-1α 
deficient mice have reduced levels of these scavengers. Interestingly, overexpression 
of  PGC-1α  in  endothelial  cells  reduced  the  accumulation  of  ROS  and  reduced  cell 
death as well
110.    Introduction   
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The succeeding section focus on the cellular mechanisms implicated in the death of 
cardiomyocytes and the cell survival pathways which can be up regulated in order to 
limit the damage caused by ischaemia-reperfusion injury. 
1.3  Cell death pathways 
Myocardial  cell  death  following  ischaemia-reperfusion  can  occur  via  numerous 
pathways namely: apoptosis, necrosis and autophagy, with the mitochondria playing a 
crucial role in all processes. The fate of cells is dependent on the availability of ATP, 
with apoptosis initiated in the presence of ATP 
111 and necrosis initiated in the absence. 
Hence,  it  could  be  proposed  that  the  majority  of  cellular  damage  caused  during 
ischaemia (where ATP levels are low) is due to necrosis, while at reperfusion, when 
ATP  levels  are  restored,  apoptosis  will  prevail.    However,  it  is  suggested  that  an 
interplay of necrosis and apoptosis signalling contribute to cellular damage during both 
ischaemia and reperfusion injury 
112. McNully et al, 2004 showed both necrosis and 
apoptosis contributed to IRI in isolated rat hearts 
113. 
1.3.1  Necrosis  
Necrotic cell death is initiated as a consequence of ATP depletion. It is characterised 
by vacuolation of the cytoplasm, breakdown of cellular plasma membranes leading to 
an infiltration of inflammatory mediators around the dying cell, without fragmentation of 
DNA 
114. Severe uncoupling of mitochondria during an ischaemic insult leads to rapid 
ATP  depletion  and  the  onset  of  cellular  necrosis.  However,  if  mitochondrial 
permeabilisation develops heterogeneously and slowly within the mitochondria, ATP 
will deplete at a slower rate triggering the apoptotic signalling pathways described in 
the section below 
115.  
1.3.2  Apoptosis 
Apoptosis  is  also  known  as  ‘programmed  cell  death’  controlled  by  distinct  cellular 
signalling pathways leading to blebbing  but  not  complete  destruction of the cellular 
membrane 
115. Apoptotic bodies containing fragmented nuclear and chromosomal DNA 
of the dying cell are recognised and removed by phagocytic cells without the activation 
of inflammatory mediators.  Apoptotic cell death is achieved via the activation of the 
caspase cascade. Caspases, which belong to a class of enzymes called proteases, 
exist in two types: initiator caspases (which activate downstream caspases, such as 
caspase 8 and 9) and effector (executioner) caspases (such as caspase 3 and 6), 
responsible for the cell damage by cleaving essential functional and structural proteins.   Introduction   
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Apoptosis can be initiated via two mechanisms, the extrinsic death receptor pathway or 
the  intrinsic  mitochondrial  pathway,  which  require  specific  signals  to  be  initiated. 
However, both converge to activate the executioner caspases.  
The extrinsic pathway starts with the activation of sarcolemmal death receptors 
by  death-inducing  ligands  (DIL)  such  as  CD95,  Fas,  TNF-α  and  TNF-related 
apoptosis-inducing  ligands  (TRAIL)  forming  a  death  inducing  signalling  complex 
(DISC). Following this, the initiator caspase-8 is triggered and subsequently it activates 
other  downstream  executioner  caspases  such  as  caspase-3.    All  DIL’s  have  been 
linked to the initiation of the extrinsic death pathway of apoptosis following ischaemia 
and reperfusion 
116.  
The  intrinsic  signalling  pathway  is  initiated  by  non-receptor  mediated 
intracellular stimuli. Intracellular damage such as oxidative stress, DNA modifications 
or  ER  stress  can  trigger  this  pathway  by  activating  B  cell  lymphoma  2  (BCL-2) 
homology  3  (BH3)-only  proteins.  This  activates  pro  apoptotic  BCL-2  associated  X 
protein  (BAX)  or  BCL-2  antagonist  protein  (BAK)  which  cause  mitochondrial  outer 
membrane  permeabilisation  (MOMP).  Anti-apoptotic  BCL-2  (BCL-2/BCL-xL)  proteins 
can prevent MOMP by binding BAX or BAK and inactivating them. Pro-apoptotic BAD 
forms a heterodimer with anti-apoptotic proteins (BCL-2/BCL-xL), inactivating them and 
thus  allowing  BAX/BAK  to  trigger  apoptosis.  The  MOMP  promotes  the  release  of 
cytochrome  c  and  apoptosis  inducing  factors.  Upon  entry  into  the  cytoplasm, 
cytochrome  c  forms  a  complex  with  apoptotic  protease  activating  factor-1  (Apaf-1).  
Binding  of  cytochrome  c  to  Apaf-1  stimulates  Apaf-1  dependent  dATP  hydrolysis, 
causing  a  conformational  change  and  oligomerisation  of  Apaf-1.    This  leads  to  the 
formation of an apoptosome. This structure cleaves and activates caspase-9, initiating 
activation of the executioner caspases, caspase-3 and -7, resulting in apoptosis
117.  
Crosstalk between the two pathways occurs through the activation of caspase-8 
in the extrinsic pathway. Caspase-8 activates another member of the BCL-2 family, 
BID, and subsequently causes MOMP. This initiates the intrinsic mitochondrial pathway 
of apoptosis




Figure 1.16: Apoptotic cell death pathways.  The extrinsic pathway is activated by death-inducing ligands 
(DIL). Binding of DIL to sarcolemmal death receptors activate a death inducing signalling complex (DISC) 
subsequently activating caspase 8. Caspase 8 activates the executioner caspases initiating apoptosis. The 
intrinsic pathway is triggered by intracellular stresses and converges onto the mitochondria. Activation of 
pro-apoptotic  signalling  complexes  cause  mitochondrial  outer  membrane  permeabilisaton  (MOMP), 
releasing cytochrome c and activating executioner caspases. The extrinsic and intrinsic pathways also 
cross talk through caspase-8/BID. 
1.3.3  Other forms of cell death 
A third process considered to contribute to cell death is autophagy, a process of self-
degradation  of  damaged  or  unwanted  cellular  components  or  organelles 
118.  In 
response to cellular stress and certain signals, some cell components are engulfed and 
sequestered  by  autophagosomes  into  the  cytosol  where  they  are  degraded  and 
removed from the cell 
118. Autophagy alongside necrosis and apoptosis occur in cardiac 
myocytes  during  myocardial  infarction,  however,  the  role  of  autophagy  in 
ischaemia-reperfusion injury is not fully defined.  Hariharan et  al, 2011 suggest that 
oxidative stress generated during ischaemia and reperfusion leads to an increase in 
autophagosomes  and  autolysosomes  resulting  in  increased  autophagic  flux  which 
contributes to IRI damage
119. In addition, Zhou et al, 2012 showed that cardiac-specific 
Mfn2  knockout  mice  had  impaired  autophagosome-lysosome  fusion  leading  to  an 
increased  accumulation  of  autophagosomes  and  hence  cardiac  dysfunction 
120, 
suggesting  a  role  for  mitochondrial  dynamics  in  autophagy.  Conversely,  emerging   Introduction   
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evidence suggest a pivotal role of autophagy in cardioprotective strategies against IRI 
121.  In  the  view  of  these  authors,  autophagy  may  increase  cell  survival  by  acutely 
removing damaged cells preventing the initiation of other cell death pathways.  Death 
processes may also share common signals. This has been termed necrapoptosis 
122. 
1.4  Protecting the heart against ischaemia-reperfusion injury  
The heart, as any living tissue, has endogenous protective mechanisms which, when 
activated, render it resistant to cell death, in other words the heart can be “conditioned” 
123 against ischaemia-reperfusion injury.  Initial studies by Murry et al, 1986 
124, showed 
that a protocol of short bursts of ischaemia interspersed with short reperfusion periods 
prior  to  a  prolonged  insult  of  ischaemia  and  reperfusion,  was  associated  with  a 
reduction in MI size by 75%. This was termed ‘ischaemic preconditioning’ (IPC) 
124.  
The phenomenon of IPC is highly reproducible in all species 
123. IPC elicits a biphasic 
pattern  of  protection,  an  acute  phase  of  protection  (transient  effect  lasting  for  2-3 
hours)  and  a  second,  delayed  phase  of  protection  (sustained  effect  lasting  24-72 
hours). This second phase is known as the second window of protection (SWOP)
125, 126.   
    Over  the years,  this protective manoeuvre  was followed by the discovery of 
other  protective  mechanisms  such  as    pharmacological  conditioning 
127  (protection 
against myocardial infarction by the administration of specific drugs), ischaemic post 
conditioning (IPost) 
128 (by using a similar procedure as IPC but applied at the moment 
of reperfusion) and also remote ischaemic conditioning 
129 (whereby, an organ or tissue 
remote  from  the  heart  is  ischaemically  conditioned  with  a  subsequent  increase  in 
resistance versus IRI in the heart).   
1.4.1  Ischaemic Preconditioning 
Since its original discovery, IPC has been extensively studied and the mechanisms by 
which  this  phenomenon  occurs  have  been  well  defined.  It  is  known  now  that  IPC 
involves complex cellular prosurvival pathways. For IPC to be successful, reperfusion 
must follow the lethal ischaemic insult 
130 to allow the triggering components to activate 
the  protective  mediators.  These  triggering  mechanisms  include  the  release  of 
adenosine, opioids, ROS, bradykinin and Ca
2+ that activate various receptor signalling 
pathways  that  converge  onto  the  mitochondria.  Initial  work  by  Liu  et  al,  1991 
demonstrated that protection afforded by IPC was blocked by an adenosine receptor 
antagonist (Gi protein coupled receptor blocker) and the protective effects of IPC could 
be  mimicked  by  exogenous  adenosine 
131.  G-protein  coupled  receptor  (GPCR) 
signalling  appeared  to  play  a  central  role  in  the  IPC  induced  protection,  other   Introduction   
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substances such as bradykinin 
132 and opioids 
133 worked in parallel with adenosine to 
elicit protection via GPCRs with the end effector being activation of protein kinase C 
(PKC), albeit via different signalling pathways 
130. 
    One of the most recognised signalling motifs resulting in cardioprotection is the 
reperfusion  injury  salvage  kinase  (RISK)  pathway 
134.  This  pathway  involves  the 
activation  and  signalling  of  kinase  proteins,  namely  phosphatidylinositol-3-kinase 
(PI3K)  and  Akt,  and  also  Ras/Raf/MEK1/2  and  ERK1/2  following  an  IPC  stimulus.  
Prior to the establishment of the RISK pathway, PI3K was shown to be instrumental, 
with attenuation of IPC’s cardioprotective effect in the presence of PI3K inhibitors 
135, 
136.  
    The serine/threonine kinase Akt is an important cellular signalling molecule that 
can be activated by the binding of ligands to cell surface receptors in the myocardium.  
Ligands  including  growth  factors,  cytokines  or  hormones  interact  with  and  activate 
receptors either by initiating the phosphorylation of intracellular domains of receptor 
tyrosine  kinases  (RTKs)  or  causing  a  conformational  change  of  G-protein  coupled 
receptors (GPCRs). Activation of Akt can result in a plethora of effects depending on 
the substrate and the receptor that is activated. Upon stimulation, the activated RTK or 
GPCR binds to the SH2 domain of the p85 subunit of PI3K, ensuing in the movement 
of the PI3K complex closer to the cell membrane. The PI3K catalytic subunit p110, 
catalyses  the  conversion  of  membrane  bound  phosphatidylinositol-3,4-biphosphate 
(PIP2)  to  phosphatidylinositol-3,4,5-triphosphate  (PIP3).  Akt  and 
phosphoinositide-dependent protein kinase-1 (PDK-1) bind to the PIP3, resulting in a 
complex of Akt/PDK-1/PIP3 at the plasma membrane 
137. Here, Akt is phosphorylated 
and  activated  by  PDK-1  at  threonine-308  and  serine-473.  Phosphorylated  Akt  is 
released  from  the  membrane  complex  and  migrates  throughout  the  cell  activating 
downstream target molecules (summarised in Figure 1.17).  Activation of Akt can be 
hindered by the inhibitory action of phosphoinositide phosphatases on PI3K induced 
production of PIP3.  Protein phosphatase and tensin homolog deleted on chromosome 
10 (PTEN), a protein-lipid phosphatase, specifically catalyses the dephosphorylation of 
PIP3 resulting in PIP2





Figure  1.17: Activation of the  PI3K/Akt pathway.  Activation  of  Akt.  Ligands/growth factors activate 
receptor  tyrosine  kinases  (RTK)  or  G-protein  coupled  receptors  (GPCR)  on  the  plasma  membrane. 
Activation  promotes  phosphorylation  of  SH2  domain  of  the  p85  subunit  of  PI3K  and  sub  sequential 
movement of the PI3K complex closer to the cell membrane. The PI3K catalytic subunit p110, catalyses 
the conversion of membrane bound phosphatidylinositol-3,4-biphosphate (PIP2) to phosphatidylinositol-
3,4,5-triphosphate (PIP3). Akt and phosphoinositide-dependent protein kinase-1 (PDK-1) bind to the PIP3, 
resulting in a complex of Akt/PDK-1/PIP3 at the plasma membrane. Akt-P is liberated into the cytoplasm to 
target downstream signalling molecules.  
 
Akt  signalling  is  central  to  numerous  cellular  processes  including  growth, 
survival,  proliferation,  metabolism,  glucose  uptake  and  also  gene  expression
139 
(summarised  in  Figure  1.18).    Akt  promotes  cell  survival  by  blocking  anti-apoptotic 
signals  and  initiating  pro-survival  signals,  these  effects  are  vital  in  times  of  cellular 
stress  such  as  ischaemia-reperfusion.  Pro-survival  signals  include  the  activation  of 
endothelial nitric oxide synthase (eNOS), which results in an increase of nitric oxide 
(NO). NO serves important roles within the heart including ventricular relaxation and 
regulation  of  vascular  smooth  muscle  proliferation.  In  the  context  of  ischaemia-
reperfusion  injury,  Akt  activation  can  increase  PKG  via  eNOS/NO  and  activate 
mitochondrial PKCε in response to IPC. This mediates the opening of the mitochondrial 
KATP channel
140 and subsequently keeps the mPTP closed, resulting in protection from 
IRI 
141.  
    Other pro-survival targets include phosphorylation and inactivation of glycogen 
synthase  kinase-3β  (GSK-3β)  and  inhibition  of  pro-apoptotic  mediators.  Insulin   Introduction   
59 
 
stimulated  Akt-phosphorylation  was  shown  to  phosphorylate  BAD  at  serine-136 
releasing  anti-apoptotic BCL-xL  from the  BAD/BCL-xL  complex.  The  dissociation  of 
BCL-xL protected cardiomyocytes from stress induced apoptosis
142.  Phosphorylation 
of BAX, at serine-184, by Akt causes a conformational change within BAX preventing 
its translocation to the mitochondria where it usually performs pro-apoptotic actions
143. 
In the heart, deletion of the BAX gene has also been shown to decrease IRI
144.  Akt can 
also  reduce  the  transcription  of  death  receptor  ligands  by  phosphorylating  and 
inactivating  the  transcription  factor  FOXO3a.    Phosphorylation  of  FOXO3a  in  the 
nucleus by Akt results in the shuttling of FOXO3a into the cytoplasm, where it remains 
inactive. Therefore the initiation of apoptotic signalling pathways are reduced 
145.  
 
Figure 1.18: Downstream targets of Akt-P  Akt is central to numerous cellular processes, it can activate 
and de-activate signalling molecules and transcription factors by phosphorylation leading to a plethora of 
effects including cellular survival and metabolism. 
     Recent advances have suggested post translational modifications other than 
phosphorylation could be involved in the protection elicited by IPC, in particular lysine 
acetylation of important signalling molecules during IRI 
146. Silent information regulator 
of transcription (SIRT-1), a class II histone deacetylase has emerged as an important 
player in IR and cardioprotection. Cardiac-specific overexpression protected the mouse 
heart from IRI; moreover this protection was linked to a reduction in oxidative stress 
through SIRT-1 mediated transcription of FoxO1 driving up regulation of pro-survival   Introduction   
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manganese superoxide dismutase and down regulation of proapoptotic molecules
147. 
Nadtochiy  et  al,  2011  demonstrated  that  lysine  acetylation  by  SIRT-1  also  occurs 
during acute IPC leading to reduction in infarct size; inhibition of SIRT-1 activity directly 
or indirectly limited this reduction
148. Moreover, this group also showed that this acute 
protection was mediated by SIRT-1, however not by transcriptional targets but by lysine 
deacetylation  of  signalling  molecules.  p53,  NFκB  and  eNOS  emerged  as  possible 
targets
146,  148.  Interestingly,  SIRT-1  also  modulates  the  autophagic  machinery
146,  a 
critical event in IRI which has recently been linked to IPC related cardioprotection
121, 149.  
These pathways are summarised in Figure 1.19.  
 
Figure 1.19: The cellular mechanisms involved in ischaemic preconditioning  IPC or pharmacological 
agents initiate the release of G-protein coupled receptor (GPCR) agonists which bind to the receptor and 
activate numerous signalling pathways. Phosphatidylinositol-3-kinase (PI3K) and Ras activation, can lead 
to activation of a number of downstream molecules such as Akt, extracellular regulated kinase (ERK), 
nitric oxide synthase (NOS) and inactivation of glycogen synthase kinase-3β (GSK-3β). These converge to 
activate the mitochondrial ATP-dependent potassium channel (KATP), closing the mitochondrial permeable 
transition pore (mPTP) resulting in protection from IRI 
1.4.2  Protective effect of IPC at reperfusion 
It was originally proposed by Jenning’s group that the protection caused by IPC was 
targeting detrimental effects caused during ischaemia 
150, however Hausenloy et al, 
2005 showed that IPC exerts its protection early in reperfusion as well 
151. This led to 
the development of post conditioning strategies, the ability to apply pharmacological or 
ischaemic conditioning after a prolonged ischaemic event, at the onset of reperfusion, a 
scenario that has a more clinically relevant application. The involvement of the RISK   Introduction   
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pathway  kinases  have  been  extensively  studied  as  a  successful  cardioprotective 
strategy  at  reperfusion 
152,  but  the  failure  of  some  groups  to  demonstrate  the 
involvement of RISK kinases in the cardioprotective effect of IPost led to speculation 
that an alternative cardioprotective pathway may exist. In this respect, Darling et al, 
2005 failed to demonstrate a role for PI3K/Akt signalling following IPost 
153 in ex vivo 
rabbit hearts.  Furthermore, in 2009 Lecerda et al demonstrated that application of 
tumor necrosis factor (TNF) at time of reperfusion could mimic IPost in the absence of 
Akt  activation  or  in  the  presence  of  the  PI3K  inhibitor  Wortmannin 
154.    The 
administration of TNF at reperfusion activated the transcription factor, signal transducer 
and activator of transcription 3 (STAT3) which leads to the initiation of pro survival 
JAK/STAT pathway. Thereby, an alternative IPost signalling pathway was proposed: 
the Survival Activating Factor Enhancement (SAFE) pathway 
155.    
1.4.3  Clinically relevant conditioning strategies 
For obvious reasons, direct ischaemic conditioning of the myocardium is not applicable 
in human subjects (apart from surgical settings such as CABG). An intriguing concept 
has emerged that exploits similar endogenous cardioprotective signalling pathways to 
that seen elicited by  direct  ischaemic pre and post conditioning  of the myocardium 
itself. This phenomenon is called remote ischaemic conditioning (RIC). An organ or 
tissue remote from the heart is subjected to short, repeated episodes of ischaemia-
reperfusion initiating cardioprotective signalling pathways that can converge onto and 
protect the heart from the consequences of lethal ischaemia-reperfusion injury. Short 
bursts of hind limb ischaemia-reperfusion cycles have been shown to successfully elicit 




the  major  ischaemic  event.    However,  the translation  of this  procedure  into  clinical 
settings has been controversial, yielding both negative and positive results
159.  
    Activation  of  pro-survival  signalling  cascades  by  ischaemic  conditioning  has 
been proven to attenuate reperfusion induced cell death. Therefore, it was suggested 
that application of appropriate exogenous factors or agents may augment endogenous 
intracellular prosurvival pathways and elicit cardioprotection. Numerous cardio-related 
drugs that are currently prescribed have been shown to have cardioprotective benefits. 
These include statins  (HMG-CoA reductase inhibitors)
160  and  angiotensin-converting 
enzyme  inhibitors  (ACE-I)
161.  Atorvastatin,  administered  during  early  reperfusion, 
reduced infarct size via the activation of the PI3K-Akt pathway
162. The protective effect 
of ACE-I are attributed to bradykinin (BK) associated activation of GPCRs
163. Moreover, 
direct  administration  of  BK  at  reperfusion  also  activated  the  PI3K-Akt  pathway
164.   Introduction   
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However, BK administration also stimulated other RISK pathway components ERK1/2 
kinase and subsequent eNOS activation leading to protection
165. 
    Interestingly,  oral  hypoglycaemic  agents  have  also  been  shown  to  reduce 
cardiovascular  morbidity/mortality.  These  include  metformin,  thiazolidineodiones  and 
most recently incretin therapies (dipeptidyl peptidase-4 inhibitors/ GLP-1 analogues)
166. 
These agents have also been investigated in animal models and will be discussed later 
in more detail. 
1.5  Diabetic heart and Ischaemia-reperfusion Injury 
1.5.1  Diabetes Mellitus 
The  incidence  of  diabetes  is  increasing  at  an  alarming  rate  throughout  the  world. 
Globally,  the  estimated  prevalence  of  diabetes  for  2010  was  285  million  and  is 
expected  to  affect  438 million  people  by  2030 
167.  In  the  UK,  there  are  2.6  million 
people  who  have  been  diagnosed  with  diabetes  (2009)  which  equates  to  a  4.1  % 
average prevalence and it is estimated that 4 million people will be diabetic by 2025 
168.  
Diabetes mellitus is a major risk factor for IHD- patients with diabetes are 2-3 times 
more likely to develop IHD 
169. 
Diabetes mellitus is a metabolic disease that is characterised by a high level of 
glucose in the blood. In normal physiological settings the control of blood glucose is 
tightly regulated. In response to an increase in circulating glucose levels, GLUT2, a 
membrane bound glucose transporter initiates the uptake of glucose passively into the 
pancreatic  β  cells  in  the  islets  of  Langerhans.  Here,  glucose  is  metabolized  by 
glycolysis, resulting in an increased production of ATP and subsequent closure of the 
ATP-sensitive  potassium  channels  in  the  cell  membrane.  This  causes  membrane 
depolarization, opening of voltage gated Ca
2+ channels and an influx of Ca
2+ into the 
β-cell. This accumulation of Ca
2+ triggers the fusion of insulin vesicles and the release 
of insulin into the bloodstream. Insulin binds to insulin specific tyrosine kinase receptors 
(IRS) on the plasma membrane of a variety of tissues, including fat, muscle and liver.  
In fat  and muscle,  insulin  binds  to  the  α-subunit  of  the  IRS  receptor  triggering  the 
tyrosine kinase activity of the β-subunit. Phosphorylation of PI3K at the p85 subunit 
activates  Akt  leading  to  the  translocation  of  the  glucose  transporter  GLUT4  to  the 
plasma membrane and entry of glucose into the cell to be used for energy production 




Figure 1.20: Blood glucose regulation.  Circulating blood glucose enters pancreatic β cells via the Glut-2 
transporter located on the plasma membrane. The generation of ATP from glucose closes the ATP-gated K 
channels causing the accumulation of K+ inside the cell, depolarisation of the membrane potential and 
subsequent  entry  of  Ca2+  into  the  cell.  Ca2+  induced  exocytosis  of  granule  releases  insulin  into  the 
circulation where it can act on peripheral tissues and promote glucose uptake. 
Glucose levels are tightly regulated by the liver. As described,  high glucose 
levels lead to an increase in insulin secretion. At the level of the liver, insulin binds to its 
receptors causing cessation of glucose production accompanied to an escalation in 
glycogen production and storage. When glucose levels fall below a threshold, glucagon 
a  hormone  released  from  the  pancreatic  α-cells,  acts  at  the  liver  to  increase  the 
production  of glucose from  the glycogen  stores.  Insulin  and  glucagon are  two  vital 
hormones required for the liver to ensure glucose levels remain in a narrow range in 
the  circulation  (Figure  1.21).  An  impaired  secretion  or  action  of  either  of  these 
hormones  can  lead  to  high  or  low  blood  glucose,  which  if  left  can  manifest  into 
metabolic conditions.  Diabetes mellitus is a metabolic disease that is characterised by 




Figure 1.21: Regulation of circulating blood glucose.  In response to low glucose, glucagon is released 
from the pancreatic α cells and acts at the liver stimulating glucose release. In response to high glucose 
insulin is released from the pancreatic β cells and acts at peripheral tissues stimulating glucose uptake 
from the circulation. 
There are two types of diabetes mellitus, type 1 diabetes and type 2 diabetes.  
Type 1 diabetes is characterized by the inability of the body to produce insulin; this is 
caused by cellular-mediated programming of the autoimmune system and subsequent 
destruction of pancreatic beta-cells, the cells responsible for insulin production. The 
prevalence of this form of diabetes is relatively low and usually starts early in life 
170.  
Whereas type 2 diabetes is known as the insulin resistant form; insulin is produced, 
however, the target tissues gradually become insensitive or resistant to the action of 
insulin and as a consequence there is an increase in circulating blood glucose levels 
171.  Moreover,  it  has  been  reported  in  type  2  diabetic  patients,  plasma  glucagon 
concentrations  are  inappropriately  high,  which  consequently  increases  the 
hyperglycaemic state driving more production of glucose from the liver
172. This form 
accounts for a high percentage of all diabetes and is historically more common in older 
age groups; however the prevalence of type 2 diabetes in children and young adults is 
also increasing especially in Westernized societies 
173.   
Alongside  the  increased  risk  that  diabetic  patients  have  in  developing  IHD, 
vascular  complications  in  chronic  diabetic  patients  are  also  possible
174  and  can  be 
classified  into  two  types:  microangiopathy  and  macroangiopathy 
175.    Diabetic 
microangiopathy is the term coined to describe the damage caused to small blood 
vessels and capillaries within the body as a consequence of chronic hyperglycaemia.   Introduction   
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The  vascular  endothelial  cells  demonstrate  no  significant  modifications  in  glucose 
transport  in  response  to  high  glucose  therefore  the  vasculature  is  particularly 
vulnerable to intracellular hyperglycaemia and the subsequent associated damage
176. 
Damage  to  these  vessels  can  lead  to  a  decreased  supply  of  oxygen  and  vital 
substrates  to  the  tissues,  which  can  result  in  adverse  clinical  outcomes  such  as 
retinopathy, nephropathy, neuropathy and diabetic foot 
177.  
Diabetic retinopathy is the most common cause of blindness in the UK, with an 
increased  prevalence  in  old  age  and  uncontrolled  diabetes
178.    Clinical  features  of 
diabetic  retinopathy  include  increased  vascular  permeability  resulting  in  macular 
oedema, vascular microaneurysms, lipoprotein drusen deposits and eventual vascular 
proliferation
179. Hyperglycaemia, oxidative stress and advanced glycation end products 
leading  to  increased  apoptosis  in  the  eye  contribute  to  these  features
180.    Diabetic 
patients  have  an  impaired  ability  to  generate  new  blood  vessels  in  response  to 
ischaemia, thereby resulting in reduced collateral vessel formation in ischaemic hearts 
and foot ulcers
181. The healing process of foot ulcers and other chronic wounds have 
been  shown  both  clinically  and  experimentally  to  be  impaired  in  diabetes.  This 
impairment is caused by several other intrinsic factors associated with diabetes such 
as neuropathy and vascular complication, but extrinsic factors such as wound infection 
and callus formation also contribute to this deficiency
182.  
Diabetic nephropathy was classically associated with type 1 diabetes, however 
its prevalence in type 2 diabetes is rising and is considered a principal cause of renal 
end-stage  disease
183.  This  diabetic  complication  is  associated  with 
hyperglycaemia-induced  formation  of  advanced  glycation  end  products 
184  or  by 
increased metabolism. This results in elevated levels of oxidative stress and activation 
of PKC driving the increased production of cytokines
183, 184. As a result, morphological 
changes of the glomerular  basement membrane and mesangial matrix occur which 
correlate with impaired glomerular filtration
183.  
Macroangiopathy as a consequence of diabetes mainly involves an accelerated 
form of atherosclerosis 
185, another risk factor for  cardiovascular disease. It affects the 
larger blood vessels within the body, where an accumulation of fatty materials such as 
cholesterol  can  stick  to  the  vessel  walls  and  impair  blood  flow 
186.    Diabetic 
complications, atherosclerosis, hypertension and many other CV risk factors such as 
old age can all interact and render the heart more susceptible to IHD 
187.   Introduction   
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1.5.2  The diabetic heart 
The diabetic heart is prone to developing pathological conditions that can contribute to 
an increased susceptibility to IHD, such as diabetic cardiomyopathy and angiopathy 
188.  
Diabetic  cardiomyopathy  causes  structural  changes  which  lead  to  abnormal 
functionality  of  the  heart;  these  include  increased  fibrosis,  myocyte  atrophy  and 
apoptosis in the extracellular space of the diabetic myocardium 
189.  These changes 
can  eventually  result  in  left  ventricular  hypertrophy  (LVH)  and  diastolic/systolic 
dysfunction 
190.    Changes  also  occur  at  the  molecular  level  including  endothelial 
dysfunction, metabolic perturbations and differences in cellular signalling 
190, described 
in further detail later.   
Treatments lowering high blood glucose have proved effective in reducing the 
clinical  complications  of  diabetes  however  they  have  not  completely  prevented 
cardiovascular events from occurring. Alternative strategies have been employed to 
target the cellular changes that may occur during hyperglycaemia. 
1.5.2.1  Oxidative stress in diabetes 
Oxidative stress caused by excessive blood glucose has been suggested to be a vital 
link  in  the  progression from  diabetes  to  cardiovascular  disease.  Oxidative  stress  is 
defined  by  a  surplus  accumulation  of  reactive  molecules,  such  as  reactive  oxygen 
species (ROS) and reactive nitrogen species (RNS).  ROS exist in numerous forms 




•OH), and in non-radical forms like hydrogen peroxide (H2O2). RNS molecules 
also  exist  including  the  free  radical  nitric  oxide  (NO)  and  non-radicals  such  as 
peroxynitrite  (ONOO
-) 
191.    These  molecules  have  numerous  beneficial  roles  within 
normal  physiology,  however  become  detrimental  if  they  are  overproduced  or  not 
sufficiently removed.  Moreover, ROS or RNS can lead to subsequent production of 
other free radicals contributing to more pronounced oxidative stress.  
 
•O2
- can be generated from numerous sources; from the vasculature via the 
action  of  oxidase  enzymes  including  NADPH  oxidase  and  xanthine  oxidase  which 
reduce O2 by one electron leading to its formation and also from the electron transport 
chain  (ETC)  within  the  mitochondria.    Under  normal  conditions, 
•O2
-  produced  is 
subsequently  converted  to  the  less  cytotoxic  radical  H2O2  via  enzymes  of  the 
superoxide dismutase (SOD) family, manganese (MnSOD) within the mitochondria and 
copper/zinc (Cu/Zn-SOD) within the cytosol and H2O2 is converted to H2O by catalase 
or gluthathione peroxidase (GPx). NO is produced and released in the vasculature,   Introduction   
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endothelial nitric oxide synthase (eNOS) a cytochrome p450 reductase-like enzyme 
uses  tetrahydrobiopterin  (BH4)  to  transfer  electrons  to  the  amino  acid  L-arginine  to 
produce NO.  




-  to cause  deleterious downstream effects. In the absence of L-
arginine or BH4, eNOS becomes uncoupled and transfers electrons to molecular O2 
and produces 
•O2
- and H2O2.  The potential sources of ROS production are summarised 
in Figure 1.22.  
 
Figure 1.22: The generation of superoxide and reactive oxygen species.  There are numerous sources of 
reactive oxygen species and free radical species in the cell including the electron transport chain (ETC) in 
the mitochondria and vascular oxidase enzymes. Under normal conditions, superoxide (•O2-) is converted 
to  the  less  toxic  radical  hydrogen  peroxide  (H2O2)  via  enzymes  of  the  superoxide  dismutase  (SOD). 
Furthermore, this radical is changed by catalase or gluthathione peroxidase (GPx) into water and oxygen.  
  Mitochondrial  overproduction  of  ROS  is  thought  to  be  the  link  between 
hyperglycaemia and diabetic complications. As described earlier, intracellular glucose 
metabolism begins with glycolysis in the cytoplasm generating pyruvate and NADH, in 
the presence of O2 pyruvate is transported into the mitochondria and enters the ETC to 
produce ATP.  An increase in intracellular glucose up regulates this process, driving 
increased generation of electron donors NADH and FADH2 which lead to an increased 
movement  of  protons  across  the  inner  membrane  and  a  subsequently  high 
mitochondrial membrane potential. This process inhibits electron transport at complex 
III, thereby increasing the lifetime of superoxide producing intermediates of ubiquinone 
such as ubisemiquinone 
192. This increase in oxidative stress has been suggested to be 
the unifying hypothesis linking the proposed mechanisms of hyperglycaemia induced 
diabetic complications 
192. The proposed mechanisms are increased polyol pathway   Introduction   
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flux,  increased  activation of PKC, increased advanced glycation end-product  (AGE) 
formation and increased hexosamine pathway flux, which are reviewed in 
193.  
1.5.2.2  Mitochondria in diabetes 
As already described, mitochondria can contribute to the increased oxidative stress 
seen  in  diabetes.  Mitochondrial  function  is  reflected  by  their  structure,  number  and 
morphology. The distortion of mitochondrial organisation, swelling of mitochondria or 
accumulation of small mitochondria has been frequently reported as a characteristic of 
the diabetic tissue 
194, 195.   
Alterations in mitochondrial morphology are linked to mitochondrial dysfunction.  
Interestingly, dynamic changes in mitochondrial morphology have been associated with 
glucose-induced  overproduction  of  ROS.  Yu  et  al,  2006  demonstrated  that  either 
inhibiting  mitochondrial  fission  or  promoting  mitochondrial  fusion  prevented  ROS 
increase under hyperglycaemic conditions in cardiac cells 
196. Their data suggests that 
mitochondrial fragmentation in response to high glucose leads to ROS overproduction 
via enhanced respiration and mitochondrial hyperpolarization 
196. In accordance with 
this  study,  Makino  et  al  2011  showed  an  increased  mitochondrial  fragmentation  in 
response  to  high  glucose  in  neonatal  cardiomyocytes,  with  an  associated  reduced 
expression  of  fusion  protein  OPA-1  and  moreover  an  increased  O-linked 
N-acetyl-glucosamine  glycosylation  (O-GlcNAcylation)  of  this  protein 
197.  Increased 
O-GlcNAcylation  of  proteins  has  been  related  to  an  increased  activation  of  the 
hexosamine pathway, a pathway that is linked to increased oxidative stress production 
in  diabetes.  In  type  2  diabetic  mice,  high  glucose  induced  an  increased 
O-GlcNAcylation  of  mitochondrial  proteins 
198  and  an  increased  O-GlcNAcylation  of 
cardiac DRP-1 (fission protein) resulting in impaired mitochondrial function 
199. 
Mitochondria  have  their  own  genome  and  the  capability  to  autoreplicate;  their 
proteins can be encoded either by the mitochondrial or by the nuclear genomes. The 
double stranded mitochondrial DNA (mtDNA) contains genes encoding ETC complexes 
and RNAs necessary for translation. Due to their close proximity to the ROS generating 
ETC complex, mtDNA are considered to be at greater risk of mutation
200.  Diabetes 
associated increased oxidative stress augments the occurrence of mtDNA mutations 
leading to a decline in mitochondrial function
200. Rate of mutation is higher in diabetic 
patients compared to non-diabetic patients
201. Left ventricle samples of diabetic GK rat 
hearts and isolated cardiomyocytes exposed to high glucose had significantly more 
mtDNA  damage,  this  resulted  in  an  associated  decline  in  mitochondrial  function
200. 
Oxidative  stress  can  also  indirectly  damage  mtDNA,  Medikayala  et  al,  2011   Introduction   
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demonstrated that ROS augmented topoisomerase DNA cleavage activity that resulted 
in greater mtDNA damage
202.  
1.5.2.3  PGC-1α and diabetes?  
Compromised  mitochondrial  biogenesis  and  hence  function  can  be  influenced  by 
environmental  stresses  and  has  been  linked  to  numerous  diseases
40,  especially 
between metabolic and cardiovascular diseases.  Inactivation or down regulation of 
PGC-1α has been implicated in diabetes
42.  
PGC-1α is essential to maintain an efficient control on energy metabolism and 
mitochondrial  functionality.  If  the  expression  or  modulation  of  this  coactivator  is 
hindered,  functional  defects  can  occur  such  as  decreased  cardiac  contractility.    A 
diabetes-associated down regulation of PGC-1α expression and its associated genes 
has been demonstrated in skeletal muscle
203, 204 and also in the heart of STZ diabetic 
rats
205.  Interestingly,  Duncan  et  al  showed  in  their  murine  model  of  the  metabolic 
syndrome that in the early phases of insulin-resistance  and diabetes, mitochondrial 
biogenesis  is  driven  by  an  up  regulation  of  the  PPARα/PGC-1α  gene  regulatory 
pathway
206.  This overexpression of PGC-1α is likely to be a compensatory mechanism 
to facilitate the use of the increased fatty acid load in the heart. In the later stages of 
diabetes or as the diabetic heart ages, the PGC-1α expression and pathway are down 
regulated  and  therefore  the  risk  of  heart  failure  may  increase 
207,  208.  Interestingly, 
Zhang  et  al,  2013  showed  that  chronic  administration  of  a  novel  small  molecule 
ZLN005, in myotubes and skeletal muscle of diabetic mice, led to activation of AMPK 
and  subsequent  up  regulation  of  PGC-1α.  This  led  to  increased  fat  oxidation  and 
improved glucose tolerance, pyruvate tolerance and insulin sensitivity
209.  
1.5.2.4  Energy metabolism in diabetes 
Myocardial energy is provided in a dynamic manner. Numerous substrates are utilized 
to  produce  ATP  in  order  to  meet  the  energy  demands  of  the  heart.  As  previously 
mentioned,  mitochondrial  fatty  acid  oxidation  (FAO)  is  the  main  source  of  energy, 
however the utilization of glucose as an energy substrate is still pivotal in maintaining 
ATP production under a variety of physiological conditions. In the diabetic heart, the 
utilization of glucose as an energy substrate is greatly decreased, with an increased 
reliance on fatty acid oxidation to provide energy (Figure 1.23). Fatty acids are a less 
efficient substrate than glucose, even though FAO generates a greater amount of ATP, 
more  oxygen  molecules  are  required  per  ATP  molecule  produced
210.    This  shift  in 
metabolism and reliance on FAO imposes stress on the cardiomyocyte contributing to   Introduction   
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eventual diabetic cardiomyopathy. Myocardial glucose utilization can be compromised 
at numerous points; in type 2 diabetic animals reduced GLUT-4 protein expression and 
depressed insulin signalling hinders the control of myocardial glucose and uptake, and 
also increases circulating free fatty acids
210, 211. Moreover, fatty acids also inhibit insulin 
signalling pathways reducing insulin action, which further hampers the use of glucose 
as an energy substrate. Folmes et al 2006 showed that fatty acids also attenuate the 
insulin regulation of AMPK, the metabolic switch in the heart in the control of glucose 
and FAO
212. Enhanced fatty acid uptake is facilitated by increased expression of fatty 
acid  transporters,  CD36  and  FABPpm,  in  STZ-induced  diabetes
213.  Furthermore,  in 
Zucker fatty rats, these transporters translocate to the cardiomyocyte plasmalemmal 
membrane to enhance fatty acid uptake
214.  
  The  nuclear  receptor,  PPAR-α,  is  a  main  regulator  of  cardiac  fatty  acid 
metabolism.  It’s target genes include those encoding proteins involved in fatty acid 
uptake  and  utilization.    In  diabetic  animal  models  during  early  phases  of  insulin 
resistance  increases  in  circulating  lipids  activate  PPAR-α  and  subsequent  genes 
involved in FAO
215. Alongside this action, PPAR-α activation reduces the expression of 
genes  that  regulate  the  uptake  and  utilization  of  glucose
215.  Removal  of  cardiac 
PPAR-α restored the expression of such genes including GLUT-4, promoting glucose 
uptake  and  improved  myocardial  recovery  following  ischaemia
216.  Interestingly, 
transgenic PPAR-α mice exhibit a metabolic phenotype similar to diabetic hearts.  It 
appears that these diabetes-associated alterations in cardiac metabolism precede the 
development of cardiomyopathy and cardiac dysfunction.   
Changes  in  cardiac  metabolism  in  the  diabetic  heart  can  influence  Ca
2+ 
homeostasis,  cardiac  efficiency,  glucotoxicity  and  eventual  mitochondrial 
dysfunction
217, all of which will influence the ability of the heart to withstand injury such 
as  IRI.  Hyperglycaemia-induced-diabetic-complications  have  been  linked  to  diabetic 
cardiomyopathy.  However  as  described,  the  decreased  uptake  of  glucose  in  the 
diabetic heart may suggest that β-oxidation of fatty acids may drive oxidative stress in 
diabetes leading to such complications.  




Figure 1.23: Energy metabolism in the diabetic heart.  Insulin resistance alongside a decrease in the 
glucose transporter Glut-4 at the plasma membrane in type 2 diabetes result in a decreased entry of 
glucose  into  the  cell  for  the  production  of  ATP.  As  a  compensatory  mechanism,  the  diabetic  heart 
becomes reliant on fatty acids as a substrate for ATP production. Free fatty acids enter the cell via the 
fatty acid transporters (CD-36/FABP) resulting in an accumulation of long chain fatty acyl CoA (LCFA-CoA). 
LCFA-CoA is transported into the mitochondria via carnitine palmitoyl transferase 1 (CPT-1) (as described 
in Figure 1.5), converted to acetyl CoA (AcCoA) and enters the Krebs cycle (KC).  An increase in cytoplasmic 
LCFA-CoA also contributes to decreased glycolysis by inhibitory actions on hexokinase, insulin receptor 
substrate 1 (IRS1) and increasing the activity of peroxisome proliferator-activated receptor alpha (PPARα). 
PPARα decreases the transcription of the glucose transporter Glut4 therefore additionally decreasing the 
possible entry of glucose into the cell. 
1.5.3  Susceptibility of the diabetic heart to ischaemia-reperfusion injury  
Numerous studies suggest that the diabetic heart is more susceptible to IRI
217, 218. This 
has  been  demonstrated  in  both  type  1  and  type  2  diabetic  models.  Utilizing  acute 
hyperglycaemia and type 1 diabetic models; Marfella et al, 2002 showed that isolated 
non-diabetic  rat  hearts  retrogradely  perfused  with  a  hyperglycaemic  (33mmol/L 
glucose) buffer had a greater infarct size following ischaemia and reperfusion ex vivo 
than rat hearts that were perfused with normoglycaemic buffer 
219.  Moreover, diabetic 
rats induced by a high dose of STZ (70mg/kg for 9 days) exhibiting blood glucose 
levels of 22mmol/L were more susceptible to ischaemia/reperfusion injury in vivo than   Introduction   
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normoglycaemic  rats 
219.    Hyperglycaemic  conditions  in  both  models  caused  a 
decreased transactivation of the hypoxic inducible factor HIF-1α, which controls the up 
regulation  of  vascular  endothelial  growth factor  (VEGF)  in  response  to  hypoxia,  an 
essential mediator of neovascularization following ischaemia 
219. An impairment of this 
axis, as seems the case in these diabetic models and other diabetic tissue
220, will lead 
to  inadequate  revascularization  of  coronary  vessels  following  ischaemia  and  hence 
could produce worse outcomes for the diabetic patient
220.   
A lower dose of STZ (50mg/kg) administered to rats for a longer time period of 
6  weeks  caused  an  increased  sensitivity  to  IRI  in  vivo  in  rats,  accompanied  by 
decreased phosphorylation of Akt, VEGF and NO and increased levels of caspase-3 
221. Interestingly, in this investigation when STZ was administered for only 2 weeks 
prior  to  experimentation,  the  opposite  outcome  was  recorded  with  a  decreased 
susceptibility to IRI and subsequent signalling changes were reversed
221.  Other rodent 
studies also showed infusing high glucose during ischaemia caused an increase in 
apoptosis and infarct size. They attributed this effect to decreased phosphorylation of 
‘pro-survival’ Akt resulting in de-phosphorylation and increased ‘pro death’ activity of 
GSK-3β 
222.  With  regard  to  the  possible  mechanism,  hyperglycaemia  in  rat 
cardiomyocytes was shown to promote p53-dependent activation of apoptosis
223. Acute 
hyperglycaemia has also been shown to increase the susceptibility to infarction in non-
rodent models; 15% dextrose infused prior to IRI in vivo or chemically induced diabetes 
(3 weeks STZ) in dogs’ increased MI size
224. Furthermore, rabbits infused with 50% 
dextrose to elicit a hyperglycaemic state of 600mg/dl prior to ischaemia, also recorded 
a greater susceptibility to infarction in vivo
225.  
Models of type 2 diabetes have also demonstrated an increased susceptibility 
to IRI; interestingly these studies were performed in vivo or ex vivo with the addition of 
fatty acid substrates in the perfusate, similar to those likely to be found in the in vivo 
scenario. The GK rat heart subjected to IRI ex vivo with extra substrates additional to 
glucose demonstrated larger infarct sizes compared to control hearts
226.  Studies of IRI 
in diabetic db/db mice in vivo also support a diabetes-associated increase in MI size
227, 
228. The sensitivity of the type 2 diabetic heart in in vivo settings has had limited study 
compared to type 1 diabetes. 
On  the  other  hand,  there  has  been  a  plethora  of  evidence  suggesting  the 
diabetic heart is paradoxically less susceptible to IRI. Investigations using a STZ-rat 
model both in vivo 
221, 229 and ex vivo 
230 demonstrated that acute diabetes (1-4 weeks 
of STZ treatment) resulted in a decreased susceptibility to IRI.  Furthermore, Nawata et   Introduction   
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al, 2002 also found that 4 weeks of STZ-induced diabetes reduced sensitivity to low 
flow  global  ischaemia  followed  by  reperfusion  in  the  Langendorff-perfused  isolated 
heart model 
231.  Interestingly, these isolated heart experiments were conducted in the 
absence  of  any  additional  substrates  other  than  glucose.    This  phenomenon  of 
protection in the acute diabetic setting was also present in other animal models such as 
alloxan-induced  diabetes  in  Yucatan  pigs
232.    Following  regional  coronary  artery 
occlusion  and  reperfusion  in  vivo,  myocardial  infarct  size  was  smaller  compared to 
control  however  global  left  ventricular  function  was  worse  in  diabetes  but  function 
within the area at risk was better. This reduction was accompanied by an increased 
expression of cell survival proteins
232.  Neonatal rat cardiomyocyte cells were protected 
against simulated IRI when incubated for 3 days with 25mM glucose compared to 5mM 
glucose in the medium. The high glucose treatment caused a reduction in necrosis, 
apoptosis and calcium content during hypoxia, alongside an increase in anti-apoptotic 
protein Bcl-2 expression. In addition, pro-apoptotic BAD shifted to its inactive state in 
the presence of 25mM glucose
233. 
In contrast to the data described thus far which suggests short term induction of 
diabetes renders the heart more resistant to IRI, long term induction of diabetes has 
also been shown to elicit a cardioprotective effect.  An 8 week induction of diabetes in 
rabbits using the chemical alloxan prior to IR resulted in a decreased MI size following 
30 minutes myocardial ischaemia and 3 hours reperfusion in vivo compared to non-
diabetic rabbits
234.  Furthermore, no difference in infarct size was seen in non-diabetic 
rabbits  infused  with  high  glucose  throughout  myocardial  ischaemia  and  reperfusion 
compared  to  controls.  They  suggested  that  the  presence  of type  1  diabetes  in  the 
rabbit  induced  a  chronic  and  metabolic  cardioprotective  state  in  the  heart 
234. 
Interestingly, a shorter (6 weeks) alloxan induction protocol in rabbits had no effect on 
the vulnerability to IRI compared to controls 
225. Intriguingly, chronic administration of 
STZ  for  12  weeks  in  rats  also  showed  a  decreased  susceptibility  to  MI;  however 
experiments were performed ex vivo with no additional perfusion substrates
235.  Other 
investigators have also shown that acute initiation of type 1 diabetes does not influence 
the susceptibility to MI. Both alloxan and STZ-treated dogs, although at a lower dose to 
previously mentioned investigations, reported no difference in MI size following IRI in 
vivo 
236.  
In 2004, Kristiansen et al 
237 used two distinct models; the GK rat and ZDF rat to 
investigate  the  susceptibility  to  IRI  in  type  2  diabetes.  They  showed  in 
Langendorff-perfused  isolated  hearts  (with  no  added  substrates),  that  MI  size  was 
smaller than their respective non-diabetic controls 
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the isolated heart model, however with a shorter ischaemic time, and it appears that 
the hearts isolated from the GK rat is less susceptible to infarction than the Wistar rat 
control 
238,  however  no  statistics  are  shown.  Of  interest  the  perfusion  buffer  also 
contained no extra substrates other than glucose.  Supporting these findings, isolated 
GK rat heart cardiomyocytes were less susceptible to mPTP opening in response to 
calcium, achieved by adding soluble Ca
2+ to a phosphate-containing medium. This was 
accompanied by a larger calcium accumulation, leading to decreased opening of the 
mitochondrial pore and reduced cardiomyocyte death 
239. Controversially, two recent 
investigations that have been performed in vivo in the GK rat showed no difference in 
the  susceptibility  to  infarct  compared  to  control  rats  following  30  or  35  minutes 
ischaemia and 2 hours reperfusion  
240, 241.  
Interestingly, Yan et al, 2013 suggest the diabetic ob/ob mouse heart in vivo 
and isolated cardiomyocytes are more vulnerable to IRI. The diabetic mice exhibited 
hypoadiponectinemia  which  impaired  AMPK-PGC-1α  signalling  resulting  in 
dysfunctional  mitochondrial  biogenesis  and  hence  more  susceptible  to  MI  injury. 
Moreover,  treating  hypoadiponectinemia  prevented  mitochondrial  dysfunction  and 
promoted cardioprotection against IRI
242.  
 
Figure 1.24: Possible intracellular changes within the diabetic heart.  Possible intracellular changes that 
may render the diabetic heart A. more or B. less susceptible to ischaemia-reperfusion injury (see text for 
more details).   Introduction   
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From  the  experimental  data  collected  thus  far  it  seems  a  common  pattern  has 
developed in the studies that have shown the diabetic heart be less sensitive to acute 
IRI they used glucose as the only substrate (ex vivo); used a short duration of diabetes 
(<6 weeks); and used a no flow IRI protocol, whereby global ischaemia is initiated by 
total  interruption  of  the  perfusate  to  the  heart.  When  experimental  protocols  better 
reflected the clinical scenario i.e. fatty acids were present in the perfusate  ex vivo, 
diabetes was more prolonged and severe and a low-flow IRI protocol was used, the 
diabetic heart was found to be more sensitive to IRI 
218.The aforementioned data is 
summarised in tables 1.1-1.3. 
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Substrates  Model of 
diabetes  Parameters 
Jones et 
al, 1999
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30min regional  
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Table  1.1:  Studies  indicating  the  diabetic  heart  is  more  sensitive  to  ischaemic  injury  compared  to 
normoglycaemic controls(tables from 
217)   Introduction   
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Ma et al, 
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Table  1.2:  Studies  indicating  the  diabetic  heart  is  less  sensitive  to  ischaemic  injury  compared  to 
normoglycaemic controls(table from 
217) 
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Table 1.3: Studies indicating no difference in the sensitivity of the diabetic heart to ischaemic injury 
compared to normoglycaemic controls(table from
 217)  
 
1.5.4  Protecting the diabetic heart against ischaemia-reperfusion injury 
1.5.4.1  Ischaemic “conditioning” 
Numerous studies have suggested that the diabetic heart is resistant to ischaemic pre 
conditioning (IPC) protocols that have been successfully shown to reduce infarct size 
caused by IR in non-diabetic hearts. For example, Kristiansen et al in 2004 showed in 
both the ZDF and GK rat, that 1 cycle of IPC could not protect  hearts from  either 
diabetic  model  from  damage  caused  by  IR
237.  Further  to  this,  Tsang  et  al,  2005 
demonstrated that 1 or 2 cycles of IPC (5 min ischaemia/10 min reperfusion) did not 
protect the GK diabetic heart from subsequent damage however when subjected to 3 
cycles  of  IPC,  infarct  size  was  reduced 
238.    Subsequently,  they  found  that  in  the 
diabetic heart the basal level of Akt phosphorylation was lower compared to the non-
diabetic  heart  and  therefore  an  increased  IPC  stimulus  is  required  to  achieve  an 
essential  level  of  Akt  phosphorylation  necessary  to  mediate  cardioprotection 
238. 
Interestingly, Sivaraman et al also showed that an enhanced IPC stimulus was required 
to achieve an essential level of Akt phosphorylation to protect atrial trabeculae isolated 
from diabetic patients
244. 
Increasing the stimulus of IPC by increasing cycle number appears important in 
diabetes; for example Bouchard et al in 1998 also demonstrated that an IPC stimulus 
consisting  of  1  cycle  of  5  minutes  ischaemia  followed  by  10  minutes  reperfusion 
(IPC-1)  was  not  sufficient  to  preserve  the  vasodilatory  response  to  5-HT;  however 
when the IPC stimulus was increased to 3 cycles this response was recovered 
245. An 
impaired vasodilatory response to 5-HT suggested an impairment of endothelial cells in 
the diabetic heart and consequently the inability to generate and release enough NO. 
In  the  same  investigation,  30  minutes  pre-treatment  with  adenosine,  an  important 
mediator of IPC 
246, mimicked the cardioprotective effect of IPC. However, 15 minutes   Introduction   
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pre-treatment, showed to be efficient in a non-diabetic heart, was ineffective
245. These 
findings  suggested  that  signalling  pathways  activated  by  adenosine  either 
endogenously or exogenously may be hindered in diabetic coronary vessels, but have 
the potential to be recovered by an increased stimuli.  
The duration of IPC cycling may also play an  important role in producing a 
protective effect in the diabetic heart; four cycles of 2 minutes ischaemia followed by 3 
minutes reperfusion was insufficient to produce protection in two separate models of 
diabetes 
237, whereas 3 cycles of 5 minutes ischaemia and 10 minutes reperfusion in 
the same animal and experimental setting was
238. 
Investigations in diabetic animals have reported a reduced sensitivity to KATP 
channel  activators 
247;  a  channel  involved  in  the  mechanism  of  protection  by 
adenosine
58  and  IPC
58.  The diabetic  heart may  need  an  increased IPC  stimulus to 
achieve  sufficient  KATP channel activation to  subsequently  inhibit the  mPTP, reduce 
apoptosis and limit myocardial cell death 
248. The suggestion of a dysfunctional KATP 
channel in diabetes was further supported by a study in alloxan/STZ induced diabetes 
in dogs 
249. 
Hotta et al, 2010 
250 failed to elicit cardioprotection with pre-treatment with an 
opioid agonist
251 or erythropoietin (EPO) 
252 in an Otsuka Long Evans Tokushima Fatty 
(OLETF)  type  2  diabetic  rat  in  vivo  model.    These  agents  known  to  mediate  IPC 
signalling through Janus kinase (Jak-2), caused insufficient phosphorylation of Jak-2 
and Akt
250. They also found an elevated level of calcineurin activity in diabetic hearts in 
accordance  with  other  studies
253.  Interestingly,  following  2  weeks  treatment  with 
Angiotensin  II  receptor  type  1  (AT1)  receptor  blockers,  valsartan  or  losartan,  EPO 
elicited a cardioprotective effect alongside  restoration of Jak-PI3K-Akt signalling 
250. 
Huisamen  et  al,  2011  supported  the  finding  that  AT1  antagonism  can  lead  to 
cardioprotection in their ex vivo rat model of insulin resistance, diet-induced obesity 
(DIO) rat 
254.  
As described, diabetes has an impact on cardioprotective signalling in the heart. A 
potential role for direct targeting of GSK-3β, a molecule downstream of many of the 
aforementioned signalling pathways, has been postulated by many groups. Ghaboura 
et  al,  2011,  found  EPO  administration  as  an  IPost  mimetric  did  not  increase  the 
phosphorylation of Akt, ERK or GSK-3β and hence protect isolated hearts from STZ 
rats. Whereas high-fat diet (HFD)-induced insulin resistance syndrome (HFD) rats were 
protected following EPO. They found that direct administration of a GSK-3β antagonist 




255.  Furthermore, Gross et al, 2007 
256 also showed that STZ-induced diabetes 
caused alterations in pathways upstream of GSK-3β, such as PI3K, Jak/STAT  and 
MAPK  pathways,  therefore  limiting  the  cardioprotective  effects  of  morphine 
administered  at  reperfusion.    Similarly,  downstream  antagonism  of  GSK-3β  was 
cardioprotective 
256. The direct inhibition of GSK-3β was also proved cardioprotective in 
a rat model of type 2 diabetes
257. 
1.5.4.2  Pharmacological “conditioning” with some anti-diabetic drugs 
Numerous risk factors coexist in the insulin resistant state including an adverse lipid 
profile  and  a  prothrombotic  milieu,  alongside  hyperglycaemia  which  contributes  to 
endothelial dysfunction and oxidative stress
258. All of which can enhance the risk of 
CVD  by  increasing  the  development  of  atherosclerosis
258.  Simply  lowering  blood 
glucose  provides  some  beneficial  effects  on  cardiovascular  risk  reduction,  however 
anti-diabetic  agents  have  proven  to  have  a  plethora  of  effects,  including  innate 
cardioprotective properties
259.  
Metformin,  an  oral  anti-diabetic  drug  from  the  biguanide,  insulin  sensitizing 
class, has been suggested to elicit cardioprotective effects 
259. The UKPDS (United 
Kingdom  Prospective  Diabetes  Study)  indicated  that  patients  receiving  this  drug 
developed  a  significantly  lower  incidence  of  cardiovascular  events 
260.  There  are 
various  mechanisms  that  have  been  suggested  to  play  a  role  in  metformin’s 
glucose-lowering effect, including inhibition of complex I of the mitochondrial respiratory 
chain 
261, decreasing hepatic glucose production 
262, increasing glucose uptake 
263 and 
stimulation  of  adenosine  monophosphate-activated  protein  kinase  (AMPK) 
264. 
However, the cardioprotective effect exerted by metformin could be independent of its 
hypoglycemic  actions.  This  statement  is  supported  by  studies  performed  in 
normoglycaemic animals exhibiting smaller infarct volumes following acute metformin 
administration 
265.   
1.5.4.2.1  Metformin 
1.5.4.2.1.1  Mechanism of action as a diabetic drug 
Metformin belongs to the biguanide class of drugs that augments or mimics insulin 
action and lowers plasma glucose levels in patients with type 2 diabetes
266. It exerts its 
glucose lowering effects through inhibition of hepatic gluconeogenesis and increases 
insulin-stimulated  glucose  uptake  in  skeletal  muscle  and  adipocytes
266.  Metformin 
inhibits complex I of the respiratory chain within mitochondria responsible for oxidative 
phosphorylation
267. Due to complex I being the entry point for NADH, inhibition leads to   Introduction   
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a  change  in  the  mitochondrial  proton  gradient  and  ATP  production  is  reduced 
producing  an  increase  in  the  AMP  to  ATP  ratio
267.  AMPK  is  also  activated  by 
metformin,  subsequently  reducing  cellular  glucose  by  promoting  glucose  uptake  in 
skeletal muscle
268, increasing oxidation of fatty acids and inhibiting glucose production 
in  the  liver
264.  Alternatively,  metformin  has  been  demonstrated  to  suppress  hepatic 
gluconeogenesis  through  the  induction  of  SIRT1  and  GCN5
269.  In  diabetic  mice, 
metformin increased the levels of these proteins with subsequent reduction in plasma 
glucose  and  insulin.  Moreover,  SIRT-1  was  increased  through  an  AMPK  mediated 
pathway.  Interestingly, levels of GCN5 were dramatically reduced in diabetic mice
269. 
Recent evidence disputes the absolute requirement of AMPK for the glucose lowering 
effect of metformin.  AMPK-independent effects of metformin, include an increase in 
AMP  levels  through  inhibition  of  AMPdeaminase  (AMPD)
270.  Administration  of 
metformin  in  mice  was  found  to  directly  decrease  energy  charge  within  the  cell, 
independent of AMPK, supressing gluconeogenesis and hence glucose levels
270, 271. 
Metformin was also found to decrease the plasma levels of free fatty acids and very 
low-density  lipoprotein,  LDL-cholesterol  and  to  increase  HDL-cholesterol,  hence 
improving  the  lipoprotein  profile  of  insulin  resistant  patients
266.  Studies  in  animal 
models and patients have also demonstrated that metformin treatment increases the 
availability  of  NO  thereby  improving  endothelium  dependent  vasodilation
272,  273. 
Somewhat  unsurprisingly,  the  beneficial  effects  of  metformin  on  cardiovascular  risk 
factors  was  reflected  by  the  United  Kingdom  Prospective  Diabetes  Study  Group 
(UKPDS) demonstrating a reduced risk of all-cause mortality in type 2 diabetic patients 
treated  with  metformin
274.  Moreover  a  39%  risk  reduction  of  myocardial  infarction 
compared  with  conventional  treatment
274.  In  addition,  a  more  recent  study  reported 
metformin  was  successful  in  reducing  mortality  in  diabetic  patients  also  with  heart 
failure
275. Metformin has been shown to be cardioprotective against IRI
266, and AMPK is 
thought to play an essential role in this.  
1.5.4.2.1.2  AMPK 
AMPK has evolved as a principal regulator of energy metabolism by phosphorylating 
key enzymes or transcription factors/coactivators in response to cellular stresses. In 
1973,  a  physiological  role  for  AMPK  was  described  whereby  acetyl-coenzyme  A 
carboxylase (ACC) was phosphorylated and dephosphorylated specifically by AMPK in 
response to changes in intracellular ATP/AMP ratio during energetic stress
276. AMPK is 
a  heterotrimeric  protein,  consisting  of  a  catalytic  α-subunit  and  regulatory  β-  and 
γ-subunit. In response to cellular stressors such as hypoxia or ATP deficiency, levels of   Introduction   
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AMP increase promoting the interaction and binding of AMP to the γ-subunit. AMP can 
activate  AMPK  by  three  mechanisms;  allosteric  activation,  phosphorylation  and 
inhibition of dephosphorylation
277. AMP promotes activation of AMPK by stimulating 
phosphorylation of threonine-172 in the activation loop of the α-subunit by upstream 
AMPK kinases LKB-1 and calmodulin dependent protein kinase kinase (CaMKK); this 
activation is facilitated by a  conformational change within the α and γ subunits 
278. The 
combined  allosteric  and  phosphorylation  effects  causes  a  >1000-fold  increase  in 
kinase activity, providing AMPK with the ability to respond to small changes in energy 
status
279. The activation and consequences of AMPK are summarised in Figure 1.25. 
 
Figure 1.25: Structure, function and activation of AMPK.  An increase in the AMP/ATP ratio promotes the 
interaction and binding of AMP to the γ-subunit, this promotes a conformational change within AMPK 
allowing  phosphorylation  and  activation  by  AMPK  modulators.  Activated  AMPK  influences  metabolic 
processes and subsequently restores the ATP/AMP ratio. 
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1.5.4.2.1.3  Metformin and cardioprotection against IRI 
An initial study by Charlon et al in 1988 demonstrated the cardioprotective potential of 
metformin 
280.  Oral administration of metformin to rats prior to permanent coronary 
artery ligation reduced infarct size 
280. Since then, metformin has been demonstrated to 
elicit  protection  against  myocardial  infarction  in  numerous  models  of  IRI  when 
administered at different time points including before ischaemia and also at the onset of 
reperfusion.  In  non-diabetic  animals,  metformin  has  consistently  demonstrated  to 
reduce infarct size. Solskov et al, 2008 showed that pre-treatment with metformin 24 
hours before being subjected an IR protocol in non-diabetic Wistar rats reduced infarct 
size ex vivo compared to control rats and that metformin treatment acutely increased 
AMPK  activity
265.    In  further  studies  using  non-diabetic  animal  models,  metformin 
administered during reperfusion  ex vivo
281-283  and  in vivo
282,  284  significantly reduced 
infarct size. Metformin given before ischaemia also elicited a cardioprotective effect
284. 
Interestingly,  following  the  conclusion  that  metformin  can  successfully  reduce 
myocardial  injury  and  preserve  cardiac  function  in  non-diabetic  rats,  a  clinical  trial 
(GIPS)-III, investigating the efficacy of metformin in non-diabetic patients presenting in 
the clinic with ST elevation myocardial infarction is now underway 
285.  
   Studies using diabetic animals have been less consistent. Calvert et al, 2008 
284 
and Bhamra et al, 2008 
281 report positive effects of metformin in diabetic mice and rats 
respectively, whereas Kravchuck et al, 2011 
286 fail to see a cardioprotective effect with 
metformin in diabetic rats. This discrepancy could result from the choice of diabetic 
model and experimental protocol.  Kravchuck et al used a neonatal STZ model of type 
2 diabetes and subjected hearts to global ischaemia 
286,  whereas, the previous studies 
used genetic or sporadic models of type 2 diabetes and ligated the coronary artery to 
induce regional ischaemia
281, 284.  Moreover, their injury was not severe enough, with an 
infarct size of only approximately 25% in diabetic hearts. It is plausible to suggest that 
this why they could not achieve a significant reduction in infarct size with metformin in 
their experimental set up. 
   The  cardioprotective  effect  of  metformin  has  been  attributed  to  numerous 
signalling  pathways,  including  AMPK  activation,  adenosine  receptor  activation  and 
activating  the  RISK  signalling  pathway.  Bhamra  et  al,  2008  demonstrated  that 
metformin treatment at the onset of reperfusion induced a significant increase in RISK 
kinase signalling, specifically an increase in phosphorylation of Akt in both Wistar and 
diabetic GK rats. Administration of a PI3K inhibitor, LY294002, abolished not only the 
Akt  activation  but  also  the  infarct  limiting  effects  of  metformin.    Furthermore,  they   Introduction   
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concluded that mPTP opening in isolated cardiomyocytes was delayed with metformin 
treatment due to the activation of PI3K/Akt signalling 
281.  In a murine model of IRI, 
Calvert et al showed that metformin’s protection was dependent on the activation of 
AMPK
284. They also showed that the phosphorylation of AMPK occurs and remains 
active  for  more  than  24  hours  following  reperfusion.  Interestingly,  without  an 
ischaemia-reperfusion protocol, AMPK was still activated following low dose metformin 
administration. Furthermore, metformin failed to reduce infarct size in cardiac specific 
AMPK-α2 dominant negative transgenic mice
287. Additional experiments showed that 
metformin-activation  of  AMPK  is  subsequently  followed  by  eNOS  phosphorylation; 
without this activation protection was lost
284, 287. The importance of AMPK in metformin 
induced  cardioprotection  was  further  elucidated  by  Yellon  and  colleagues, 
metformin-associated reduction in infarct size was abolished by the co-administration 
of Compound C, an AMPK inhibitor. This inhibitory effect of Compound C was only 
produced when added during the first 5 minutes of reperfusion, suggesting that AMPK 
activation may occur early in reperfusion
283.  
Adenosine release and the subsequent activation of its receptors is known to 
trigger  the  RISK  pathway  and  lead  to  infarct  size  limitation
288.  Intracellular  AMP,  a 
modulator of AMPK activity
289, also contributes to the intracellular release of adenosine. 
Blocking  the  intracellular  transport  of  adenosine  outside  the  cell  with 
nitrobenzylthioinosine  or  using  8-p-sulfophenyltheophylline  (an  adenosine  receptor 
blocker) during reperfusion prevented the infarct reducing effects of metformin in non-
diabetic  rat  hearts  suggesting  an  importance  of  adenosine  in  metformin  associated 
protection
282.  Whether  adenosine  plays  a  role  in  the  diabetic  heart  has  not  been 
investigated. Recent studies have implicated PPAR-α and it’s associated coactivator 
PGC-1α in the cardioprotective action of metformin. Barreto-Torres et al, 2012 showed 
that metformin increased phosphorylation of AMPK leading to improved recovery of 
cardiac function during acute IR, a reduction in cell death and an increased respiration 
at  complexes  I  and  II  with  a  subsequent  reduction  in  mPTP  opening  in  isolated 
mitochondria. These protective effects of metformin were abolished in the presence of 
a PPAR-α inhibitor, however, intriguingly no changes in PPAR-α or PGC-1α expression 
were seen following the acute metformin treatment used in this model 
290.   
Data resulting from the use of acute metformin treatment as a cardioprotective 
agent  have  produced  mostly  positive  outcomes;  however  type  2  diabetic  patients 
usually take metformin on a long term or chronic basis. Not only has metformin been 
shown to decrease damage caused by IRI but animal models receiving metformin for 
longer periods of time have shown that this drug can limit cardiac remodelling and the   Introduction   
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development of heart failure
287, 291.  Gundewar et al, 2009 showed that a single dose of 
metformin  at  reperfusion  reduced  infarct  size  but  did  not  prevent  cardiomyopathy 
whereas chronic administration of metformin for 4 weeks was successful in limiting 
cardiac hypertrophy and associated deteriorations in heart function. Chronic metformin 
treatment is thought to improve mitochondrial biogenesis, by activating AMPK, eNOS 
and PGC-1α
287. Studies investigating the chronic effects of metformin treatment on the 
heart are more limited, with no studies being conducted in aged, diabetic animals. 
1.5.4.2.2  GLP-1 associated therapies 
Incretins  are  a  group  of  gastrointestinal  hormones  that  cause  an  increase  in  the 
amount of insulin released by the pancreas after eating, even before blood glucose 
become elevated 
292. Enteral nutrition stimulates the secretion of the incretin hormones, 
glucagon-like  peptide-1  (GLP-1)  and  glucose-dependent  insulinotropic  polypeptide 
(GIP).    GIP  is  synthesised  in  the  enteroendocrine  K  cells  in  the  proximal  intestine 
whereas GLP-1 is derived from proglucagon and synthesised in the enterendocrine L 
cells  in  the  distal  ileum 
293.  Circulating  GLP-1  has  two  isotypes:  GLP-1  (7-36)  and 
GLP-1(7-37),  GLP-1(7-36)  is  accountable  for  80%  of  active  GLP-1
293,  294.  
Physiologically, GLP-1(7-36) is rapidly degraded by the enzyme dipeptidyl peptidase-4 
(DPP-4)  resulting  in  its  metabolite  GLP-1  (9-36)
295.    In  adults,  normal  plasma 
concentrations of GLP-1 are ~5-10 pmol/L in a fasting state and ~15-50pmol/L in a fed 
state
296. These hormones exert their effects by binding to G-protein coupled receptors 
expressed on the pancreatic α and β cells. In a glucose-dependent manner, GLP-1 
binds  to  GLP-1  receptor  triggering  G-protein  receptor  activation,  increasing  cAMP 
levels and subsequently enhancing insulin secretion from β-cells
297.  Alongside these 
insulin stimulating effects, GLP-1 also suppresses glucagon release from α-cells in a 
PKA-dependent manner
298 and slows gastric emptying, resulting in an overall decrease 
in circulating blood glucose.    
Classical  studies  by  Nauck  and  colleagues,  demonstrated  that  the  incretin 
effect was diminished in subjects with type 2 diabetes
299. They attributed this effect to 
defective GIP action and reduced GLP-1 secretion.  This is summarised in Figure 1.26. 
Incretin-based  therapies  have  been  developed  in  an  attempt  to  recover  GLP-1 
stimulated  glucose  control  in  type  2  diabetes.  GLP-1  receptor  agonists/analogues 
(exenatide and liraglutide), which are resistant to degradation by DPP-4, can be given 
to increase activity at GLP-1 receptors and promote insulin secretion. However, these 




300. Interestingly, numerous experimental investigations showed that GLP-1 or 
GLP-1 analogues also elicit cardioprotective effects against myocardial IRI
301-309. 
 
Figure  1.26:  The  incretin  effect.  Blood  glucose  is  controlled  following  an  oral  glucose  load  by  the 
incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).  In type 
2 diabetes the incretin effect is reduced by a  decreased release of  these peptides.    GLP-1 is  rapidly 
degraded  by  an  increased  level  of  the  enzyme  dipeptidyl  peptidase-4  (DPP-4)  further  reducing  the 
signalling of available GLP-1 to its receptor. As a consequence, diminished insulin secretion does not 
prevent the release of glucagon, increasing circulating blood glucose.  
1.5.4.2.3  DPP-4 inhibitors 
Incretins  have  a  very  short  life  time  due  to  a  circulating  protease  DPP-4  therefore 
DPP-4 inhibitors, also known as the gliptins, have emerged as a promising class of 
glucose lowering agents. This class of drugs have also attracted particular interest from 
cardiologists, due to their positive effect on the cardiovascular system
310. DPP-4 exists 
in two forms, as a membrane-spanning and a soluble serine aminopeptidase enzyme, 
that  can  cleave  and  degrade  peptides  and  proteins
311.    Inactivation  of  DPP-4  by 
pharmacological or genetic inhibition led to an increase in levels of bioactive GLP-1 
and  GIP,  confirming  its  effect  on  these  hormones
294.  DPP-4  rapidly  degrades 
GLP-1(7-36)  resulting  in  its  metabolite  GLP-1  (9-36)
311.      Prevention  of  GLP-1 
breakdown by DPP-4 inhibitors enhances the level of intact GLP-1, thereby promoting 
insulin secretion and inhibiting glucagon secretion.  Interestingly, DPP-4 activity has 
been reported to be up regulated in type 2 diabetes 
312, 313.   DPP-4 levels and activity   Introduction   
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are suggested to be modulated at  the transcriptional level.  Increased DPP-4  levels 
were  demonstrated  as  a  marker  for  hypoxia/HIF-1  induction  in  several  cancer  cell 
lines
314.  Interestingly,  reduced  serum levels of DPP-4  were also  observed following 
metformin treatment
315. 
Substrates for DPP-4 degradation are proline- or alanine-containing peptides, 
therefore  DPP-4  is  not  specific  for  GLP-1  and  targets  a  wide  range  of  substrates. 
These  include  chemokines,  growth  factors  and  neuropeptides
310  including  B-type 
natriuretic peptide (BNP)
316, neuropeptide Y (NPY)
317, stromal cell-derived factor 1α 
(SDF-1α)
318 and substance P
319. Treatment with a DPP-4 inhibitor, sitagliptin was also 
associated  with  a  significant  reduction  in  the  pro-inflammatory  chemokine  MCP-1. 
MCP-1 is involved in regulating the homing of monocytes to atherosclerotic plaques 
and visceral fat, two processes that are frequently seen in diabetic patients
320. Hence, 
the inhibition of this enzyme leads to modifications in the activity of several cardioactive 
and vasoactive peptides that can produce a plethora of effects including vascular and 
myocardial protection. Inhibition of DPP-4 can also result in some disadvantageous 
downstream effects.  The possible effects of DPP-4 inhibition are summarised in Figure 
1.27. 
 
Figure  1.27:  Targets  for  dipeptidyl  peptidase-4  (DPP-4)  degradation.  DPP-4  can  degrade  numerous 
substrates, inhibition of this enzyme can result in many advantageous cellular changes but can also cause 
some unwanted effects.  Advantageous effects include  the  up regulation of stromal-derived factor 1α 
(SDF-1α),  glucagon  like  peptide-1  (GLP-1)  and  B-type  natriuretic  peptide  (BNP)  which  results  in  the 
activation of pro survival pathways. Inhibition of DPP-4 activity also causes down regulation of the pro-
inflammatory  chemokine  MCP-1.  However,  prevention  of  degradation  of  neuropeptide  Y  (NPY)1-36 
enhances the unwanted vasoconstriction of blood vessels and inhibits the generation of pro angiogenic 
NPY(3-36).   Introduction   
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1.5.4.2.4  Cardioprotection elicited by DPP4 inhibition 
Numerous  DPP-4  inhibitors  are  commercially  available  including  vildagliptin  and 
sitagliptin amongst others. Gliptins have been shown to elicit cardioprotective effects; in 
insulin resistant DIO rats, pre-treatment with a vildagliptin-analogue attenuated infarct 
size  and  improved  metabolic  control,  moreover  this  cardioprotective  effect  was 
attributed to increased phosphorylation of Akt and ERK
321. Interestingly, no protection 
was  seen  in  the  non-diabetic  control  rats
321.      However,  sitagliptin  was  protective 
against IRI in vivo in normoglycaemic mice, with the infarct limiting effect positively 
correlating with the duration of treatment.  Gliptins are proposed to limit myocardial 
injury during IR in animal models at least partly by increasing intracellular cAMP levels 
and promoting cAMP-dependent activation of PKA
322.  
Vildagliptin given intravenously in a swine model of IRI in vivo prior to ischaemia 
stabilized  electrophysiological  properties  of  the  heart  leading  to  decreased  infarct 
size
323.  Isolated  mitochondria  from  rat  cardiomyocytes  produced  less  ROS  and 
subsequently mitochondrial were less depolarized in response to DPP-4 inhibition
323. 
The  majority  of  pre-clinical  studies  have  shown  protection  by  reducing  DPP-4 
activity
310;  the  survival  rate  of  DPP-4
-/-  mice  following  permanent  ligation  of  the  left 
anterior descending coronary artery (LAD) was improved compared in DPP-4
+/+ mice, 
however infarct size was not significantly reduced. Hearts from DPP-4
-/- mice contained 
higher  levels  of  phosphorylated  Akt,  phosphorylated  GSK-3β  and  atrial  natriuretic 
peptide  (ANP).  Interestingly,  these  mice  also  had  increased  mRNA  levels  of 
PPAR-α
324.  DPP-4
-/- mice are resistant to the development of STZ-induced diabetes
325.  
Sauve  et  al,  2010  used  diabetic  mice  to  assess  the  cardioprotective  potential  of 
sitagliptin. Interestingly, post MI survival was improved by pharmacological inhibition of 
DPP-4  with  an  accompanying  increase  in  phosphorylated  Akt  but  no  difference  in 
infarct size was seen. Acute administration of sitagliptin in vivo to non-diabetic DPP-4
-/- 
mice  improved  recovery  from  subsequent  IRI  compared  to  their  littermate  controls. 
Furthermore, sitagliptin administered ex vivo immediately prior to IR protocol exerted 
no direct cardioprotective effect
324. These results suggest the inhibition of DPP-4 could 
modify  cardiovascular  outcomes  independent  of  glucose  regulation.  The  preclinical 
evidence strongly suggest a cardioprotective role for DPP-4 inhibitors, however  the 
majority of these studies were conducted in young healthy animals, or acutely diabetic 
animals  with  no  other  co-morbidites.  Therefore  studies  are  required  to  investigate 
DPP-4 inhibitors in more clinically relevant models.   Introduction   
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1.6  Ageing heart and ischaemia-reperfusion injury  
1.6.1  Ageing and the cardiovascular system 
1.6.1.1  Age related changes in the vasculature 
There are many age related alterations that occur in the CV system in general and in 
the  heart  in  particular.  Increasing  age  correlates  with  thickening  and  reduced 
compliance of the arterial wall; this is caused by vascular smooth muscle hypertrophy, 
enhanced  intimal  thickness,  fragmentation  of  the  internal  elastic  membrane  and 
increased collagen leading to more collagen cross-linking in arterial walls
326. Alongside 
arterial thickening, a dilatation of major arteries and arterial stiffness occur presenting 
as  increased  systolic  blood  pressure  and  widening  of  pulse  pressure
327.  Venous 
changes  can  also  occur  with  ageing,  however  these  changes  predominantly  effect 
peripheral vessels rather that those within the heart per se. One of the most prevalence 
venous changes is the reduced compliance of veins in the lower limbs, with a reduction 
observed in venous compliance in the calf of old versus young humans
328.  The most 
common manifestations of chronic venous disease are varicose veins, which contain 
incompetent valves and increased venous pressure, and dilated cutaneous veins
329. 
The  overall  reduced  compliance  of  lower  limb  veins  are  thought  to  affect  the  total 
venous return of blood to the heart. 
1.6.1.2  Age related changes in the heart 
1.6.1.2.1  Structural alterations of the heart 
Structurally, aged hearts undergo left ventricular hypertrophy, have enlarged but fewer 
cardiomyocytes and an overall increase in collagen content 
330. Alongside, these heart 
specific changes, alterations in the vasculature and response to baroreceptor reflexes 
also  occur.  These  structural  changes  impact  the  functional  properties  of  the  heart, 
causing changes in diastolic function and responses to pharmacological stimulation 
330. 
There are numerous factors that contribute to these modifications including cumulative 
damage caused by increased oxidative stress 
331, changes in genetic programming 
331, 
increased  cell  death  and  systemic  ageing 
330.  These  changes  make  ageing  a 
recognized risk factor for  the occurrence cardiovascular events associated with an 
increased prevalence of infarction and poor clinical recovery following MI 
332.  
Within  the  ageing  myocardium,  an  increased  ventricular  wall  thickness  to 
chamber size ratio leads to an increased ventricular mass
333; however some studies 
report that this may be caused by other co-existing diseases rather than the intrinsic   Introduction   
92 
 
myocardial  ageing  process
326,  334.  This  increased  thickness  of  the  ventricular  wall 
alongside  more  collagen  and  less  ventricular  cardiomyocytes  combine  to  augment 
significant ventricular dysfunction
326, 335.  
1.6.1.2.2  The impact of ageing within the cardiomyocyte 
Cardiomyocytes are the major constituent of the ventricular and atrial walls of the heart; 
recent evidence proposes the existence of cardiac stem cells driving the regeneration 
of  cardiomyocytes,  however,  decrease  in  cell  number  with  age  suggests  this 
regeneration capacity is an insufficient compensatory mechanism.   Correct control of 
ion homeostasis is critical to maintain cardiac function; old age has been linked to a 
defective  and reduced expression of the sarcoplasmic reticulum (SR) Ca
2+  ATPase 
pump leading to reduced re uptake of Ca
2+ into the SR
336, 337 resulting in a significant 
prolongation of isovolumetric relaxation  of  the ventricles,  moreover  adenoviral gene 
transfer  of  this  Ca
2+  pump  restores  diastolic  function  in  the  aged  rat  heart
338.  
Expression and function of ATP sensitive K
+ channels are also reduced with old age 
affecting  the  electrical  activity  of  the  cardiomyocyte
339.      Interestingly,  at  rest,  left 
ventricular systolic function remains unchanged with no age-related deteriorations in 
ejection  fraction,  cardiac  output  or  stroke  volume;  however  these  parameters  are 
decreased in response to exercise
326. In comparison, left ventricular diastolic function is 
affected by increasing age
340. 
Cardiomyocytes  in  the  ageing  myocardium  undergo  changes  at  both  the 
molecular and cellular level that lead to an increased susceptibility to cellular stress. 
This can result in an increased number of enlarged and dysfunctional cardiomyocytes 
and subsequently a reduced number of functional cardiomyocytes. Damage to DNA 
during the ageing process has attracted much attention and has been the subject of 
intense research. Telomeres are repetitive sequences at the ends of chromosomes 
that protect chromosomes from degradation. They maintain their length via the addition 
of  DNA  repeat  sequences  (TTAGGG)  by  the  reverse  transcriptase  enzyme, 
telomerase.  However  ageing  results  in  the  loss  of  telomere  reserves  leading  to 
eventual  shortened  DNA  sequences
341.  A  decrease  in  telomere  length  has  been 
observed  in  the  ageing  rat  myocardium
342.  Interestingly,  patients  diagnosed  with 
dyskeratosis congenita, a congenital disorder that resembles premature ageing had 
decreased telomere length which was associated with increased mortality
343.   
Telomere shortening leads to activation of DNA damage signalling pathways 
subsequently  activating  p53  and  hence  triggering  induction  of  apoptosis  and 
senescence
341. Intriguingly, studies have demonstrated that telomere shortening in the   Introduction   
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heart  inducing  p53  activation,  specifically  leads  to  mitochondrial  and  metabolic 
alterations through repression of PGC-1α and β
344.   Therefore telomere shortening 
may  contribute  to  1)  increased  death  of  cardiomyocytes,  therefore  reducing  their 
number and 2) decreased mitochondrial biogenesis and function in the ageing heart. 
As well as telomere shortening, mutations and alterations in nuclear and mitochondrial 
gene expression result in an altered cardiomyocyte phenotype in the aged heart 
345, 346. 
Age  related  changes  in  the  nucleus  therefore  have  been  suggested  to  trigger 
mitochondrial  dysfunction  and  impact  on  the  production  of  mitochondrial  free 
radicals
347.  
Interestingly,  a  shift  from  fatty  acid  towards  carbohydrate  metabolism  was 
observed in mice hearts at 5 versus 30 months
348. Based on the observations made by 
Luptak et al, 2007
349, this transition acts perhaps as an adaptive response.  These 
authors found that glucose uptake was enhanced in GLUT-1 transgenic (GLUT-1 TG) 
mice, and that young and old transgenic mice had similar recovery following IR, which, 
in addition, exceeded the recovery that was seen in wild type mice of similar ages. In 
the  old  GLUT-1  TG  mice  during  the  reperfusion  phase,  glucose  oxidation  was 
substantially  higher than fatty  acid  oxidation  compared to  old  wild  type  mice.  They 
speculate  that  the  reduction  in  fatty  acid  oxidation  limits  the  deleterious  effects  of 
excessive oxidation such as production of ROS
349, 350.   
1.6.1.2.3  Ageing and mitochondria 
Mitochondrial  dysfunction  has  been  reported  in  ageing  tissues  including  the  heart. 
Fannin et al, 1999 showed a decreased rate of oxidative phosphorylation and activity of 
cytochrome oxidase enzyme in in mitochondria from aged compared to the adult rat 
heart.  These  changes  were  specific  to  the  interfibrillar  and  not  subsarcolemma 
mitochondria
351.  Moreover  a  decrease  in  electron  transport  at  complex  III  due  to 
variations  at  the  cytochrome  c  binding  site  led  to  altered  oxidative  phosphorylation 
contributing to increased ROS production in the ageing heart
352.  
The  formation,  stability  and  function  of  complexes  of  the  ETC  rely  on  the 
presence of the phospholipid cardiolipin (CL) in the inner membrane
353. CL is vital for 
the  correct  functioning  of  cytochrome  c  oxidase  (complex  IV  of  ETC)  during 
mitochondrial energy metabolism. Two CL binding sites on cytochrome c oxidase have 
been suggested to be involved in the proton transport activity of this complex
354. The 
apoptotic mediator cytochrome c preferentially binds to this monolayer of CL, in this 
bound  state  cytochrome  c  is  not  released  limiting  the  initiation  of  cell  death 
pathways
355.  A decrease in CL expression has been reported in the ageing heart
356   Introduction   
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with this loss of CL associated with an increased production of ROS. This was caused 
by dysregulation of the cytochrome c oxidase complex and an increase in unbound and 
hence  released  pro-apoptotic  cytochrome  c  in  the  aged  heart
356,  357.    Interestingly, 
cytochrome  c  bound  to  CL  was  released  following  peroxidation  with  a  radical 
initiator
355. Alongside a decline in oxidative phosphorylation function, numerous studies 
reveal a wide variety of changes within the mitochondria during ageing; these include 
disorganisation  of  mitochondrial  structure,  accumulation  of  mtDNA  mutations  and 
increased  production  of  ROS  leading  to  oxidative  damage  to  DNA,  proteins  and 
lipids
358.  
The initial proposal of the free radical theory of ageing by Harman in the 1950s 
suggested  that  intracellular  ROS  are  causal  for  the  process  of  ageing  and  a 
determinant  of  lifespan
359.    This  led  to  an  intensive  area  of  research  and  the 
development  of  the  mitochondrial  free  radical  theory  of  ageing
360-362.  This  theory 
suggests  that,  during  oxidative  phosphorylation,  ROS  are  produced  from  the  inner 
mitochondrial membrane and lead to oxidative induced mtDNA damage. The location, 
lack of protective histones and relatively little DNA repair activity of mtDNA, increase 
the susceptibility to oxidative induced damage resulting in mutated mtDNA 
358. Since 
mtDNA  encodes  for  proteins  within  the  respiratory  chain,  mutations  lead  to  an 
increased  production  of  ROS  triggering  a  cycle  of  mitochondrial  dysfunction  and 
oxidative  damage.    Furthermore,  autophagocytosis  cannot  efficiently  remove  these 
damaged, enlarged mitochondria mainly due to their size, causing further accumulation 
of oxidized products within lysosomes
363.  
The role of ROS as the underlying stressor that leads to mtDNA mutations is 
central to this theory; however inconsistent results with ROS-limiting interventions in 
extending  lifespan  have  proved  to  be  controversial
358.  Mice  overexpressing  ROS-
limiting  catalase  led  to  an  increase  in  lifespan
364  and  mice  lacking  Sod2  exhibited 
neonatal lethality
365, 366 supporting the fundamental role of ROS in ageing. However, in 
contrast Perez and others showed that the interference with antioxidant enzymes lead 
to decreased oxidative damage but had no influence on lifespan
367. Interestingly, some 
mice that accumulate mtDNA mutations during adult life exhibit no substantial increase 
in oxidative stress
368. These controversies led to the hypothesis of the gradual ROS 
response 
369. This theory postulates that ROS act as signalling molecules in normal 
physiology that lead to adaptive changes in response to stress
369, 370. Toxicity caused 
by  ROS  is  well  controlled  by  the  antioxidant  system  however  as  ROS-independent 




358. This is supported by the critical role of low levels of ROS required for the 
initiation of cardioprotective signalling cascades
371.   
Several other mechanisms contribute to increased mitochondrial ROS formation 
in the aged heart amongst which there is an increased production or accumulation of 
H2O2. Production of H2O2 from the reduction of O2
•- was increased in 14 and 18 months 
old rat hearts compared to 3 month old rat hearts
372, moreover the age-related increase 
in H2O2 was abolished by the inhibition of monoamine oxidase (MAO)-A in the OMM, 
an enzyme that leads to enhanced formation of O2
•-  373. The protein p66
Shc has also 
been  implicated  in  enhanced  production  of  H2O2  and  ROS  within  the  ageing 
mitochondria
374.  This  protein  upon  translocation  into  the  mitochondria  oxidises 
cytochrome  c  leading  to  production  of  H2O2;  mice  lacking  this  protein  exhibit  an 
increased  lifespan  consequential  of  a  reduced  production  of  ROS
375,  and 
ROS-mediated endothelial dysfunction
376. Inhibition of p66
Shc also results in protection 
from IRI
377 and expression of both MAO and p66
shc increase with age.  Interestingly, 
translocation of this protein was shown to be mediated by phosphorylation at serine36 
residue by PKC-β in response to oxidative stress and led to initiation of apoptosis and 
increased  mPTP  opening
378,  379.  Moreover,  phosphorylated  p66
Shc  level  was 
demonstrated  to  be  increased  with  age
380.  Enhanced  ROS  formation  can  also  be 
attributed  to  mechanisms  other  than  the  direct  release  from  the  mitochondria; 
increased ROS production resulted from an increased expression of NADPH oxidase 
subunit  p47
phox  in  aged  mice  myocardium
381  alongside  a  decreased  anti  oxidative 
capacity in aged rat hearts
382, 383.  Ageing associated changes within the cardiomyocyte 




Figure 1.28: Molecular and cellular changes in ageing cardiomyocytes:  
 
1.6.2  Ischaemia-reperfusion injury in the aged heart 
The impact of mitochondrial dysfunction, increased oxidative stress and abnormal Ca
2+ 
handling in the aged myocardium results in basal disturbances in cardiac function. The 
myocardium is in a compromised state, and therefore when subjected to a stress such 
as ischaemia-reperfusion injury, the ability for the heart to recover is hindered 
384. In the 
clinical setting, elderly patients experienced increased mortality during MI, with those 
surviving exhibiting greater cardiac damage compared to younger patients even with 
efficient and successful reperfusion
385.   This has also been well-documented in animal 
investigations
384.  Isolated  heart  preparations  conducted  using  hearts  from  aged 
(24 months)  Fischer  344  rats  exhibited  decreased  hemodynamic  recovery  and 
increased  creatine  kinase  release  compared  to  younger  counterparts  (6-8  months) 
following ischaemia and reperfusion
386, 387.  
Numerous signalling defects have been linked with ageing associated increases in 
vulnerability to IRI (Figure 1.29).  Myocardial ionic imbalance has been demonstrated in 
the ageing heart; Jahangir et al, 2001 suggest mitochondria from the aged heart have a 
decreased tolerance to increased Ca
2+ levels that occur during cardiac injury
388. In line 
with  this,  O’Brien  et  al,  2008  showed  an  increased  accumulation  of  Ca
2+  during 
ischaemia and early reperfusion in cardiomyocytes isolated from 24  month old rats 
compared to 3 month old rats
389, which in turn leads to mitochondrial Ca





.  Tani  et  al,  1997  also  demonstrated  decreased  ischaemic  tolerance  in 
aged rats in relation to increases in intracellular Na
+ after ischaemia
390. Interestingly, 
this investigation suggests an age-related increase in the susceptibility to myocardial 
injury starts to manifest at middle age in rats (approximately 12 months of age)
390. Loss 
of intrinsic tolerance to IR was also manifested at 12 months in mice and exaggerated 
with age increasing up to 22-24 months
391. Other studies in mice also demonstrated 
increased  infarct  size  in  aged  mice
392,  393,  however  one  study  suggested  mice  at 
13 months  of  age  had  no  increased  susceptibility  to  injury.  Of  note,  the 
ischaemia-reperfusion protocol used in this study was shorter
394.   
Enhanced ROS formation in response to IRI has been documented in the aged 
rat heart. Strategies that limit oxidative damage have proved successful in improving 
cardiac function and decreasing oxidative stress within the myocardium
395, 396. Systemic 
administration  of  the  antioxidant  acetylcarnitine  before  ischaemia  increased  the 
transcription of mtDNA, leading to augmented mitochondrial protein synthesis of ETC 
subunits. This resulted in enhanced cytochrome c oxidase activity, restoring oxidative 
phosphorylation  in  aged,  rat  hearts 
397.  Increased  generation  of mitochondrial  ROS 
during ageing and subsequently in ischaemia-reperfusion has been demonstrated to 
impact  the  mPTP,  firstly  by  increasing  on  its  formation  and  secondly  on  its  open 
probability, both leading to increased cell death
65, 398. 
 
Figure  1.29:  The  main  processes  that  are  suggested  to  contribute  to  enhanced  damage  caused  by 
ischaemia-reperfusion injury in the ageing heart.   Introduction   
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1.6.3  Protection against infarction in the aged heart 
1.6.3.1  Loss of conditioning against IRI in the aged heart  
Considering that the defective changes that exist in the aged heart lead to increased 
susceptibility to ischaemia-reperfusion injury, converge or involve the mitochondria, it is 
somewhat unsurprising that the protective effects of IPC that also involves modulation 
of the mitochondria are more difficult to achieve 
399. The majority of studies show that 
cardioprotection by IPC is ineffective in the ageing heart
384. One cycle of IPC in aged 
hearts
399 or isolated cardiomyocytes
389 from 24 month old rats did not enhance the 
recovery
399 or cell viability
389 following IR compared to hearts from 6 or 3 month old 
rats, respectively. Furthermore, infarct size could not be limited using one or two cycles 
of IPC prior to IR in 12
400, 18-20 
401 and 22
402 month rats. Interestingly, Schulman et al, 
2001 showed that increasing the IPC stimulus to 3 cycles protected the aged heart 
from  IRI  compared  to  control  hearts 
401.    However,  Abete  et  al  did  not  see  a 
cardioprotective effect when cycle number was increased to four in their model
399. Of 
note,  in  this  study  prolonged  ischaemia  was  only  applied  for  20  min  with  40  min 
reperfusion  in  comparison  to  35  min  ischaemia  and  120  min  reperfusion  used  in 
Schulman’s investigation, which may account for the inconsistent finding. IPC was also 
ineffective in an in vivo mouse model of IR in mice greater than 13 months of age
394. 
Interestingly, in vivo investigations in larger animal models oppose these findings and 
suggest IPC is still protective against IRI in aged rabbits
403 and sheep
404. However, this 
outcome  was  questioned  in  respect  to  their  suitability  as  ‘ageing’  animal  models; 
protection  was  still  afforded  in  2-4  year  old  rabbits  where  lifespan  is  usually 
approximately  13  years  and  in  6-8  year  sheep  where  lifespan  is  approximately  20 
years
384, 405. Maximal lifespans of experimental animals are shown in Table 1.4. 
Laboratory animal  Life expectancy 
Mice  2 years 
Rats  3-4 years 
Rabbits  8-10 years 
Sheep  ~ 20 years 
Table 1.4: The life expectancy of laboratory animals: 
  Pharmacological preconditioning has also been suggested to be ineffective in 
the aged heart




406,  this  protection  was  not  possible  in  old  rodents.    Acute 
preconditioning with either adenosine
407 or an opioid agonist 
408 was unable to protect 
isolated hearts of 18 and 24-26 month old mice. Adenosine receptor activation mimics 
IPC by leading to the activation of similar intracellular pro-survival kinase cascades as 
IPC
409.  Downstream to adenosine, the direct activation of PKC or mitoKATP channels 
also failed to limit infarct size in isolated old rat hearts (18-20 months)
401.  
1.6.3.2  Why is it difficult to condition the aged heart? 
The  effectiveness  of  myocardial  IPC  or  pharmacological  conditioning  in  young  and 
healthy  animals  and  the  mechanisms  behind  this  protection  have  been  intensively 
investigated 
410.  Both trigger a diverse array of signalling cascades, most of which 
seem to converge towards the preservation of mitochondria’s structure and function.  
There is less data regarding the state of these signalling cascades during the 
ageing  process,  as  a  result,  mechanisms  are  unclear  regarding  the  increased 
myocardial susceptibility to IRI in ageing.  We think that the impairments that occur in 
the ageing process may lead to increased susceptibility to IRI. Some authors discuss 
the possible signalling motifs and interactions that could be affected in the aged heart 
that lead to lack of protection by IPC, summarised in Figure 1.30 
384.  For example, 
impaired  mitochondrial  function  including  regulation  of  redox  signalling  and  energy 
production, defective IPC signalling including defective ligand/receptors signalling and 
alterations of signalling molecules in the RISK pathway and SAFE pathway 
384 and an 
altered threshold for IPC to trigger protective signalling are underlying mechanisms that 
may render the aged heart ineffective to IPC. However, more experimental evidence 
has started to emerge.  
Levels of endogenous ligands can limit the cardioprotective response to IPC, 
reduced IL-6, a component of the SAFE pathway was found in aged mice hearts
411.  
Levels  of  Insulin-like  growth  factor  1  (IGF-1),  a  ligand  that  can  initiate  the  RISK 
pathway, and it’s receptor IGF-1 were decreased in aged hearts
412. Bradykinin (BK), 
another well-known cardioprotective signalling molecule can activate  both  the RISK 
pathway  and  the  PKC  dependent  pathway,  decreased  expression  of  BK  receptors, 
specifically BK receptor-2, were found in 24month rat heart myocardium
413.  Central for 
protection  mediated  by  IPC  is  PKC;  PKCε  translocates  between  intracellular 
compartments to modulate its cardioprotective effect. This translocation was impaired 
in middle aged mouse hearts
394 and aged rat hearts
414, moreover expression of PKCε 
in the soluble fraction of isolated rat hearts was decreased in the 24months age group   Introduction   
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compared to 5months age group 
415. However, age does not impact on the total level of 
this protein
384, 414.  
The mitochondrial KATP channel is implemented in the protective effect elicited 
by IPC; interestingly an aged related decrease is seen in its activity in the rat heart
416.  
Boe et al, 2013 demonstrated that the inhibitory effect of cytosolic ATP on channel 
activity was enhanced in the aged rat heart as a possible consequence of metabolic 
impairment seen during ageing
417. Upon application of an IPC stimulus a small amount 
of ROS is required to initiate protection via the KATP channel
371, 418; the redox sensitive 
nature of this protection was demonstrated by the inhibition of IPC in the presence of a 
free  radical  scavenger,  N-2-mercaptopropionyl  glycine  (MPG)
419.  Interestingly,  MPG 
applied at reperfusion prevented protection by IPC 
419.  Connexin 43 (Cx43), a gap 
junction protein that is also found in the mitochondria, is required for the activation of 
mitochondrial KATP channels and subsequent cardioprotection by IPC
420,  421. Morever, 
reduced  levels  of  Cx43  prevented  the  release  of  protective  ROS  in  response  to 
diazoxide stimulation
422.  Interestingly, Cx43 is decreased in the aged myocardium
394, 
however cardiac Cx43 has been shown to be localised in subsarcolemmal (SSM) not 
interfibrillar (IFM) mitochondria
423. The majority of other mitochondrial defects appear to 
be localised in IFM in the ageing heart; the inability to pre-condition Cx43
-/- mice may 
suggest SSM play an important role in the loss of IPC in aged heart
420.   
An important role for SIRT-1 activity has been suggested during IR and also 
IPC
146, 148, interestingly SIRT-1 activity decreases with age
424, therefore a deficiency in 
SIRT-1 activity has been suggested as a potential reason for the loss of IPC in the 
aged heart. However, Adam et al, 2013 show that even though SIRT-1 deacetylase 
activity is decreased during IR; IPC and resveratrol, a SIRT-1 agonist, failed to protect 
the aged heart. Moreover, inhibition of SIRT-1 did not limit infarct size in their aged, ex 
vivo rat model but did decrease functional recovery following IR. Controversially, they 
conclude  based  on  their  results  that  there  is  no  direct  role  for  SIRT-1  in  IPC  and 
moreover loss of SIRT-1 activity does not account for ineffective IPC in aged heart 
425. 
Blunted activation or expression of RISK kinase signalling molecules has been 
suggested  to  exist  in  the  ageing  heart.  Impairment  of  expression  of 
activation/deactivation  of  Akt,  GSK-3β,  ERK  or  p38,  important  mediators  of 
cardioprotection  in  IPC
134  would  lead  to  decreased  effectiveness  of  IPC
384. 
Interestingly, by increasing the stimulus of IPC in the aged heart, protection can be 
restored in some models of  ageing, suggesting that the impaired signalling can be 
recovered.  Acute phoshophorylation of Akt during IPC is a component of the RISK   Introduction   
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pathway leading to protection, however, intriguingly the aged failing heart has been 
linked  with  increased  basal  levels  of  Akt-phosphorylation
426. Whether high  levels  of 
signalling molecules prior to stress prevent their acute activation and the initiation of 
cardioprotective signalling is yet to be fully investigated but may provide an interesting 
area of research. 
 
Figure 1.30: Cardioprotection in the ageing heart.  One cycle of ischaemic preconditioning is insufficient 
to  protect  the  aged  heart  against  damage  following  ischaemia-reperfusion  injury.    The  mechanisms 
proposed to explain the loss of protection include decreased expression of bradykinin-2-receptor (BK-2R), 
decreased release of insulin-like growth factor-1 (IGF-1) and expression of its receptor IGF-1R, decreased 
levels  and  activation  of  reperfusion  injury  salvage  kinases  (RISK)  and  survival  activating  factor 
enhancement (SAFE) signalling, and mitochondrial changes. Three cycles of ischaemic preconditioning 
recovers the diminished signalling and protects the ageing heart. 
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1.7  Ageing and diabetes in myocardial ischaemia-reperfusion 
injury 
1.7.1  Hypotheses and aims 
As far as we know there are not yet experimental studies which have investigated the 
effect of these two aggravating factors, or co-morbidities, on myocardial infarction. The 
reasons for this are likely to be associated with the experimental costs and the time 
constraints involved in maintaining ageing, diabetic colonies. Nevertheless, considering 
the  emergent  ageing  human  population  and  increasing  incidence  of  diabetes,  such 
studies may prove crucial for developing successful cardioprotective strategies specific 
for this sector of the population. 
The main  aim  of the studies presented  in this  thesis  was to  investigate the 
influence of two comorbidities (diabetes and age) on the susceptibility to myocardial 
infarction in an experimental model.  For this purpose we used a diabetic rat strain, the 
Goto-Kakizaki rat (a commonly used model of type 2 diabetes) at different ages (3, 8, 
12 and 18 months). As a normoglycaemic control, we used the Wistar rat (which is the 
parent strain for the GK rat). 
We hypothesise that: 
A.  The diabetic heart will age quicker than the normoglycaemic heart and therefore 
will be more susceptible to infarction and less amenable to cardioprotection in 
comparison to the non-diabetic heart of the same age. 
Aims: 
1.  To assess ischaemia-reperfusion injury as a function of age and duration of 
injury (chapter 3.1) 
2.  To assess the effectiveness of IPC at different ages (chapter 3.2) 
3.  To assess the cardioprotective effect of anti-diabetic drugs known to protect 
in  young  animals  under  acute  administration,  when  given  as  chronic 
treatment in middle aged and older animals (chapter 4). 
B.  Modifications  in  the  pro  survival  signalling  pathways  within  the  diabetic 
cardiomyocytes may contribute to the susceptibility to infarction and decreased 




1.  To  assess  to  the  state  of  mitochondria  in  aged  and/or  diabetic  animals 
(Chapter 3). 
2.  To  assess  the  state  of  the  crucial  intracellular  systems  implicated  in 




Diabetes  seems  to  accelerate  the  ageing  process  in  the  heart  in  relation  to  the 
susceptibility to infarction and the decreased cardioprotective potential of the ageing 
heart.  The  alteration  in  the  endogenous  cardioprotective  signalling  within  the 
cardiomyocyte seems to be at least partially responsible of these changes. 










2. GENERAL METHODS  
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For the investigations which will be described in the following chapters, I learned and 
employed 2 models of ischaemia-reperfusion and a number of biological techniques: 
-  Ex  vivo  myocardial  ischaemia-reperfusion  injury  using  a  Langendorff  system 
(constant pressure, retro-perfused heart) 
- In vivo myocardial ischaemia-reperfusion injury 
-A series of molecular biology techniques applied to whole cardiac tissue or to isolated 
cardiomyocytes or cell lines. 
These  techniques  will  be  described  in  detail  in  the  present  chapter,  with  particular 
details related to specific subjects added in the respective results chapters. 
2.1  Animals 
Rat  models  were  used  in  the  studies  described  throughout  this  thesis.  Initial 
characterisation of models used the standard Sprague Dawley lab rat (300-350g); all 
investigative work used both the non-diabetic Wistar rat and the type 2 diabetic Goto 
Kakizaki rat.  
2.1.1  Animal models of Diabetes 
Animal  models  used  to  investigate  diabetes,  have  been  created  by  different 
methods  such  as  feeding  modified  diets,  administration  of  drugs  toxic  to  the 
pancreas, and inbreeding spontaneous mutations and genetic engineering 
427. This 
has  resulted  in  the  availability  of  many  different  diabetic  animal  models 
428.  
However,  translating  results  gained  from  these  animal  models  of  diabetes  into 
clinical settings must be interpreted with caution as none of the models completely 
reflect the human pathology of diabetes. 
2.1.1.1  Type 1 Diabetes 
Type  1  diabetes  is  characterized  by  the  insufficient  production  of  insulin  as  a 
consequence  of  autoimmune  destruction  of  pancreatic  β  cells  in  the  islets  of 
Langerhans 
429. The main experimental models used to investigate this disease are 
created by the administration of toxic compounds that prevent the production of 
insulin.  These compounds include streptozotocin (STZ) and alloxan.  STZ is  an 
alkylating  agent  based  nitrosurea  derivative 
430,  which  interferes  with  numerous 
cellular processes such as glucokinase function  and glucose transport,  and can General methods 
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also cause DNA strand breaks 
431. To induce diabetes in rodents with this agent, 
the administration of a series of low doses is preferable to avoid the high mortality 
associated with using a single high dose 
432.  Alloxan is a toxic glucose analogue, 
which  preferentially  accumulates  in  the  beta  cells  of  the  pancreas,  causing 
excessive  production  of  hydroxyl  free  radicals  and  destruction  of  the  beta  cells 
hence mimicking type 1 diabetes 
433. In essence, the primary etiopathology caused 
by administration of these toxins has little autoimmune component and does not 
truly reflect the pathology of type 1 diabetes in the human 
432. Therefore, it could 
be argued that the translation of findings from these particular animal models of 
type 1 diabetes to the clinical setting may be problematic.  
  Alternatively, genetic or spontaneous models can be employed in investigating 
type 1 diabetes, with a vast amount of data collected using non-obese diabetic (NOD) 
and congenic NOD mice 
434. Rat models include the diabetes-prone BB rat, the LETL 
rat, the KDP rat and the congenic LEW rat. The BB rat derived from an outbred Wistar 
rat colony that exhibited spontaneous hyperglycaemia and ketoacidosis, are the most 
extensively studied rat model of type 1 diabetes 
435. 
2.1.1.2  Type 2 diabetes 
Type 2 diabetes in humans is a metabolic disorder which is usually detected during 
adult-hood 
436.  There  are  a  few  rodent  models  of  this  form  of  diabetes,  for  an 
extensive review of animal models in diabetes please refer to 
427.  Both the db/db 
mice 
437 and the Zucker diabetic fatty (ZDF) rat 
438 are models that express other 
co-morbidities such as obesity and dyslipidemia as well as glucose intolerance 
439. 
The  Otsuka  Long  Evans  Tokushima  Fatty  (OLETF)  rat  originates  from  the 
inbreeding of Long-Evans rats which exhibit glucose intolerance 
440, these rats are 
mildly  obese  and  the  diabetic  phenotype  is  more  dramatic  in  males.    Another 
model of type 2 diabetes is the Goto-Kakizaki (GK) rat, described in greater detail 
below.  
2.1.1.2.1  The Goto-Kakizaki rat 
The GK rat is an established model of type 2 diabetes, developed by the selective 
inbreeding over  numerous generations of Wistar rats  that exhibited hyperglycaemia 
and glucose intolerance 
441, 442. The polygenic GK rat spontaneously becomes diabetic 
early in life, showing glucose insensitivity in their pancreatic beta cells with the diabetic 
status increasing with age.  They exhibit mild basal hyperglycaemia, impaired glucose-
induced  insulin  secretion,  decreased  β-cell  mass,  hepatic  and  peripheral  insulin General methods 
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resistance with vascular complications often seen in diabetic patients 
443.  A reduced 
expression  of  the  glucose  transporters  GLUT-2  and  GLUT-4,  and  insulin  receptors 
have been also observed in the GK rat, contributing to the insulin resistant state in 
these  animals
444.  As  the  GK  rat  ages,  severe  hyperglycaemia  develops,  however 
insulin levels remain constant
445. The plateauing effect of weight gain with age in this 
model is likely to be related to the absence of an age-related impairment of peripheral 
insulin
445. However, the lean nature of this model of type 2 diabetes allows investigation 
of diabetes without other complications such as obesity 
446.   
Male and female Goto-Kakizaki (GK) rats (a mild, non-obese diabetic model 
427, 
447)  were  initially  obtained from Taconic (Denmark). They  were  used  to  establish a 
colony in the Central Biological Services Unit (BSU), which I supervised throughout my 
studies. The animals were kept in house until they reached 3, 8, 12 and 18 months of 
age.  These ages are thought to represent the ages shown in Table 2.1, in humans
448. 
Male  Wistar  rats  (normoglycaemic)  were  obtained  from  Charles  River  UK  Limited 
(Margate, UK) and kept in house until they also reached 3, 8, 12 and 18 months of age. 
All animals received humane care and studies were performed in accordance with the 
United  Kingdom  Animal  (Scientific  Procedures)  Act  of  1986.    To  perform  these 
experiments I was trained in Modules 1-4 in the UCL BSU and granted a Home Office 
Personal License for working with animals. In addition, I obtained a grant from Servier 
to  visit  their  laboratories  in  Paris,  France  to  learn  the  surgical  model  of  injury  and 





6  18 
12  30 
18  45 
24  60 
30  75 
36  90 
Table 2.1: The rat’s age in months and its relationship with human age in years (data taken from
 448) 
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2.1.2  Biological parameters 
Blood glucose, glycated  haemoglobin A  (HbA1c), body mass and heart mass were 
recorded as needed and the time points of these measurements were included in the 
respective chapters. 
HbA1c  is  a  measure  of  glycated  haemoglobin.  Glycation  is  a  form  of  non-
enzymatic or non-controlled glycosylation 
449. The diabetic subjects who have higher or 
uncontrolled blood glucose also have more glycated haemoglobin.  Therefore the level 
of HbA1c can be used as a marker for diabetes. HbA1c was measured using an A1C 
now+  test  kit  (Bayer,  UK).  Blood  glucose  was  measured  using  Accu-chek  system 
(Roche) in the overnight fasted animals.  
For both tests the animals were placed in a heating chamber to increase the 
visibility and accessibility of the tail vein, and a small pin-prick of blood was collected 
for  each test.  Subsequently,  the  animals  were  left  to  recover  for  at  least  48  hours 
before any experimental investigations. This is because heat stress has been shown to 
be protective against myocardial ischaemia-reperfusion injury for a period up to 24-36 h 
following the procedure. 
2.2  Assessment of Infarction using ex vivo and in vivo models 
2.2.1  Langendorff model of retroperfused isolated heart  
2.2.1.1  Introduction 
The mammalian isolated heart model was first described by Oscar Langendorff in the 
late  19
th  century  and  is  still  a  very  important  and  widely  used  technique  in  the 
laboratory setting today 
450.  Oscar Langendorff developed the method based on work 
completed  earlier  that  century  by  Elias  Cyon  from  the  Carl  Ludwig  Institute  of 
Physiology in Leipzig, Germany, on the isolated perfused frog heart 
451.  Both methods 
were instrumental in aiding the understanding of heart physiology throughout the late 
19
th and into the early 20
th century. Incredibly, only few modifications have been made 
to  the  original  method  described  by  Langendorff  and  the  technique  still  remains 
instrumental  in  modern  cardiovascular  and  pharmacology-based  research  today. 
Throughout the last couple of decades and into the millennium, the technique has not 
only furthered our understanding of heart physiology but has also been essential in 
investigating and manipulating cell signalling pathways  implicated in cell survival  or 
affected by pathologies such as diabetes, hypertension or heart failure 
452. General methods 
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The principle of the method has remained true to the original description coined 
by Langendorff himself; the heart is perfused in a retrograde fashion via a cannula 
inserted  into  the  aorta.    The  perfusate  (normally  physiological  crystalloid  solution) 
moves into the heart via the aorta, in the opposite direction to normal physiological 
flow. This retrograde movement of perfusate causes the aortic valve to close under 
pressure  and  prevents  fluid  from  entering  the  left  ventricle.  Closure  of  the  valve 
therefore initiates movement of the perfusate through the right and the left coronary 
ostia located at the aortic root, through the coronary arterial vasculature and into the 
right  atrium  via  the  coronary  sinus.  This  essentially  allows  the  preparation  to  run 
without any fluid filling or emptying in either ventricle (Figure 2.1). 
 
Figure 2.1: Schematic representation of retrograde perfusion of the heart.  Krebs Henseleit Buffer (KHB) 
enters the heart via the aorta: (1) The aortic valve closes under pressure and prevents fluid from entering 
the left ventricle (2) Movement of  the perfusate through the right and the left coronary ostia  (3+4) 
Movement of perfusate through the coronary arterial vasculature (5) Entry into the right atrium via the 
coronary sinus and (6) coronary flow. 
  For complete presentation of the isolated heart model I need to mention an 
alternative model of the isolated, perfused heart: the working heart model. The working 
heart model was developed by Neely and colleagues
453-455. Briefly, the perfusate enters 
the heart by a cannula placed in the left atria, passes through the left ventricle and exits 
via the aorta. This mode allows the heart to pump fluid and utilize the normal circulatory 
pathway through the ventricles and is used primarily to assess cardiac function 
456. General methods 
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  In my studies, I used only the Langedorff preparation which is considered a 
better model for investigating infarction following ischaemia-reperfusion injury, which 
was the main end point of my experiments.  
2.2.1.2  Constant flow or constant pressure perfusion? 
In the original Langendorff preparation, the heart was perfused at a constant pressure 
by placing the reservoirs to an adequate height.  However, in 1939 a modification was 
made by Katz, in which he changed the mode of perfusion. Instead of the heart being 
perfused at a constant pressure, he perfused hearts at a constant flow and measured 
the coronary perfusion pressure, using this as a tool to assess the coronary vascular 
resistance. Hence, Langendorff experiments can be conducted in two different modes: 
constant pressure or constant flow.  Each mode has its advantages and disadvantages 
and  the  choice  is  usually  dependent  on  the  aim  of  the  experimental  investigation. 
Modern constant flow systems use a peristaltic pump to deliver desired set volumes of 
perfusate into the heart. This is very easily controlled and monitored by a computer 
program  called  Lab  Chart.    Constant flow  mode  may  be  preferred for  investigating 
coronary vascular tone or smooth muscle and endothelial function. Using a known flow 
rate and perfusion pressure (measured by a pressure transducer placed in before the 
perfusion  cannula)  a  derivation  of  Ohm’s  law  can  be  used  to  calculate  coronary 
vascular  resistance 
452.  Hence,  in  whole  heart  preparations,  the  drugs  that  have 
potential vasoactivity can be easily and directly investigated.   
  The  original  constant  pressure  system  set  up  by  Langendorff  is  still  most 
commonly used today. Constant pressure systems can easily be achieved as a low 
cost option for laboratories, by positioning a glass chamber containing a set volume of 
perfusion buffer at a specific height above the tip of the perfusion cannula which is 
inserted  into  the  aorta.  However,  constant  pressure  can  also  be  achieved  in  other 
ways. Langendorff used a sealed pressurised chamber with a connected manometer to 
measure and maintain a constant pressure of perfusate through the heart. Working on 
the same principle, pressure control circuits using peristaltic roller pumps creating a 
negative  feedback  pressure  control  loop  combined  with  modern  plastic  chamber 
apparatus are now very popular. The main advantages of this regulated system are: 
smaller  perfusate  volumes  are  needed,  continuous  measurement  of  coronary  flow 
based on calibration of pump speeds, ease of switching between constant flow and 
constant pressure and also that two chambers can be simultaneously or alternatively 
used for the investigation of compounds or agents throughout the experiment. This 
mode is certainly advantageous and more physiological when investigating ischaemia General methods 
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and  reperfusion.  For  example,  during  constant  flow  mode,  when  the  isolated  heart 
enters ischaemia, autoregulatory changes such as adjustment to heart rate and muscle 
contraction cannot occur. The constant pressure set up is shown in Figure 2.2. 
 
Figure 2.2: Constant pressure Langendorff system controlled by Peristaltic pump 
 
2.2.1.3  Langendorff isolated rat heart-experimental steps 
2.2.1.3.1  Preparation of the Langendorff rig and perfusion buffer 
My  investigations  used  the  Langendorff  constant  pressure  perfusion  system 
(ADInstruments,  Chalgrove,  UK)  demonstrated  in  figure  2.  The  rig  was  regularly 
thoroughly cleaned with warm water to ensure all perfusion tubes are clean and free of 
any  precipitated  salts  and  the  surrounding  water  bath  systems  were  heated.  The 
perfusion  buffer  I  used  was  modified  Krebs  and  Henseleit  (KHB)  physiological  salt 
solution containing mM: NaCl 118.5, NaHCO3 25.0, KCl 4.8, MgSO4 1.2, KH2PO4 1.2, 
CaCl2 1.7 and glucose 11.0 (Table 2.2). To maintain a pH of 7.4, the buffer was gassed 
with 95% O2/5% CO2. 




Compound  Molecular Weight  mM  g/L 
NaCl  58.44  118  6.896 
NaHCO3  84.01  25  2.1 
d-Glucose  180.2  11  1.98 
KCl  74.55  4.7  0.35 
MgSO4.7H2O  246.5  1.22  0.3 
KH2PO4  136.1  1.21  0.165 
Mix thoroughly then 
add 
     
CaCl2.2H2O  147  1.84  0.27 
Table 2.2: Krebs and Henseleit (KHB) physiological salt solution composition 
 
2.2.1.3.2  Anaesthesia and excision of the heart 
Prior to any surgical procedure including excision of the heart, the animals need to be 
under general anaesthesia. There are numerous anaesthetics and delivery methods 
none of which are completely ideal, most commonly used is an intraperitoneal (I.P.) 
injection of barbiturates (thiopental/sodium pentobarbital) or  an inhalation of volatile 
anaesthetics (Halothane, Isoflurane). The latter is rarely used for an excision of the 
heart procedure as complicated equipment is required for administration and induction. 
Also,  inhaled  volatile  anaesthetics  can  be  cardioprotective;  this  is  an  important 
consideration in studies like those conducted in this thesis assessing cardioprotective 
regimens.      Sodium  pentobarbital  is  usually  the  preferred  method  of  induction  in 
non-recovery experiments; it is a barbiturate that has depressant activity on the central 
nervous  system  (CNS)  by  enhancing  the  action  of  GABA  at  the 
GABAA-receptor/chloride  channel 
457.  It  provides  deep  anaesthesia  in  animals; General methods 
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however, care must be taken as these compounds can have a very narrow therapeutic 
window where deep anaesthesia quickly develops into cardiorespiratory suppression. 
When used as a single injection of 50-60 mg/kg I.P. the rate of anaesthesia can be 
very safe and effective.  
Rats were injected with 55 mg/kg sodium pentobarbital with 300 units heparin 
I.P. Heparin was added to reduce any potential risk of coronary thrombus formation. 
The rats were placed in a clean box in a stress-free environment and monitored for loss 
of consciousness. Eventual loss of the pedal withdrawal reflex demonstrated that the 
animal was under surgical anaesthesia. Now it could be removed from the box and 
positioned supine for easy access to the chest. Briefly, an incision was made through 
the skin to expose the sternum and then the diaphragm. To expose the thoracic cavity 
the diaphragm  was cut and two diagonal incisions made from the base of the ribs 
towards the upper part of the forelimbs, to create a clamshell thoracotomy. The heart 
was slightly raised by cradled fingertips and the aorta, vena cava and pulmonary artery 
were excised in one movement. The heart was placed in ice cold KHB to clear the 
blood and to stop beating to preserve the organ from any possible ischaemic damage. 
2.2.1.3.3  Cannulation of the aorta and perfusion of the coronary system 
If necessary, the heart was gently cleaned of any connective tissue to expose the aorta 
whilst in the ice cold KHB solution. If the aorta was too long, a cut below the branching 
was made and then it was held by the forceps on either side of the opening and gently 
slipped  over  the  cannula  whilst  supplying  low  flow  of  warm,  oxygenated  KHB. The 
aorta was carefully positioned so that the cannula sat above the ostia of the coronary 
arteries and was then held in place by a crocodile clip.  The aorta was secured to the 
cannula by a suture and the clip removed. The heart immediately started to contract as 
the KHB flowed in a retrograde fashion through the coronary system. Any remaining 
blood was washed out and the heart turned pink as regular heart beat returned. Any 
remaining connective tissue or fat was removed to clean the preparation. 
2.2.1.3.4  Measuring physiological parameters 
Next, an opening was made by removing the left atrial appendage and a deflated, latex 
balloon inserted via the open atria through the mitral valve and into the left ventricle, 
this allowed measurement of cardiac function throughout the experiment. The balloon 
is attached to a catheter which connects to a pressure transducer and bridge amplifier. 
The balloon, the catheter and the transducer communicate with each other and are 
filled with distilled water, with no air bubbles to disrupt the fluid continuity. The size and General methods 
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material of the balloon is very important; the balloon must not be too large to obstruct 
the natural rhythm of the heart but must be large and sensitive enough to be able to 
recognise  any  changes  that  occur  throughout  the  experiment.  Using  tips  of 
unlubricated  latex  condoms  are  now  very  popular  due  to  their  thin,  flexible  and 
biological compatible nature. Commercially available latex balloons did not always fulfil 
these  criteria  and  therefore  homemade  cling  film  balloons  were  also  often  used. 
However, the cling film balloons need to be replaced regularly due to their properties 
changing  over  time  and  usage,  especially  in  ischaemia/reperfusion  investigations, 
where the balloon will undergo more stress.  
The balloon was then precisely inflated within the left ventricle using a syringe 
to give a preload (resting) left ventricular end diastolic pressure (LVEDP) of 8-10mmHg 
to  optimise  left  ventricular  pressure  without  over-loading  the  heart  according to the 
Frank–Starling curve 
452. The rhythmic pressure of contraction which the heart exerted 
onto  the  balloon,  transferred  via  the  attached  transducer  and  was  visualised  on  a 
computer screen.  From this recording, left ventricular systolic pressure and heart rate 
(HR) were monitored and used to calculate rate pressure product (RPP) or workload 
efficiency of the heart and also the left ventricular developed pressure (LVDP) was 
measured. Another incision was made at the base of the pulmonary trunk not only to 
facilitate coronary venous drainage but also to give access to the temperature probe 
which was inserted into the heart via this aperture.  Lastly, the flow rate was adjusted to 
give a perfusion pressure of 70 mm/Hg and set at this value for the entire experiment 
i.e. in constant pressure mode. The heart was then left to stabilise.  
2.2.1.3.5  Ischaemia 
Following  stabilisation,  Langendorff  heart  preparations  can  be  used  to  investigate 
ischaemia-reperfusion injury.  Two degrees of ischaemia can be applied: Global or 
regional  ischaemia.  Global  ischaemia  is  achieved  simply  by  preventing  flow  to  the 
entire  heart  for  a  set  period  of  time  by  turning  off  the  flow  to  the  entire  heart. 
Temperature  is  maintained  externally  by  bathing  the  heart  in  a  KHB  filled,  water 
insulated  jacket  at  37°C.    Alternatively,  regional  ischaemia  can  be  applied.  This  is 
considered  to  represent  an  acute  myocardial  infarction  whereby  a  blockade  in  the 
coronary system occurs. Regional ischaemia is achieved by passing a suture through 
the surface of the heart to surround the left anterior descending coronary artery (LAD), 
the  vessel  that  supplies  the  left  ventricular  coronary  system  with  perfusate.  The 
consistency of the rat coronary system 
458 allows reference points to be used to place 
the suture around the LAD (Figure 2.3). Ideally, the suture placement will allow for General methods 
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approximately 50% of the left ventricle to be ‘risk zone’. When required, the suture can 
be temporarily tightened using a snare system created from pipette tips and occlude 
the  LAD  hence  causing  ischaemia.  In  constant  pressure  mode,  at  least  a  30% 
reduction  in  coronary  flow  and  developed  pressure  is  expected  to  confirm  correct 
positioning of the suture.  When using regional ischaemia, it is important to place the 
suture before inserting the intraventricular balloon to prevent any possible puncturing.  
 
Figure 2.3: Reference points used to ensure suture is placed surrounding the left anterior descending 
coronary artery (LAD):  
2.2.1.3.6  Reperfusion  
Reperfusion  is  an  essential  part  of  a  Langendorff  experiment;  in  either  ischaemic 
models it involves the return of the flow to the ischaemic area. In the case of global 
ischaemia, it is simply by switching the pump controller back on or a three-way tap to 
open. In regional ischaemia, flow is re-established by loosening the snare system; as a 
sign of sufficient reperfusion, one would expect at least an initial partial recovery of 
coronary flow and developed pressure. It is important that the suture remains intact for 
area  at  risk  determination.    Traditionally  120  minutes  of  reperfusion  was  used  for 
isolated  rat  heart  preparations  however  recent  studies  have  shown  a  clear  infarct 
demarcation after 60 minutes 
459, 460, this is explained further in characterisation of the 
model section. 
2.2.1.4  Essential criteria for a successful Langendorff experiment 
To  achieve  consistent  and  reproducible  data  using  the  Langendorff  isolated  heart 
model  there  are  key  stages  throughout  the  experiment  that  need  special  attention. 
Firstly, accurate preparation of the buffer and sufficient heating and oxygenation are 
required to reach an appropriate pH prior to  perfusing  the heart
461. This should be 
monitored using a blood gas analyser to ensure that the pH is consistent throughout 
the experiment.  Perfusion tubing should be carefully checked to ensure no air bubbles General methods 
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are in the system, which could block coronary arteries and result in a deleterious or a 
complete loss of function in the perfused heart. 
Excision of the heart and cannulation of the aorta are the most important and 
sometimes most difficult steps of the experiment. Care must be taken in the handling 
and excision of the heart, any damage caused to the organ can lead to inconsistent 
results 
462,  463  and  a  sufficient  length  of  aorta  is  required  to  allow  for  successful 
cannulation. Speed of cannulation and hence return of coronary perfusion to the heart 
is vital, prolonged cannulation time can either lead to myocardial damage or activation 
of stress signalling pathways causing the heart to enter a preconditioned state 
464, 465. 
The depth at which the cannula is inserted into the aorta can cause numerous 
problems and is normally signalled by an unexpectedly high or low flow rate through 
the heart. High flow rates often indicate a tear in the aortic wall, which can occur during 
instrumentation of the heart or a damaged aortic valve possibly caused by the cannula 
being inserted too deep and then being removed during cannulation. It is therefore 
difficult to tell whether the increased flow rate is indicative of perfusion through the 
coronary  branches.  Low  flow  rates  often  coincide  with  poor  heart  function  and 
arrhythmias;  this  can  often  be  caused  by  a  deeply-positioned  cannula  partially 
occluding the coronary ostia and therefore restricting coronary flow. Embolisation of the 
coronary vessels by air bubbles or buffer particulate can also cause low flow rates.  
  Maintaining  temperature  throughout  the  entire  procedure  is  an  essential 
component of an isolated heart perfusion. Temperature should be tightly controlled; a 
small  fluctuation  in  temperature  by  as  little  as  2°C  can  lead  to  distinct  changes  in 
myocardial  contractility  and  heart  rate 
463,  466.  Temperature  change  can  lead  to 
substantial  differences  in  end  point  assessment  of  cell  death  following  ischaemia-
reperfusion
467.  Triggering  of  signalling  pathways  that  lead  to  preconditioning-like 
cardioprotection can occur in response to either hypothermia 
468 or hyperthermia 
469 
and will interfere with studies investigating cardioprotective manoeuvres. Therefore it is 
vital  that  temperature  is  continuously  monitored  and  adjusted  throughout  the 
experiment.  
  To ensure consistency of data analysis and interpretation of results, exclusion 
criteria are set for heart preparations that undergo technical errors and display some of 
the aforementioned problems. These exclusion criteria should be strictly adhered to 
and are summarised in Table 2.3. 




Parameter  Rat heart 
Time to perfusion (min)  >3 
Coronary flow (ml/min)  <10 or >28 
Sustained Arrhythmias (min)  >3 
Heart rate (beats per min)  <150 or >400 
Left ventricular developed pressure (mm Hg)  <70 
Rate Pressure Product (mm Hg/sec)  <17000 
Table 2.3: Exclusion criteria for rat Langendorff experiments.  The numbers displayed for each criterion 
are the minimum value accepted to deem a heart appropriate for experimental investigation. 
 
2.2.1.5  Advantages and disadvantages of the Langendorff isolated heart 
There are numerous advantages and disadvantages of the Langendorff isolated heart, 
these are outlined in Table 2.4. 
Advantages  Disadvantages 
  Provides highly reproducible results    Heart is vulnerable to damage caused 
by  excision  and  oedema  caused  by 
crystalloid solutions 
  Cost effective    Heart  can  be  inadvertently 
preconditioned 
  Not  as time consuming or  technically 
demanding as other techniques 
  Retrograde perfusion can cause aortic 
valve  incompetence  if  perfusion 
pressure is high 
  High  data  output  from  a  single 
experiment 
  Non physiological coronary flow rate 
  Physiological  preparation  (whole 
myogenically beating heart) 
  Lacks  normal  humoral  and  neuronal 
regulation General methods 
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Advantages  Disadvantages 
  Direct  assessment  of  cardioprotective 
myocardial drugs   
 
  Pathological  parameters  easily 
controlled  and  assessed  (hypoxia, 
arrhythmias,infarction) 
 
  Cardiotoxicity assessment of potential 
drug compounds 
 
Table 2.4: Advantages and disadvantages of the Langendorff isolated heart preparation 
 
2.2.2  In vivo coronary artery occlusion/2 hour reperfusion (non-recovery 
model) 
2.2.2.1  Introduction 
In  vivo  myocardial  ischaemia-reperfusion  injury  is  however  a  more  physiologically 
relevant model.  The heart is being supplied with blood not a crystalloid buffer solution, 
allowing for inflammatory factors to contribute to cell death and to investigate whole 
body influence on infarct size.   
2.2.2.2  Surgical Procedure 
The  Surgical  procedure  is  summarised  in  Figure  2.4.  Rats  were  anesthetised  with 
sodium pentobarbital (20mg/kg intraperitoneally).  Surgical depth of anaesthesia was 
confirmed by the loss of the pedal withdraw reflex, the area of fur surrounding the 
incision  point  was  shaved  and  the  rats  secured  onto  a  self-regulated  temperature 
control mat (CMA450, Harvard apparatus) on a flat board (A).  The flat board was tilted 
to a 45° angle (B), the rats were intubated and ventilated with a Harvard ventilator 
(room air, 70 strokes/min, tidal volume: 8-9ml/kg). Body temperature was maintained at 
37.4±1°C by means of a rectal probe thermometer attached to the temperature control 
system and electrical activity of the heart monitored by placement of ECG probes (C).  
A lateral thoracotomy was performed between 4
th and 5
th intercostal space (D) and a 
chest clamp inserted to expose the heart (E).  The pericardium was gently removed 
and location of LAD was confirmed by sight. A 6-0 suture passed around the LAD by a 
sweeping semi-circular motion from left to right to ensure the suture did not puncture 
the exposed lung (F). The loop system was carefully placed onto the sutures and left 
on the surface of the heart (G). Following stabilisation, the suture was tightened using General methods 
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the loop system to create LAD ligation and clamped to maintain pressure throughout 
the  experiment  (H).    Regional  ischaemia  was  confirmed  by  ST  segment  elevation, 
blanching and colour change of the myocardium (I). After 30 minutes of ischaemia, the 
loops were pulled free to loosen the suture and reperfuse the vessel for 120 minutes.  
Successful  reperfusion  was  classified  by  colour  return  to  the  occluded  area  and  a 
decrease in ST elevation seen during ischaemia. Typical ECG changes are shown in 
Figure 2.5.  Depth of anaesthesia was checked every 5 min throughout the experiment 
and animals were topped up as needed.  
 
Figure 2.4: Surgical steps for In vivo coronary artery occlusion/ reperfusion model.  (A). Fur was removed 
around the incision point and the rats secured onto a self-regulated temperature control mat on a flat 
board (B) The flat board was tilted to a 45° angle and the rats were intubated (C). Insertion of rectal probe 
thermometer and placement of ECG probes. (D) A lateral thoracotomy 4th and 5th intercostal space (E) 
Chest clamp inserted to expose the heart (F) Removal of the pericardium, LAD located and a 6-0 suture 
passed around the LAD by a sweeping semi-circular motion from left to right to (G). The loop system 
placed onto the sutures and left on the surface of the heart (H). Tightening of the suture caused LAD 




Figure 2.5: Typical ECG changes during ischaemia-reperfusion model.  A. During stabilisation normal ECG 
profile  seen.  B.  Upon  occlusion  of  the  LAD,  elevation  and  widening  of  the  ST  segment.  C.  During 
reperfusion, ST segment elevation is decreased, often accompanied by an anterior Q wave. 
 
2.2.3  In vivo coronary artery occlusion/reperfusion (recovery model) 
2.2.3.1  Surgical Procedure 
Rats were anesthetised with a cocktail containing ketamine (65 mg/kg), xylazine (13 
mg/kg), and acepromazine (1.5 mg/kg) (I.P) and the surgical procedure performed as 
described above, however during ischaemia Buprinorphine was administered I.P. At 
the end of ischaemia, the suture was left surrounding the LAD and the ends cut short to 
tuck into the chest cavity. The intercostal space was closed with a 4-0 suture and the 
skin incision closed with wound clips. Care was taken to remove the air from the chest 
cavity  by  creating  an  end  positive  pressure  and  the  skin  simultaneously  clamped 
together before stapling.  The ventilator was removed and the rat immediately received 
a loose supply of carbogen (95% O2/5% CO2) to aid recovery. The rat was kept warm 
and was monitored until it regained its ‘righting reflex’. Depending on the aim of the 
study, the animal can be allowed to recover upwards of 2 hours. Although successfully 
performed whilst learning the technique, this method was not used to generate results 
in this thesis. General methods 
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2.2.4  Infarct size determination 
Infarct  size  is  determined  by  triphenyltetrazolium  chloride  (TTC)  staining.  TTC  is  a 
reducing  agent  which  can  cross  cellular  membranes  to  react  with  intracellular 
dehydrogenases such as NADPH, to form a formazan pigment. In viable tissue, TTC 
reacts with preserved NADPH within cells and forms a red precipitate. However, dead 
cells have disrupted membranes which allow enzymes’ to wash out, less therefore the 
reaction cannot occur and the tissue appears as a pale white colour.  Other surrogate 
end-points such as enzyme release, cell viability in cultured cells and recovery of post 
ischaemic function are often used; however these are not accurate measurements of 
tissue  death.  Though,  TTC  method  of  staining  has  become  very  reliable, 
considerations  still  must  be  taken  for  false  negative  or  false  positive  staining.  For 
example, tissues could stain positive (red) because sufficient enzyme washing out has 
not occurred. 
2.2.4.1  Preparation of TTC solution 
TTC  powder  was  dissolved  in  a  buffer  (pH  of  7.4)  obtained  by  mixing  a  2  part 
phosphate buffer system. Initially, two phosphate buffer solutions were made: a high 
pH solution (1) consisting of Na2HPO4
 [0.1M] and a low pH solution (2) consisting of 
NaH2PO4
 [0.1M]. To make 0.1M stock solutions of (1) and (2): the molecular weight of 
NaH2PO4 is 120 therefore 12g was mixed in 1L of distilled water for solution (1) and the 
molecular weight of Na2HPO4 is 142 therefore 14.2g was mixed in 1L of distilled water 
for solution 2. To give a final pH of 7.4, these solutions were mixed in a ratio of 8 parts 
of solution 1 to 2 parts of solution 2.  An appropriate volume of TTC solution was made 
fresh for each day of use, for each heart 10 mls is sufficient. TTC solution was used at 
1% weight/volume (1g/100ml), i.e. for 10 mls 100 mg of powder was added.  
2.2.4.2  Regional Ischaemia infarct assessment 
On  completion  of  regional  ischaemia/reperfusion  protocol  either  ex  vivo  or  in  vivo, 
hearts  undergo  a  two-step  staining  procedure  using  Evans  blue  dye  and  TTC.  For 
Langendorff perfused hearts: at the end of reperfusion, the suture surrounding the LAD 
was permanently retied and Evans blue (0.5% in distilled water) was infused via the 
cannula into the coronary system. For in vivo hearts: at the end of reperfusion, the 
heart was removed as  described (section  2.2.1.3.2).  The heart was attached to a 
cannula via the aorta and secured with a suture. The heart is perfused with warmed 
modified KHB and the blood cleared from the coronary system. The LAD was then 
permanently re-occluded and Evans blue (0.5% in distilled water) was infused via the General methods 
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cannula  into  the  coronary  system.      The  dye  defines  the  area  at  risk  within  the 
myocardium,  by  perfusing  and  staining  all  regions  supplied  above  the  LAD  suture 
occlusion.  The area at risk remains a pale pink colour as the suture prevents entrance 
of blue dye in the arteries below it. This process is summarised in Figure 2.6. Hearts 
are decannulated, weighed, wrapped in cling film (to prevent freeze-drying) and then 
frozen at -20°C. Freezing of the hearts is not essential; however it allows for easier 
slicing and puts the heart into a rigor state. If fresh hearts are put into TTC the tissue 
enters contracture which can distort the infarct making analysis very problematic.  
 
Figure 2.6: Evans blue staining at the end of reperfusion.(1) In vivo hearts were excised from the animal 
following an ischaemia-reperfusion protocol, cannulated via the aorta and perfused with warm KHB to 
remove the blood (2). For all hearts: (3) the suture was then permanently retied occluding the LAD. (4) 
0.5% Evans Blue dyed was then perfused via the aorta to dilineate the area at risk (AAR) within the left 
ventricle. 
 
2.2.4.3  Global Ischaemia infarct assessment 
In this case, the use of Evans blue dye is not necessary as all the heart was at risk 
during ischaemia.  On completion of global ischaemia/reperfusion, hearts undergo a 
one-step staining protocol using TTC.  Hearts were decannulated, weighed, wrapped in 
cling film (to prevent freeze-drying) and then frozen at -20°C.  General methods 
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2.2.4.4  General heart slicing and TTC staining protocol 
The  frozen  hearts  were  sectioned  perpendicular  to  the  long  axis  into  a  number  of 
slices, for most rat hearts 5, 2-3mm slices are appropriate. Heart slices were arranged 
and compressed for a few minutes under a heavy block to prevent any curling when 
entering warm TTC solution. Heart slices were then incubated in 10 ml pre-warmed 1% 
TTC solution in a 37°C water bath for 20 min, every 5 min the tubes were swirled to 
ensure  equal  incubation  of  all  slices.  Following  TTC  incubation,  the  regionally 
ischaemic  hearts  should  express  3  colours:  red,  white  and  blue  and  the  globally 
ischaemic hearts just red and white (Figure 2.7).  The hearts were then incubated in 
10% formalin solution overnight to help increase the contrast between the viable (red) 
and non-viable (white) tissue.  
 
Figure  2.7:  Heart  slicing  and  infarct  staining.  Hearts  are  removed  from  the  freezer  and  sliced 
perpendicular to the long axis into 5 slices. Slices incubated with 1% TTC solution should express 3 colours: 
red, white and blue. 
 
2.2.4.5  Infarct size measurement 
The following day, heart slices were arranged in order from apex to base between two 
glass plates, compressed to a 2mm thickness and scanned into a digital image using a 
flatbed scanner. The image was calibrated, enabling the conversion of slice area to 
slice volume, allowing for computerised analysis of infarct volume within each slice (for 
global ischaemia) and within the risk zone of each slice (for regional ischaemia) using 
image J software. Regional ischaemia was used for all infarction studies in this thesis, 
and the results are expressed as infarct to risk zone ratio (I/R%). General methods 
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2.3  Characterisation of the Langendorff isolated heart model 
2.3.1  Introduction 
The  Langendorff  isolated  heart  model  has  been  well  characterised  by  many 
laboratories; the most common experimental protocol used for the isolated rat heart is 
35 min of ischaemia followed by 120 min reperfusion 
450. This protocol was deemed 
successful due to the length of ischaemia and reperfusion causing reproducible levels 
of cell death to allow for accurate examination of potential cardioprotective strategies. 
Reperfusion  time  is  extremely  important,  not  only  to  allow  for  reperfusion  injury  to 
occur, but also when assessing infarct size using TTC staining.  As described earlier, 
accurate TTC staining requires adequate ‘wash out’ of dehydrogenase enzymes, if this 
does not occur results can be misleading.  In 2009, Ferrera et al, demonstrated that 60 
min of reperfusion was enough to assess function and infarct size with TTC in the 
Langendorff rat model. They found no significant differences in infarct size in control 
groups or hearts subjected to IPost followed by either 60 min or 120 min reperfusion 
459. Therefore, characterisation of different reperfusion times following hearts subjected 
to ischaemia was needed to ensure this could be repeated in our Langendorff model. 
To confirm successful set up of the Langendorff preparation in my hands, as a positive 
control, I also subjected 2 groups of hearts to IPC protocols followed by either 60 min 
or 120 min reperfusion.  
2.3.2  Experimental protocol 
For determination of infarct size, Sprague Dawley rats (300-350g) were anesthetized 
with sodium pentobarbital (55 mg/kg I.P.) and heparin (300 IU). The hearts were rapidly 
excised,  placed  into  ice  cold  Krebs-Henseleit  buffer,  and  quickly  mounted  onto  a 
Langendorff constant pressure perfusion system (ADInstruments, Chalgrove, UK). The 
hearts were perfused via the aorta with modified Krebs-Henseleit bicarbonate buffer 
(KH) (mM: NaCl 118.5, NaHCO3 25.0, KCl 4.8, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.7 and 
glucose 11.0). The buffer was gassed with 95% O2/5% CO2 to maintain a pH of 7.4. A 
suture was placed around the LAD and secured in place by a snare created from two 
pipette tips. A fluid filled latex balloon was inserted into the left ventricle through an 
incision in the left atrial appendage and inflated to a left ventricular end developed 
pressure  (LVEDP)  of  8-10mmHg.    Perfusion  pressure  was  set  at  70mmHg,  LVDP, 
heart  rate  (HR)  and  coronary  flow  (CF)  were  permanently  monitored  and  the  rate 
pressure  product  (RPP)  calculated.  An  electronic  thermo  probe  inserted  into  the 
pulmonary artery continuously monitored temperature which was kept in range of 37°C 
± 0.5.    General methods 
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  Following stabilization, hearts were randomly assigned to receive one of the 
protocols summarized in Figure 2.8. Regional ischaemia was initiated by tightening the 
suture around the LAD and holding it in place with the snare. The snare was then 
removed and the hearts reperfused for either 60 or 120 min.  At the end of this period 
the suture was permanently tied to occlude the LAD and Evans blue dye (0.25% in 
saline) was infused through the aorta to delineate the risk zone, with the myocardial 
tissue not at risk staining blue. Hearts were stored at -20°C for several hours before 
being transversely sliced into 2mm thick sections and incubated in TTC.  The slices 
were then transferred to 10% formalin overnight for better delineation between zones. 
The following day the slices were scanned into the computer for analysis. Image J was 
used to calculate the infarct to risk zone ratio (I/R%). 
 
Figure 2.8: Langendorff experimental protocols.  Hearts isolated from Sprague-Dawley rats were isolated 
and  subjected  to  one  of  the  following  protocols:  (1)  Control  (60  min  reperfusion)  (2)  IPC  (60  min 
reperfusion) (3) Sham (60 min reperfusion) (4) Control (120 min reperfusion) (5) IPC (120 min reperfusion) 
or (6) Sham (120 min reperfusion. At the end of each protocol hearts were collected for infarct size 
assessment (I/R%-Infarct to risk zone ratio). General methods 
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2.3.3  Infarct  size  in  Sprague  Dawley  rats:  reperfusion  time  and 
assessment of ischaemic preconditioning 
To confirm successful set up of the model it was important to assess the procedural 
damage caused to the heart during the experimental procedure itself, these are known 
as ‘sham’ experiments. For results to be deemed statistically significant, the difference 
between  groups  should  be greater  than the  damage  produced  by  the  sham  alone. 
Sham experiments are simply hearts that are perfused with KHB in Langendorff mode 
for  the  same  duration  of  an  ischaemia/reperfusion  experiment  but  they  are  not 
subjected to any injury.  There was no difference in the necrotic tissue extent between 
sham matched experiments for ischaemia/60 min reperfusion and ischaemia/120 min 
reperfusion (I/R%: 10.1±2.1 vs 12.1±1, p=NS), that is 135 min and 195 min ex vivo. 
Another important step in validating the Langendorff regional ischaemia model 
was the reproducibility of the suture placement, i.e. the area at risk in the myocardium 
(AAR). For an experiment to be accepted AAR must be between 45-65% of the left 
ventricle.  If  the  AAR  was  outside  of  these  limits,  it  was  likely  that  either  the  main 
coronary artery was ligated and the injury will be extremely severe and the heart may 
die during the procedure, or lower branches have been occluded by the suture and in 
this  case,  the  injury  will  be  minimal  and  will  give  a  false  positive  result.  AAR  was 
consistent between all groups shown in Figure 2.9 . 
Infarct size assessment showed that there was no significant difference in I/R% 
between the hearts reperfused for 60 min compared to 120 min (I/R%: 43.7±2.3 vs. 
45.1±3.9,  p=NS,  Figure  2.10).  My  results  confirmed  that  60  min  of  reperfusion 
following  release  of  the  snare  is  sufficient  to  give  a  reproducible  and  accurate 




Figure 2.9: Area at risk (AAR) in isolated Sprague-Dawley rat hearts subjected to ischaemia-reperfusion 
protocols.  No difference was recorded in the area at risk (AAR) delineated by Evan’s  blue staining, 
between hearts subjected to sham, control or IPC protocols. 
 
Figure  2.10:  Comparison  of  reperfusion  times  in  isolated  hearts  isolated  from  Sprague-Dawley  rats 
subjected  to  either  sham  or  control  protocols.  Infarct  size  assessment  showed  that  there  was  no 
significant difference in the infarct to risk zone ratio (I/R%) between the hearts reperfused for 60 min 
compared  .to  120  min  in  either  protocol.  Statistical  analysis  was  determined  using  One-way  ANOVA 
followed by Tukey’s post hoc analysis, p<0.001, n>4. 
IPC has proven to be a highly reproducible, protective phenomenon against IRI 
in numerous species 
123.To further validate the model, I assessed whether Sprague 
Dawley  rat  hearts  could  be  protected  against  IRI  by  3  cycles  of  IPC  and  whether 
different  lengths  of  reperfusion  affected  the  outcome  of  this  cardioprotective 
manoeuvre. IPC reduced infarct size in Sprague Dawley hearts by approximately 50% 
and there was no difference between 60 min or 120 min reperfusion (I/R%: control, 
43.7±2.3  vs.  IPC,  22.8±2.3  for  1  hour  reperfusion,  and  control,  45.0±3.9  vs.  IPC, 




Figure 2.11: Comparison of reperfusion times in isolated hearts from Sprague-Dawley rats subjected to 
control or ischaemic preconditioning (IPC) protocols.  Infarct size assessment showed that there was a 
significant  reduction  in  infarct  to  risk  zone  ratio  (I/R%)  when  IPC  was  applied  prior  to  ischaemia-
reperfusion irrespective of reperfusion time. Statistical analysis was determined using One-way ANOVA 
followed by Tukey’s post hoc analysis, p<0.001, n>6. 
 
2.4  Isolated adult cardiomyocytes 
2.4.1  Introduction 
Myocyte isolation has been performed for almost 40 years. Since Powell and Twist 
described a rapid technique for the isolation and purification of adult cardiac muscle 
cells 
470,  it  has  become  a  widely  used  and  scientifically  important  tool.  Many 
investigators simply use enzymatic digestion of the left ventricle using agitation and 
dicing techniques, however, an alternative reproducible method yielding high quality 
cardiomyocytes  is  the  use  of  the  Langendorff  isolated  heart  method.  This  method 
perfuses the heart with digestion buffer via the coronary system ensuring that minimal 
damage  is  caused  to  the  heart  cells  and  that  equal  exposure  of  the  ventricles  to 
digestion occurs.  
2.4.2  Standard Isolation protocol 
Hearts were extracted and rapidly hung via the aorta onto a cannula attached to a 
simplified Langendorff system, and perfused with a constant flow rate of 10ml/min.  For 
collagenase digestion, a stock perfusion solution was prepared (Table 2.5), and then 






g/500ml  g/L  g/2L 
NaCl  130  3.79  7.59  15.18 
KCl  5.4  0.2  0.4  0.8 
MgCl2   1.4  0.066  0.133  0.266 
Na2HPO4  0.4  0.028  0.057  0.114 
HEPES   4.2  0.5  1  2 
pH to 7.3 at 37ºC 
Glucose †   10  0.9  1.8  3.6 
Taurine †   20  1.25  2.5  5 
Creatine †   10  0.655  1.31  2.62 
Table 2.5: Composition of the stock perfusion solution required for isolation of cardiomyocytes. 
 
Stock Perfusion Solution  Final concentration  Addition to volume 
stated in first column 
(1) 50 mls (to clear heart 
of blood)  750 µM CaCl2  37.5 µl of 1M CaCl2 
(2) 50 mls (to arrest 
heart)  100 µM EGTA  2 mg of EGTA 
(3) 40 mls (to digest 
heart) 
100 µM CaCl2 and 
0.5mg/ml Collagenase 
40 µl of 100mM CaCl2 
15-20 mg of collagenase 
(4) 50 mls (to re-introduce 
CaCl2)  0.5 mM CaCl2  25 µl of 1M CaCl2 
(5) 50 mls (to re-introduce 
CaCl2)  1 mM CaCl2  50 µl of 1M CaCl2 
Table  2.6:  Additional components to  be added to  each specific  stock perfusion solution  on day of 
isolation. 
Hearts were initially perfused with solution (1), containing a low concentration of 
calcium which is required to initiate a stable contraction and clear the heart of blood. 
After 4 minutes of perfusion with solution (1), any remaining solution (1) was carefully 
removed  and  replaced  with  solution  (2).  Solution  (2),  containing  EGTA,  arrests  the 
heart to prevent contracture of the cardiomyocytes. Following 4 minutes perfusion with General methods 
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solution (2), any remaining solution was carefully removed and replaced with solution 
(3) to initiate enzymatic digestion.  Solution (3) contained type II collagenase and was 
re circulated to allow for 8minutes of digestion or until the heart appeared swollen and 
changed colour.  The heart was sectioned below the atria, and the ventricular tissue 
was cut up into smaller pieces and resuspended in 20 mls of solution (3). This solution 
was kept at 37 °C and agitated gently with pure O2 for between 15 and 20minutes to 
continue digestion. Pieces of ventricular tissue were finally teased apart using a cut 
Pasteur pipette.  
Undigested tissue was removed by filtration through a piece of sterile gauze 
and the remaining suspension was left for 8 minutes to allow viable cardiomyocytes to 
form a pellet at the bottom of the falcon. The supernatant containing dead cells was 
removed and the pellet of live cells was resuspended gently in warmed solution (4), 
and  then  repeated  using  solution  (5).  Myocytes  were  finally  resuspended  in  M199 
medium  with  added  penicillin  (100 IU/ml),  streptomycin  (100 IU/ml),  L-carnitine  (2 mM), 
creatine (5 mM), taurine (5 mM) and BSA (2g/L) (Medium 199, Sigma, UK) and plated on pre-
laminated 6 well plates for 2-24 hours prior to experimental investigations described in 
later chapters.  
2.4.3  Isolation of cardiomyocytes from old, diabetic rat hearts 
Traditional collagense type II digestion worked when characterising the model using 
young,  healthy  Sprague  Dawley  rats,  however,  problems  arose  when  attempting to 
isolate  old  and  diabetic  cardiomyocytes.    Modifications  of  the  method  included 
increasing  the  concentration  of  collagenase,  increasing  digestion  time  and  allowing 
cells to pellet for longer however the yields were still disappointing. For old, diabetic rat 
hearts, better results were obtained when the digestion was performed with Liberase 
TM (Roche applied science), which consists of an equal ratio blend of highly purified 
Collagenase  I  and  II  and  also  the  neutral  protease  thermolysin,  giving  a  higher 
protease activity. Liberase-digestion protocol was previously characterised by another 
lab  member.  The  same  stock  perfusion  buffer  was  used  Table  2.5,  however  the 
additions were adjusted as shown in Table 2.7.  
   General methods 
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Stock Perfusion Solution  Final concentration  Addition  to  volume 
stated in first column 
(1) 50 mls (to clear heart 
of blood) 
750 µM CaCl2  37.5 µl of 1M CaCl2 
(2) 50 mls (to arrest heart)  100 µM EGTA  2 mg of EGTA 
(3)  30  mls  (to  digest 
heart) 
(Stablise  solution  in 
incubator  for  at  least  30 
min prior to use) 
0.2 mg/ml Liberase 
0.14 mg/ml Trypsin   
5x10
-3 U/ml DNAse 
12.5 µM CaCl2 
5 mg of Liberase 
167 µl of 2.5% Trypsin  
1.5 µl of 100U/ml DNAse  
3.75 µl of 100 mM CaCl2 
(4)  18  mls  (to  stop 
Liberase  and  re-
introduce CaCl2 ) 
12.5 µM CaCl2 
10%  Fetal  Bovine  Serum 
(FBS) 
25 µl of 10 mM CaCl2 
2 ml of 100% FBS 
(5)  19  mls  (to  stop 
Liberase  and  re-
introduce CaCl2) 
12.5 µM CaCl2 
5% FBS 
25 µl of 10 mM CaCl2 
1 ml of 100% FBS 
Table 2.7: Additional components to be added to stock perfusion solution on day of isolation 
Hearts were subjected to the same protocol of perfusion as described above 
solutions (1) to (5). However, a slower reintroduction of calcium was required. 10 ml 
aliquots  of  solution  (5)  were  made  containing  increasing  concentrations  of  CaCl2 
(60µM-1mM). Cells were resuspended and left to pellet in each solution until 1 mM 
CaCl2 was introduced.  
2.5  Western  Blot  Analysis  to  detect  protein  expression  or 
activation status 
2.5.1  Introduction 
Western  Blot  Analysis  is  an  analytical  method  by  which  protein  expression, 
identification  and  quantification  can  be  assessed.  It  is  a  powerful  and  reproducible 
method,  consisting  of  three  distinct  steps:  (1)  SDS-PAGE  gel  electrophoresis  to 
separate a complex mixture of proteins based on their size, (2) Western blotting to 
transfer proteins from a gel to a membrane support and (3) detection of proteins using 
horse-radish peroxidase (HRP)-linked antibodies.    General methods 
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2.5.2  Extraction and quantification of protein samples 
Protein  can  be  extracted  from  a  variety  of  sources  including  whole  tissue  samples 
(heart), primary cells (cardiomyocytes) or cell lines (HL-1). All 3 can be subjected to 
different  protocols  such  as  drug  treatments,  hypoxia  or  ischaemia/reperfusion  and 
samples collected at different time points to assess protein expression, activation or 
translational modifications using Western Blot analysis.  
2.5.2.1  Sample collection (tissues and cells)  
Whole  heart  samples  were  collected  using  the  Langendorff  set  up;  hearts  were 
prepared as described in section 2.2.1.3.3, cannulated via the aorta and retrogradely 
perfused with oxygenated KHB.  Following the desired protocol, hearts were cut below 
the atria and immediately snap frozen using liquid N2 and stored at -80°C until used. 
Heart tissue was homogenised using a PBS based homogenisation buffer containing a 
phosphatase inhibitor, a protease inhibitor and EDTA to preserve proteins of interest 
and  their  activation  states.  Protease  and  phosphatase  enzymes  are  usually  tightly 
controlled  within  cellular  compartments  and  play  a  vital  role  in  many  signalling 
pathways, however homogenisation and subsequent cell lysis disrupts the regulated 
cellular environment. Hearts were homogenised at 100mg/ml using an electric tissue 
homogeniser and kept on ice.  
2.5.2.2  Protein content determination 
Protein content was determined using bicinchoninic acid (BCA) protein assay (Sigma, 
UK)  and  an  automated  96-well  plate  reader  (Fluostar  Omega,  BMG  Labtech).  The 
assay consists of two distinct reactions: BCA is an alkali colorimetric assay reagent 
containing Cu
2+, in the presence of protein, peptide bonds reduce Cu
2+ to Cu
1+ leading 
to the completion of reaction 1 and the formation of a light blue complex (the biuret 
reaction). Reaction 2 involves BCA chelating Cu
1+ in a temperature sensitive reaction 
aided by the three amino acid residues cysteine, tyrosine and tryptophan. The intensity 
of the purple-coloured product  is  proportional to the level of protein in the sample. 
Plates were read at an absorbance wavelength of 563nm and contained a series of 
samples with known protein concentrations (0-2mg/ml protein).  All samples were run 
in duplicate.  A protein standard curve was created by plotting absorbance against the 
protein concentration of the known samples and used to determine the concentration of 




Figure 2.12: Typical protein standard curve using a BCA assay 
 
2.5.2.3  Sample preparation 
Based on the result of the protein content determination described above, samples 
were corrected to equal concentrations. All samples were adjusted to the sample that 
contained  the  lowest  concentration  of  protein  by  adding  different  volumes  of 
homogenisation  buffer  (Table  2.8).  All  heart  samples  were  diluted  in  Laemelli  lysis 
buffer  (Sigma,  UK)  containing  5%  β-mercaptoethanol,  at  a  1:1  ratio.    β-
mercaptoethanol denatures the proteins and Laemelli lysis buffer ensures a uniform 
charge across samples. Plated cardiomyocytes and HL-1 cells were simply collected 
by  washing  with  warm  PBS,  followed  by  addition  of  100µl  of  Lamelli  lysis  buffer 
containing  5%  β-mercaptoethanol  and  then  the  wells  scraped  and  collected  into 
ependorffs. Samples were then heated to 80-90°C for 10 minutes to ensure protein 
denaturation. Finally, samples were centrifuged at 8000 rpm for 5 minutes, and kept on 
ice. 
 
Table 2.8: The adjustment of samples to give equal protein concentrations within in sample. 
GK3-1 GK3-2 GK3-3 GK3-1 GK3-2 GK3-3 GK3-1 GK3-2 GK3-3
1.113 0.946 1.275 0.850 1.000 0.742 0.150 0.000 0.258
GK8-1 GK8-2 GK8-3 GK8-1 GK8-2 GK8-3 GK8-1 GK8-2 GK8-3
0.995 1.471 1.767 0.950 0.643 0.535 0.050 0.357 0.465
GK12-1 GK12-2 GK12-3 GK12-1 GK12-2 GK12-3 GK12-1 GK12-2 GK12-3
1.555 1.438 1.569 0.608 0.658 0.603 0.392 0.342 0.397
GK18-1 GK18-2 GK18-3 GK18-1 GK18-2 GK18-3 GK18-1 GK18-2 GK18-3
1.605 1.134 1.501 0.589 0.834 0.630 0.411 0.166 0.370
The number highlighted in red represents the sample with the lowest concentration of protein. 
Homogenisation Buffer volume required (ml) Sample volume required (ml) Concentration of protein (mg/ml)General methods 
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2.5.3  Gel electrophoresis 
Electrophoretic  separation  of  proteins  is  performed  using  gels  containing  Sodium-
dodecylsulfate (SDS) and Polyacrylamide (PAGE) gels. SDS is an ionic detergent that 
denatures multimeric proteins and polypeptide chains so that all proteins have similar 
charge:mass ratios; this allows size to be the sole determinant of migration rate. When 
an electrical field is applied, smaller proteins migrate faster through the gel than larger 
proteins therefore proteins can be separated according to their molecular weight. SDS-
PAGE gels contain pores made from a solution of acrylamide monomers being cross 
linked into a polyacrylamide chain matrix. The percentage of the gel is related to the 
pore size and this can be adjusted by the amount of acrylamide added. The rates at 
which proteins migrate are affected by the electrical field applied and the pore size. 
SDS-PAGE electrophoresis was conducted using the Mini Protean III system 
(BioRad, UK). Different gel percentages were made in respect to the protein of interest 
being  analysed,  gel  compositions  are  shown  in  Table  2.9,  TEMED  and  APS  were 
added immediately prior to use. Gels were made by pouring approximately 3.5mls of 
resolving gel between two glass plates held in a casting frame, 50% isopropanol was 
gently pipetted onto the unset resolving gel to ensure it set flat. Once the resolving gel 
was set, the isopropanol was removed and TEMED and APS added to the stacking gel. 
Quickly, 1ml (or the volume needed to fill the remaining space between the plates) was 
pipetted between the plates on top of the resolving gel and either 12 or 15 well combs 
were inserted into the stacking gel to provide wells for sample loading. Plates were 
removed  from  the  casting  frames,  placed  into  running  tanks,  immersed  in  running 
buffer  (0.25mM  Tris-Base,  0.19M  glycine,  0.1%  SDS)  and  the  combs  removed. 
Molecular weight marker (BioRad, UK) was loaded into the first well on the left hand 
side of the gel, and lamelli-diluted protein samples loaded from left to right into the 
wells.  An electric field was applied to the gel (180-200V) until the bromophenol blue 
dye had run off the gel and in some cases until the blue 50mW marker was near the 
bottom to allow for a further separation of proteins.  




Volume to add 
to make two 10 
% resolving 
gels. 
Volume to add 





1M Tris-HCl (pH 8.8)  3.75 ml  3.75 ml   
1M Tris-HCl (pH 6.8)  -  -  0.625 ml 
30% Acrylamide  3.34 ml  2.66 ml  0.75 ml 
Water  2.795 ml  3.432 ml  3.456 ml 
10% SDS  100 μl  100 μl  50 μl 
Add the following when ready to pour gel between plates 
TEMED  7.5 μl  7.5 μl  7.5 μl 
10% Ammonium 
Persulphate 
75μl  75μl  75μl 
Table 2.9: Composition of SDS-PAGE gels 
 
2.5.4  Transfer of proteins from the gel to a membrane support 
Gels  were  carefully  removed  from  glass  plates  and  transferred  onto  polyvinylidene 
fluoride (PVDF) membranes (Amersham, UK) using semi-dry transfer.  Briefly, PVDF 
membranes  were  activated  by  pre-soaking  in  100%  methanol  and  equilibrated  in 
transfer buffer (25mM Tris-base, 0.19M glycine, 20% v/v methanol). Stacking gels were 
removed  from  the  plates,  leaving  resolving  gels  to  be  placed  on  top  of  pre-wetted 
PDVF membranes.  This created a sandwich of PVDF membrane with gel in between 4 
pieces of pre-soaked blotting paper. Air bubbles were removed by rolling a pipette 
across the upper most blotting paper, and semi-dry transfer cell was closed. The gel 
was set to transfer at 10V with a current limited at 1A for up to 2 gels and at 15V with a 
current limited at 1.5A for 4 gels for 45 minutes. General methods 
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2.5.5  Membrane blocking and antibody incubation 
PDVF  membranes  were  blocked  overnight  to  prevent  non-specific  binding  of 
antibodies, in either 5% skimmed milk or 5% bovine serum albumin (BSA) dissolved in 
PBS-Tween (PBS  Tablets  (Sigma, UK) containing: 10mM phosphate buffer, 2.7mM 
KCl, 137mM NaCl and 0.1% Tween 20 (Sigma, UK)). Milk contains casein; a highly 
prevalent  phosphoprotein,  therefore  5%  BSA/PBS-T  was  used  for  blocking  when 
assessing  Akt  phosphorylation  within  samples  to  prevent  any  possible  non-specific 
binding. Membranes were probed with rat  specific primary antibodies diluted in 5% 
BSA/milk in PBS-T at 1:1000 (unless stated otherwise) for 3 hours at room temperature 
or overnight at 4°C on a continuous shaking platform. Prior to washing, membranes 
were  incubated  with  primary  antibody  to  α-tubulin  at  1:10000  for  45  minutes. 
Membranes  were  then  washed  for  one  hour  with  PBS-T,  changing  solution  every 
10minutes  to  remove  unbound  antibody,  before  incubation  with  the  horseradish 
peroxidase(HRP)-linked  secondary  antibody  (Cell  signalling,  UK)  for  another  hour. 
Washing was repeated as before.  
2.5.6  Protein detection using enhanced chemiluminescence (ECL) 
The primary antibodies used have a binding region specific to the protein of interest 
and  the  secondary  antibody  binds  to  a  species-specific  portion  of  the  primary 
antibodies. Secondary antibodies were linked to HRP. When incubated with the ECL 
reagent, HRP catalyses the oxidation of luminol, a reaction which emits light.  This light 
can  then  be  detected  with  autoradiography  film  and  represents  the  localisation  of 
primary antibody bound to specific proteins on the membrane.  
  Membranes were incubated in ECL reagent (GE healthcare, UK) on a shaking 
platform for 2 minutes before the membrane is carefully placed face down onto flat 
Saran  wrap.  The  Saran  wrap  was  folded  around  the  membrane  before  turning  the 
membrane face up and removing any air bubbles. The Saran-wrapped membrane was 
secured into an X-ray film cassette (Kodak, UK) and exposed to Hyperfilm ECL high 
performance  chemiluminescence  film  (GE  Healthcare,  UK).  Different  exposure  time 
was required to optimise band intensity. The film was developed and fixed using Kodak 
processing chemicals (Sigma, UK). Films were left to dry and annotations of molecular 
markers were made using the  membranes. Films were transferred to computerised 
images using a flatbed scanner and the intensity of the bands quantified using Image J. General methods 
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2.6  Immunoprecipitation  
Immunoprecipitation (IP) in combination with Western Blot analysis is routinely used to 
detect post-translational changes of specific proteins. Briefly, specific antibodies bind to 
the protein of interest in solution to form antibody-protein complexes. These complexes 
are precipitated out of solution with the addition of insoluble binding proteins. Protein A 
(agarose) or Protein G (sepharose) are most commonly used and often referred to as 
‘beads’.  Centrifugation  of  the  solution  promotes  pelleting  of  the  antibody-protein 
complex  attached  to  the  beads.  These  complexes  can  then  be  diluted  in  Lamelli 
sample buffer and treated as described in chapter 2.5.  
2.6.1  Preparation of lysates from heart tissue 
Hearts  were  cleared  of  blood  and  snap  frozen  as  described  in  section  2.5.2.1. 
Homogenisation  buffer  (PBS,  phosphatase  inhibitor,  protease  inhibitor,  EDTA) 
(500 μl/300mg tissue) was added to the tissue placed in round bottom microfuge tubes 
and incubated on ice for 20 minutes on ice. For experiments investigating PGC-1α, 10 
μM  Nicotinamide  (NAM)  a  deacetylase  inhibitor  was  added  to  the  homogenisation 
buffer. The tissue was emulsified with an electric homogeniser and then spun for 3 min 
at 4000 rpm. The supernatant was aspirated and the pellet re-suspended in 300 μl lysis 
buffer. For experiments investigating cytosolic proteins a non-denaturing lysis buffer 
was used. For nuclear proteins, RIPA (RadioImmunoPrecipitation Assay) lysis buffer 
was used for  nuclear membrane disruption  (Table 2.10). The homogenised sample 
was vortexed 3 times for 15 sec, centrifuged for 10 min at 16000 rpm and then the 
supernatant was collected and protein content was quantified (as described in section 
2.5.2.2). 
 
Non-denaturing lysis buffer  RIPA(RadioImmunoPrecipitation Assay) 
buffer (in PBS) 
20 mM Tris HCl pH 8  1% NP-40 
137mM NaCl  0.1% SDS 
10% Glycerol  0.5% NaDeoxycholate 
1% NP-40  Immediately before use add: 
2mM EDTA  Protease inhibitors (Roche) General methods 
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Immediately before use add:  Phosphatase inhibitors (Roche) 
Protease inhibitors (Roche)   
Phosphatase inhibitors (Roche)   
Table 2.10: Lysis buffer compositions:  
2.6.2  Immunoprecipitation  
Following protein determination, 500 μg of protein was diluted in at least 3 volumes of 
PBS containing TSA and protease inhibitors (for PGC-1α, NAM was also added). To 
this solution, the antibody specific to the protein of interest was added and rotated 
overnight at 4°C. Following this incubation step, a mixture of protein A and protein G 
beads were added to the mixture and the solution containing protein sample, antibody 
and beads were rotated for 2-4 hours at 4°C. Tubes were centrifuged at 3000 rpm for 
30 sec at 4
°C and the supernatant carefully and completely removed (Figure 2.16). The 
bead/protein/antibody complex was then washed three times with 500 µl of ice-cold 
lysis  buffer.  Between  each  wash,  the  beads  were  pelleted  by  centrifugation.    To 
minimize  the  background,  the  supernatant  was  completely  removed  between  each 
wash step. The bead/protein/antibody complex was resuspended in 100 µl of 2x lamelli 
sample buffer and mixed gently.  The sample was boiled at 90–100
° C for 5–10 min to 
dissociate the immunocomplexes from the beads and then centrifuged at 13000 rpm to 
pellet the beads. The supernatant was carefully removed and used to load onto an 
SDS-PAGE  gel  to  separate  proteins  prior  to Western  blot  analysis  as  described  in 
sections 2.5.3-2.5.6.  





Figure  2.13:  Illustration  of  immunoprecipitation  process.  (1)  Antibody  added  to  heart  sample  and 
sample rotated overnight (2) Antibody binds to protein of interest (3) Protein A/G beads added to solution 
and  rotated  for  a  further  2-4  hours  (4)  Solution  centrifuged  to  leave  a  pellet  consisting  of  the 
antibody/protein/bead complex. 
   
2.7  Biochemical assays 
2.7.1 Measurements of intracellular ATP in heart tissue 
Experiments were conducted to investigate the basal levels of adenosine triphosphate 
(ATP) in the ageing and diabetic heart and whether drug treatments affected the level 
of this metabolite. A well characterised ATP-bioluminescent assay kit (FL-AA, Sigma, 
UK) was used to determine the concentration of ATP in heart samples. In the presence 
of ATP and luciferin, luciferase an enzyme from fireflies can catalyse a light emitting 
reaction.  This  2  step  reaction  is  summarised  in 
 
Figure 2.14. The amount of light emitted is proportional to the concentration of ATP.  
ATP  concentration  was  determined  in  heart  samples  using  a  96  well  plate  reader 




Figure 2.14: Illustration of reaction of luciferase in presence of ATP 
Briefly heart homogenates were diluted 1 in 10 in homogenisation buffer and 
incubated at 95°C on a heating block for 1 min. A clear 96-well plate was prepared with 
heart samples, standards and blanks. ATP standards were made using the supplied 
ATP concentrate which was diluted to 1mg/ml. From this stock concentration a serial 
dilution was performed to give standards in [µM]: 0.4, 0.2, 0.1, 0.05, 0.025, 0.0125 and 
0.00625.  The  ATP  bioluminesence  assay  mix  was  used  at  1:25  fold  dilution  with 
supplied ATP assay dilution buffer, and was prepared seperately for each run. Next, 
the assay plate was prepared. 100 µl of the assay mix was transferred to the required 
wells  of  a  white-bottomed  plate,  suitable  for  the  measurement  of  luminescence. 
Following the incubation, 100 µl of each sample was transferred from the sample plate 
to the assay plate and luminescence was immediately read using 96 well plate reader. 
Luminescence was read every 9 seconds for 6 cycles. The amount of ATP in each 
sample was calculated with the use of a standard ATP curve (example shown in Figure 
2.15). 
 
Figure 2.15: Typical ATP standard curve 
 General methods 
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2.7.2  Measurement of free radicals in heart tissue 
Intracellular reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 
well  known  molecules  that  play  a  vital  role  in  disrupting  cellular  signalling  during 
oxidative stress.  Experiments were performed using the OxiSelect In vitro ROS/RNS 
Assay Kit (Cell Bio Labs) to measure total free radical presence in samples from aging 
and  diabetic  rat  hearts.    The  assay  used  a  specific  fluorogenic,  ROS/RNS  probe 
dichlorodihydrofluorescin  DiOxyQ  (DCFH-DiOxyQ)  which  reacted  with  free  radicals 
within the samples including hydrogen peroxide (H2O2), peroxyl radical (ROO
∙), nitric 
oxide  (NO)  and  peroxynitrite  anion  (ONOO
∙).  Briefly,  the  DCFH-DiOxyQ  probe  was 
primed and then stabilized in its highly reactive DCFH form. On contact with a ROS or 
RNS species (for example in tissue samples or standards) DCFH was rapidly oxidized 
to  its  fluorescent  form  2’,7’-dichlorodihydrofluorescein  (DCF)  (Figure  2.16). 
Fluorescence  was  proportional  to  the  total  level  of  ROS/RNS  within  the  samples. 
Relative fluorescence was measured using a 96 well plate reader FLUOstar Omega 
(BMG  LabTech)  at  480  nm  excitation  /  530  nm  emission.  Unknown  samples  were 
compared against a hydrogen peroxide or DCF standard. This method was conducted 
according to the manufacturer’s instructions.   
 
Figure  2.16:  Illustration  of  how  fluorescence  is  produced  in  response  to  reactive  oxygen/nitrogen 
species 
 General methods 
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2.8  Electron Microscopy imaging of mitochondria 
The transition electron microscope (EM) was used to assess mitochondrial appearance 
within the heart samples.  This method uses electrons rather than light to visualize fine 
details of cells at high magnifications.  The electromagnetic lens within the microscope 
focuses the electrons into a thin beam. The electrons scatter in accordance with the 
density of the material they shine upon.  Any un-scattered electrons remain in line with 
the  beam  and  a  shadow  image  is  projected  which  can  then  be  visualized  by  the 
operator. 
2.8.1  Sample collection and preparation 
Samples used to analyse mitochondrial appearance were taken from the hearts which 
also supplied material for Western Blot analysis.  As described in section 2.2.1.3.3, 
hearts were cleared of blood using the Langendorff apparatus. Prior to freeze clamping 
a small section of the heart apex were collected and stored in EM fixative. Ultrathin 
sections were then prepared using an in house service by Mark Turmaine, UCL. 
2.8.2  Assessment of structure and organisation of mitochondria 
All samples were blindly coded and ultrathin sections were viewed with a Joel 1010 
transition  electron  microscope  (Joel  Ltd,  Warwickshire,  UK.).  From  these  ultrathin 
sections, at least 6 electron micrographs of each section were viewed and photos of 
the  interfibrillar  mitochondria  taken  in  each  heart.  The  photos  for  each  heart  were 
assessed for structural and organisational differences examined. Heart samples were 
grouped according to similarities. Subsequently the codes were revealed. 
2.9  Statistical Analysis 
All statistical analyses were conducted using GraphPad Prism 5 software. Student’s t 
test  was  applied  to  the  data  when  a  comparison  was  made  between  two  groups 
(treated  vs.  non-treated).  In  experiments  where  a  comparison  was  made  between 
multiple groups, an Analysis of Variance (ANOVA) was used followed by appropriate 
post-hoc  analysis  (Bonferroni’s  test).    In  experiments  where  parameters  were 
repeatedly  measured  for  example  before  and  after  a  drug  treatment,  data  was 
analysed using a repeated measures ANOVA.  Comparison between groups at multiple 
time-points was analysed by two-way repeated measures (mixed model) ANOVA with 
a Bonferroni correction for multiple comparisons. Statistical significance was assumed 






3. ISCHAEMIA-REPERFUSION INJURY IN AGEING 
AND DIABETIC HEARTS 
   Ischaemia-reperfusion injury in an ageing and diabetic heart 
144 
 
3.1  Susceptibility to infarction in ageing and diabetes 
3.1.1  Introduction:  The old diabetic heart and myocardial infarction  
Elderly, type 2 diabetic patients have been suggested to have an enhanced probability 
of developing heart failure, an increased prevalence of AMI and subsequently poor 
clinical recovery following a lethal event 
332, 471.  Experimental research has identified 
both the aged heart and the diabetic heart as separate entities which could render the 
heart more susceptible to damage caused by ischaemia and reperfusion. Surprisingly, 
there are limited investigations that use animal models that represent both risk factors. 
Understanding the alterations that occur within the aged and diabetic myocardium in 
the  experimental  setting  could  assist  in  the  development  of  cardioprotective 
interventions that are required to improve clinical outcomes in this group of patients. 
There has been great discrepancy between clinical and animal data, regarding 
the susceptibility of the diabetic heart to IRI. Experimental results from animal models 
of  diabetes  have  yielded  confusing  results,  suggesting  the  diabetic  heart  is  either 
more
219, 223, 224 or less
235, 237, 238 susceptible to IRI. Moreover some investigations see no 
influence of diabetes on infarct size
229, 240, 241. The discrepancy in the outcome of animal 
investigations has been attributed to the choice of animal model, experimental protocol 
and severity of diabetes
218. Clinically, Fazel et al, 2005 showed that diabetic patients 
presenting with AMI had similar or lower release of cardiac markers of injury such as 
troponin  or  creatine  kinase  myocardial  band  (CK-MB)  which  suggested  a  smaller 
infarction. However, these diabetic patients exhibiting lower levels of infarct markers 
experienced worse clinical outcomes compared to the non-diabetic patients 
472. In line 
with this study, Alegria et al, 2007 demonstrated that infarct size was only modestly 
higher and left ventricular ejection fraction (LVEF) modestly lower in diabetic patients 
compared  to  non-diabetic  patients  with  acute  ST-segment  elevation  MI,  however 
mortality rate was 4 to 6 fold higher in the diabetic group
473. 
3.1.2  Hypothesis and aim 
Based on these apparent contradictory data, we hypothesised that the diabetic heart, 
may develop smaller infarcts but could be more susceptible to ischaemic damage i.e. 
the  threshold  at  which  infarct  size  translates  into  worse  outcomes  is  lower  for  the 
diabetic heart and that age may additively effect this threshold for damage. Using an 
inbred lean model of type 2 diabetes (T2D), Goto Kakizaki (GK) rat and its original 
source, the normoglycaemic Wistar rat, at different ages (between 3 and 18 months). 
We aimed to determine the infarct size in isolated ageing, diabetic hearts subjected to Ischaemia-reperfusion injury in an ageing and diabetic heart 
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ischaemia times during ischaemia and reperfusion protocols using different lengths of 
ischaemia. 
3.1.3  Experimental Protocols 
3.1.3.1  Animals 
Male Goto-Kakizaki (GK) rats (a mild, non-obese, insulin resistant diabetic model 
427, 
447) and male Wistar rats (normoglycaemic) were obtained from Taconic (Denmark) and 
Charles River UK Limited (Margate, UK), respectively. They were kept in house until 
they  reached  3,  8,  12  or  18  months  of  age;  all  animals  received  humane  care  in 
accordance  with  the  United  Kingdom  Animal  Scientific  Procedures  Act  of  1986.  
Fasting blood glucose levels (Accu-chek system, Roche) and HbA1c (A1C now+ test 
kit. Bayer, UK) were measured at least 48hours prior to excision of the heart to avoid 
the upregulation of cardioprotective stress proteins 
474. Body weight and heart weight 
were recorded on the experimental day. 
3.1.3.2  Langendorff Isolated heart perfusions 
For determination of infarct size, GK and Wistar rats of 3, 8, 12 and 18 months of age 
were anesthetized with sodium pentobarbital (55 mg/kg I.P.) and heparin (300 IU). The 
hearts were rapidly excised, placed into ice cold Krebs-Henseleit buffer, and quickly 
mounted  onto  a  Langendorff  constant  pressure  perfusion  system  (ADInstruments, 
Chalgrove, UK), described in detail in Chapter 2. Briefly, the hearts were perfused via 
the  aorta  with  modified  Krebs-Henseleit  bicarbonate  buffer  (KH)  (mM:  NaCl  118.5, 
NaHCO3 25.0, KCl 4.8, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.7 and glucose 11.0). The 
buffer was gassed with 95% O2/5% CO2 to maintain a pH of 7.4. A suture was placed 
around the LAD and secured in place by a snare created from two pipette tips. A fluid 
filled latex balloon was inserted into the left ventricle through an incision in the left atrial 
appendage  and  inflated  to  a  left  ventricular  end  diastolic  pressure  (LVEDP)  of  8-
10mmHg.  Perfusion pressure was set at 70mmHg, left ventricular developed pressure 
LVDP, heart rate (HR) and coronary flow (CF) were permanently monitored and the 
rate pressure product (RPP) calculated. An electronic thermo probe inserted into the 
pulmonary artery continuously monitored temperature and was kept in range of 37°C ± 
0.5. 
For infarct analysis (n=6 per group) hearts were randomly assigned to receive 
sub-lethal (20 min regional ischaemia) or lethal (35 min regional ischaemia) followed by 
60 min reperfusion (summarised in Figure 3.1).  Regional ischaemia was initiated by 
tightening the suture around the LAD and holding it in place with the snare. The snare Ischaemia-reperfusion injury in an ageing and diabetic heart 
146 
 
was then removed and the hearts reperfused for 60 min.  At the end of this period the 
suture was permanently tied to occlude the LAD and Evans blue dye (0.25% in saline) 
was infused through the aorta to delineate the risk zone, with the myocardial tissue not 
at  risk  staining  blue.  Hearts  were  stored  at  -20°C  before  being  transversely  sliced, 
incubated in triphenyltetrazolium chloride solution (TTC; 1% in phosphate buffer) and 
TTC  transferred to 10% formalin overnight.  The following day the slices were scanned 
and the volume of infarction within the risk zone (I/R %).  
 
Figure 3.1: Scheme of Langendorff experiments performed.  For infarct analysis (n=6 per group) hearts 
were randomly assigned to receive A. sub-lethal (20 min regional ischemia) or B. lethal (35 min regional 
ischemia) followed by 60 min reperfusion. 
 
3.1.3.3  Statistical Analysis 
As described in Chapter 2, the values are presented as mean ± standard error mean 
(SEM) and analysed by one-way ANOVA, followed by a Tukey post hoc comparison 
using  GraphPad  Prism  5.0  (GraphPad  Software  Inc,  San  Diego,  California,  USA). 
Differences within the data were considered statistically significant when P < 0.05. 
3.1.4  Results 
3.1.4.1  Blood glucose and HbA1c  
Clinically,  patients  are  considered  diabetic  with  HbA1c  reading  of  >48  mmol/mol. 
However,  due  to  rapidly  expanding  blood  volumes  in  young  growing  animals  the 
HbA1C  fraction may  be  kept  "artificially"  low  by  the  constant  expansion  of  red  cell 
numbers.  Therefore  in  these  investigations,  the  diabetic  status  was  considered  at 
HbA1c values> 40 mmol/mol, a status achieved at approximately 8 months of age in Ischaemia-reperfusion injury in an ageing and diabetic heart 
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the GK rat. Blood glucose and HbA1c levels increased with age in the GK rat (p<0.05). 
In the 3 month age group, blood glucose levels were within diabetic range (9.6±0.4 
mmol/L), however HbA1c was within the non-diabetic threshold (23.7mmol/mol). GK 
rats had higher blood glucose and HbA1c levels than their counterpart Wistars, with the 
exception of the 3 month GK group having similar HbA1c levels to the 3 month Wistar 
group.  Data is summarised in Figure 3.2. 
 
Figure 3.2: Blood Glucose and HbA1c levels in ageing and diabetic rats.   A. Fasting blood glucose levels 
(Accu-chek system, Roche) and B. HbA1c (A1C now+ test kit. Bayer, UK) were taken at least 48 hours prior 
to  excision  of  the  heart.  Data  is  shown  as  mean  ﾱ  S.E.M,  n≥10.*p<0.05  versus  3  month  Wistar 
measurement. **p<0.005, ***p<0.001 versus 3 month GK measurements.  Diabetic status increased with 
age  in  the  GK  rat.  One  way  ANOVA  and  Tukey’s  post  hoc  analysis  were  used  for  statistical  analysis 
between all groups. 
 
3.1.4.2  Phenotypic changes associated with age and diabetes  
The diabetic Goto-Kakizaki rats were lighter than the non-diabetic Wistar rats in all age 
groups;  however  their  heart/body  weight  ratio  (HW/BW%)  was  significantly  greater 
(p<0.001). HW/BW% decreased significantly in the Wistar rats over time (Pearson R
2 
0.97; p=0.013), driven by a large increase in body mass; this trend was absent in the 
Goto-Kakizaki  rats  (Pearson  R
2  0.03;  p=0.82),  whose  body  mass  stayed  relatively 
constant after the age of 8 months. These parameters are summarized in Table 3.1. 




   3 months  8 months  12 months  18 months 
   Wistar  GK  Wistar  GK  Wistar  GK  Wistar  GK 
Heart weight 




















%  0.521  0.586  0.420  0.542*  0.362  0.559*  0.327  0.587* 
Table 3.1: Summary of biological parameters.  Body mass was recorded prior to excision of the heart. 
Heart mass was measured following isolated Langendorff heart preparation. Data is represented as mean 
ﾱ  S.E.M,  n≥18.  *P<0.05  versus  counterpart  wistar  at  each  age  group.  One-way  ANOVA  was  used  to 
determine statistical significance. 
 
 
Figure 3.3: Heart to body weight ratio in ageing diabetic and non-diabetic rats.  Heart/body weight ratio 
(HW/BW%) was calculated following the experimental investgations. Data was analysed using Pearson’s 
regression analysis and demonstrated that the hypertrophy that exists in the diabetic heart did not appear 
to worsen with age. 
   Ischaemia-reperfusion injury in an ageing and diabetic heart 
149 
 
3.1.4.3  Cardiac function during ischaemia and reperfusion in the ageing 
and/or diabetic heart  
Functional  parameters  of  the  isolated  hearts  were  monitored  throughout  each 
experimental protocol. In diabetic hearts, data collected during the 20 min ischaemia 
experiments, suggested baseline function to deteriorate in relation to age; at 3 months 
the baseline RPP in GK rat hearts was significantly higher than in the 18 months age 
groups (p<0.05), however there was no significant difference between 8, 12 and 18 
months (P=NS). HR also followed this pattern, with a significantly faster HR noted in 
the 3 month versus 12 and 18 months age groups (P<0.005). HR was also significantly 
lower in the 18 month versus the 12 month age group, but no significant difference was 
noted between hearts from 3 and 8 month GK rats (P=NS). The percentage of LVDP 
recovery following 20 min ischaemia and 60 min reperfusion was higher in the 3 month 
group compared to all other age groups, however this trend did not reach statistical 
significance. Data from these experiments are summarised in Figure 3.4. 







Figure 3.4: Cardiac function assessment in the diabetic heart subjected to 20 min ischaemia/ 60 min 
reperfusion.  A. Rate Pressure Product (RPP) B. Left ventricular end diastolic pressure (LVEDP) C. Left 
ventricular developed pressure (LVDP) D. Coronary flow E. Heart Rate (HR) and F. % recovery of LVDP 
following 20 min ischaemia/60 min reperfusion. LVEDP. LVDP and HR were monitored via an inserted 
ventricular  latex  balloon,  RPP  was  calculated  as  HR  x  LVDP  as  a  measure  of  cardiac  workload.  No 
significant difference was in any of the parameters in the ageing, non-diabetic heart. Data is shown as 
mean  ﾱ  S.E.M,  n≥6.  Comparison  between  groups  at  multiple  time-points  was  analysed  by  two-way 
repeated measures (mixed model) ANOVA with a Bonferroni correction for multiple comparisons. One 
way ANOVA followed by a Tukey Post-Hoc analysis were used for statistical analysis between groups. 
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  Cardiac  function  data  monitored  throughout  35  min  ischaemia/reperfusion 
experiments in GK hearts showed a similar pattern to the shorter ischaemic duration. 
Baseline  RPP  output  deteriorated  with  age;  3  and  8  month  GK  hearts  had  a 
significantly higher cardiac output than their aged counterparts (p<0.05), moreover no 
difference was seen between 12 and 18 months hearts.  In the 8 month group, LVEDP 
following  induction  of  ischaemia  was  significantly  increased  compared  to  the  other 
groups (p<0.005) but the recovery was similar. Initial readings of LVDP showed no 
significant difference between the age groups; however throughout stabilisation LVDP 
deteriorated in the 12 and 18 months groups compared to the younger groups. Of note, 
coronary flow was significantly lower in the 3 month age group throughout the entire 
protocol compared to the other groups (p<0.05). At the end of reperfusion, LVDP in the 
3 month group recovered to 70% of the baseline compared to only 49% recovery in the 
18 month group.  Data from these experiments are summarised in Figure 3.5. 
In non-diabetic Wistar rats, RPP and LVDP function were significantly reduced 
in  hearts  isolated  from  the  18  month  group  compared  to  3  and  12  month  groups 
(p<0.005) when subjected to 20 min ischaemia and subsequent reperfusion. Coronary 
flow values were similar between all age groups with a reduction in flow noted in the 18 
month age group; however this did not reach statistical significance. Hearts isolated 
from the 18 month non-diabetic group had a significantly slower HR compared to all 
other  groups  (P<0.005).  The  percentage  of  LVDP  recovery  was  only  significantly 
reduced in the 18month group. Data summarised in Figure 3.6. 
 







Figure 3.5: Cardiac function assessment in the diabetic heart subjected to 35 min ischaemia/ 60 min 
reperfusion.  A. Rate Pressure Product (RPP) B. Left ventricular end diastolic pressure (LVEDP) C. Left 
ventricular developed pressure (LVDP) D. Coronary flow E. Heart Rate (HR) and F. % recovery of LVDP 
following 20 min ischaemia/60 min reperfusion. LVEDP. LVDP and HR were monitored via an inserted 
ventricular latex balloon, RPP was calculated as HR x LVDP as a measure of cardiac workload. A significant 
reduction in LVDP recovery was seen the ageing, diabetic heart. Data is shown as mean ﾱ S.E.M, n≥6. 
Comparison between groups at multiple time-points was analysed by two-way repeated measures (mixed 
model) ANOVA with a Bonferroni correction for multiple comparisons. One way ANOVA followed by a 
Tukey Post-Hoc analysis were used for statistical analysis between groups. 
 




Figure 3.6: Cardiac function assessment in the non-diabetic heart subjected to 20 min ischaemia/ 60 min 
reperfusion.  A. Rate Pressure Product (RPP) B. Left ventricular end diastolic pressure (LVEDP) C. Left 
ventricular developed pressure (LVDP) D. Coronary flow E. Heart Rate (HR) and F. % recovery of LVDP 
following 20 min ischaemia/60 min reperfusion. LVEDP. LVDP and HR were monitored via an inserted 
ventricular latex balloon, RPP was calculated as HR x LVDP as a measure of cardiac workload. A significant 
reduction in LVDP recovery was seen the aged, diabetic heart. Data is shown as mean ﾱ S.E.M, n≥6. 
Comparison between groups at multiple time-points was analysed by two-way repeated measures (mixed 
model) ANOVA with a Bonferroni correction for multiple comparisons. One way ANOVA followed by a 
Tukey Post-Hoc analysis were used for statistical analysis between groups. 
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The 18 month Wistar heart had significantly worse RPP function compared to 
the  other  age  groups  (P<0.05)  when  subjected  to  35  min  ischaemia/reperfusion 
whereas no significant differences were seen in coronary flow (p=NS).  Similar to the 
function recorded for 20 min ischaemia, HR was significantly slower throughout the 
experimental protocol in the 18 month age group compared to 3 and 8 month groups 
(P<0.005), HR did not differ between 12 and 18 months hearts (p=NS).   LVDP function 
at baseline was significantly lower in the 18 month age group compared to the other 
groups.  During ischaemia function declined further and less recovery was seen during 
reperfusion,  however  this  value  did  not  reach  significance  (p=0.052).  Data  is 
summarised in Figure 3.7. 





Figure 3.7: Cardiac function assessment in the non-diabetic heart subjected to 35 min ischaemia/ 60 min 
reperfusion.  A. Rate Pressure Product (RPP) B. Left ventricular end diastolic pressure (LVEDP) C. Left 
ventricular developed pressure (LVDP) D. Coronary flow E. Heart Rate (HR) and F. % recovery of LVDP 
following 20 min ischaemia/60 min reperfusion. LVEDP. LVDP and HR were monitored via an inserted 
ventricular  latex  balloon,  RPP  was  calculated  as  HR  x  LVDP  as  a  measure  of  cardiac  workload.  No 
significant differences in functional parameters were seen the ageing, non-diabetic heart. Data is shown 
as mean ﾱ S.E.M, n≥6. Comparison between groups at multiple time-points was analysed by two-way 
repeated measures (mixed model) ANOVA with a Bonferroni correction for multiple comparisons. One 
way ANOVA followed by a Tukey Post-Hoc analysis were used for statistical analysis between groups. 
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Interestingly, at 3 months of age the non-diabetic and diabetic heart had similar 
RPP  function  throughout  ischaemia  and  reperfusion,  however  at  8  months  RPP  is 
superior in the diabetic versus the non-diabetic heart.  Function begins to deteriorate at 
12months in the diabetic heart, with decreased RPP output compared to aged matched 
Wistars; at 18 months RPP is similar in both the diabetic and non-diabetic heart (Figure 
3.8). Young Wistar hearts subjected to 20 min ischaemia had significantly greater RPP 
function during ischaemia and reperfusion compared to hearts subjected to 35 min 
ischaemia. This function was superior than hearts subjected to either 20 min or 35 min 
ischaemia and reperfusion in the 18 month Wistar group. Interestingly, no difference in 
function was noted in hearts subjected to 20 min or 35 min ischaemia and reperfusion 
in either the young or old diabetic group (Figure 3.9). 
  
 
Figure 3.8: Comparison of RPP in the diabetic versus non-diabetic heart.   Rate Pressure Product (RPP) 
was calculated as Heart rate (HR) x Left ventricular developed pressure (LVDP) and compared between 
diabetic GK rats and non-diabetic Wistar rats at A. 3 months of age B. 8 months of age C. 12 months of age 
and D. 18months of age. Data is shown as mean ﾱ S.E.M, n≥6. Comparison between groups at multiple 





Figure 3.9: Comparison of RPP in the diabetic and non-diabetic heart subjected to either 20 min or 35 
min ischaemia followed by reperfusion.  Rate Pressure Product (RPP) was calculated as Heart rate (HR) x 
Left ventricular developed pressure (LVDP) and compared between diabetic GK rats and non-diabetic 
Wistar rats at A. Non-diabetic Wistar rat hearts B. Diabetic Goto-Kakizaki (GK) rats. 3 month old non-
diabetic hearts subjected to 20 min ischaemia and 60 min reperfusion had significantly greater cardiac 
function compared to hearts of the same age subjected to 35 min ischaemia and 60 min reperfusion. In 
contrast, no difference was seen between the 3 month diabetic hearts subjected to either 20 or 35 min 
ischaemia followed by 60 min reperfusion. Data is shown as mean ﾱ S.E.M, n≥6. Comparison between 
groups at multiple time-points was analysed by two-way repeated measures (mixed model) ANOVA with a 
Bonferroni correction for multiple comparisons were used for statistical analysis between groups. 
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3.1.4.4  Age and diabetes contribute to susceptibility to infarction  
Infarction that developed after 20 and 35 min of ischaemia followed by reperfusion was 
compared between non-diabetic Wistar and diabetic GK rats at different ages. In this 
model, 20 min regional ischaemia is not sufficient to develop a significant infarct in 
normoglycaemic hearts.  In fact, this model is often used to investigate stunning 
475 and 
not cell death.  
‘Pre-diabetic’ 3 month GK rat hearts were less vulnerable to a 20 min ischaemic 
insult  (I/R%: 30  ± 4.3) than to a longer 35 min  ischaemic insult (I/R%: 46.6 ± 4.1). 
However, 8 month old GK rat hearts following either 20 min and 35 min  ischaemia 
developed a similar infarct (I/R%; 35.5 ± 2.5 vs. 39.4 ± 2.3, P=NS). Similar data were 
obtained  in  the  12  month  and  18  month  age  groups  which  developed  comparable 
infarct sizes following both 20 and 35 min ischaemia: I/R% was 43.2 ± 3.7 (20 min) vs. 
42.0 ± 3.9 (35 min) (P=NS); I/R% 55.5 ± 4.7 (20 min) vs. 62.1 ± 6.0 (35 min), (P=NS). 
Interestingly, at the oldest age, the infarct sizes were significantly greater compared to 
the younger age groups (39.4% ± 2.3, 42.0 ± 3.9, vs. 62.1 ± 6.0, p<0.005). Data are 
summarised in Figure 3.10.  In contrast, the non-diabetic Wistar rat hearts subjected to 
20 min of ischaemia in 3, 8 and 12 months age groups developed significantly less 
damage compared to 35 min ischaemia. However, in the 18 month group there is no 
significant difference in the infarction following 20 or 35 min ischaemic insult, similar to 
that seen in the diabetic hearts from 8-18 months. Data are summarised in (Figure 
3.11).    Moreover, the comparatively lower  infarct size seen in the younger diabetic 
animals  compared  to  their  non-diabetic  counterparts  when  subjected  to  35  min 
ischaemia and reperfusion is lost as the diabetic heart ages; with the 18 month groups 
exhibiting similar infarct sizes (I/R%: 62.1 ± 6.0 in GKs and 59.6 ± 4.1 in Wistars). 
These  data  seem  to  indicate  that  the  age-induced  susceptibility  to  infarction  is 




Figure 3.10: The variations in susceptibility to ischaemia with age and diabetes (GK rats).  Infarct size is 
expressed as the ischaemic volume within the area at risk of the left ventricle (% I/R). All hearts were 
stabilized for 40 min, subjected to either 20 min (black bars) or 35 min (white bars) of coronary artery 
occlusion followed by 60 min reperfusion. The diabetic GK rat heart exhibits an increased susceptibility to 
20 min ischemia between 8-18months, whereas the youngest GK group is less susceptible to shorter 
ischaemia. Data is shown as mean ﾱ S.E.M, n≥6. One way ANOVA and Tukey’s post hoc analysis were used 
for statistical analysis between all groups 
 
Figure  3.11: The variations in the susceptibility to  ischaemia  with age (Wistar rats).  Infarct size is 
expressed as the ischaemic volume within the area at risk of the left ventricle (% I/R). All hearts were 
stabilized for 40 min, subjected to either 20 min (black bars) or 35 min (white bars) of coronary artery 
occlusion  followed  by  60  min  reperfusion.  The  non-diabetic  Wistar  rat  hearts  develop  an  increased 
susceptibility to shorter ischaemia with old age. Data is shown as mean ﾱ S.E.M, n≥6. One way ANOVA and 
Tukey’s post hoc analysis were used for statistical analysis between all groups. 




3.1.5  Summary of results 
In summary, in the setting of type 2 diabetes, even at a young age, shorter ischaemic 
time caused equivalent damage to lethal ischaemia. This increased susceptibility was 
not evident in ‘pre-diabetic’ 3 month hearts. The 18 month diabetic group demonstrated 
a greater vulnerability to lethal IRI compared to all other groups.  Interestingly, the non-
diabetic 3 month, 8 month or 12 month rat hearts were not vulnerable to a shortened 
ischaemic time whereas this effect manifested at 18 months.   Even though our results 
support previous findings in isolated heart preparations that non diabetic hearts have 
larger infarcts than diabetic hearts when subjected to lethal ischaemia, this difference 
was lost in old age. In regard to function, the non-diabetic heart at young and middle 
age maintains good basal properties and recovery of function following both 20 min or 
35 min ischaemia and reperfusion, however hearts isolated from the 18 month group 
have  a  decreased  ability  to  recover  following  ischaemia/reperfusion. In  the  diabetic 
heart,  basal  function  and  functional  recovery  following  ischaemia/reperfusion 
deteriorated  earlier  in  life,  in  both  the  12  and  18  month  group’s  compared  to  the 
younger diabetic rat hearts.  
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3.2  Is ischaemic preconditioning possible in the aged, diabetic 
heart? 
3.2.1  Introduction 
The observations from the previous section suggest that type 2 diabetes and age in 
combination  render  the  heart  more  vulnerable  to  damage  caused  by 
ischaemia-reperfusion  (IR).  Ischaemic  preconditioning  (IPC),  a  cardioprotective 
strategy  involving  a  short  protocol  of  ischaemia  and  reperfusion  prior  to  sustained 
ischaemia has been successful in reducing lethal cell injury in experimental models 
124; 
how this phenomenon works has been extensively studied.  Briefly, IPC causes the 
release of G-protein coupled receptor (GPCR) agonists such as adenosine/bradykinin, 
which  bind  to  the  receptor  and  activate  numerous  signalling  pathways.  
Phosphatidylinositol-3-kinase (PI3K) activation, can lead to stimulation of a number of 
downstream molecules, directly phosphorylating and activating Akt.  Other signalling 
molecules  involved  in  IPC  include  extracellular  regulated kinase  (ERK),  nitric  oxide 
synthase  (NOS),  inactivation  of  glycogen  synthase  kinase-3β  (GSK-3β)  and  also 
protein kinase C (PKC).  These converge to activate the mitochondrial ATP-dependent 
potassium  channel  (KATP),  closing  the  mitochondrial  permeability  transition  pore 
(mPTP) resulting in protection from IRI 
141.  
The  animal  data  suggests  that  the  diabetic  heart  is  resistant  to  ischaemic 
conditioning  such  that  the  IPC  stimulus  needs  to  be  increased  to  induce 
cardioprotection 
245.  Similar  to  studies  examining  cardioprotection  in  diabetes, 
conditioning the aged heart has also remained controversial.  In animal studies using 
rodent models, most  studies show that the protective effect of IPC is lost with age
384, 
however in in vivo studies using rabbits
403 and sheep models
404, the protective effect of 
IPC  is  enhanced.    Of  course,  these  investigations  use  different  experimental  IPC 
protocols and a diverse range of animal models, which could, to some extent, explain 
the discrepancies. As far as we know, assessment of the cardioprotective effects of 
IPC  has  not  been  performed  in  animal  models  exhibiting  both  co-morbidities. 
Therefore,  studies  investigating  cardioprotection  in  ageing,  diabetic  models  could 
provide a vital link in the translational process of basic research into clinical practice.  
3.2.2  Hypothesis and aim 
We  hypothesised  that  age  and  diabetes  combined  may  alter  the  effectiveness  of 
ischaemic preconditioning. Using an inbred lean model of type 2 diabetes (T2D), Goto 
Kakizaki (GK) rat and its original source, the normoglycaemic Wistar rat, at different Ischaemia-reperfusion injury in an ageing and diabetic heart 
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ages (between 3 and 18 months), we aimed to determine if an increased IPC stimulus 
of 3 cycles is able to achieve cardioprotection in an animal model exhibiting both old 
age and type 2 diabetes.  
3.2.3  Experimental protocols 
3.2.3.1  Langendorff Isolated heart perfusions 
Langendorff isolated heart experiments were performed as described in the previous 
section.  For infarct analysis (n=6 per group) hearts were randomly assigned to receive 
control (35 min regional ischaemia) or IPC (3 cycles of 5 min global ischaemia/10 min 
reperfusion)  prior  to  35  min  regional  ischaemia,  followed  by  60  min  reperfusion 
(summarised in Figure 3.12).  The staining and the quantification of the infarct were 
performed as previously described. 
 
Figure 3.12: Scheme of Langendorff experiments performed.  For infarct analysis (n=6 per group) hearts 
were randomly assigned to receive A. Control (35 min regional ischemia) or B. IPC (3 cycles of 5 min global 
ischaemia/10 min reperfusion preceding 35 min regional ischemia) followed by 60 min reperfusion. 
 
3.2.4  Results 
3.2.4.1  The  diabetic  heart  manifests  a  decreased  recovery  of  function 
following IPC at a younger age than non-diabetic hearts 
In the non-diabetic heart, IPC caused a similar recovery of LVDP function at 3, 8 and 
12 months of age, however recovery in the 18 month group was significantly lower Ischaemia-reperfusion injury in an ageing and diabetic heart 
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(p<0.05) (Figure 3.13A.).  Interestingly, in the diabetic heart, a decline in recovery of 
LVDP occurred in both the 12 and 18 month groups (Figure 3.13B.).  IPC did not have 
a significant impact on functional recovery compared to the control group in the non-
diabetic hearts in this model (Figure 3.14). In the diabetic heart, IPC trended to improve 
function compared to control at 3 and 8 months, with a reduction in recovery in the two 
older age groups, however due to the spread of the data these findings did not reach 
significance  (Figure  3.15).  All  other  parameters  are  shown  in  Figure  3.16  for  non-
diabetic heart and in Figure 3.17 for the diabetic heart. 
 
Figure  3.13:  Recovery  of  function  following  ischaemia-reperfusion  :  Percentage  recovery  of  Left 
ventricular developed pressure (LVDP) following 3 cycles of ischaemic preconditioning followed by 35 min 
ischaemia and 60 min reperfusion A. Non-diabetic Wistar rat hearts and B. Diabetic Goto-Kakizaki (GK) rat 
hearts at 3, 8, 12 and 18 months of age. The diabetic heart demonstrated a decreased recovery of LVDP 
function at an earlier age than the non-diabetic heart.  Data is shown as mean ± S.E.M, and is calculated 
by comparing the value recorded at the last time point as a percentage of the value recorded at the first 
time point. n≥6. One way ANOVA followed by a Tukey Post-Hoc analysis were used for statistical analysis 
between groups. 




Figure 3.14: Recovery of function following ischaemia-reperfusion in the non-diabetic heart.  Percentage 
recovery of Left ventricular developed pressure (LVDP) following either Control (35 min ischaemia/60 min 
reperfusion) or IPC (3 cycles of ischaemic preconditioning prior to 35 min ischaemia/60 min reperfusion) 
in non-diabetic Wistar rat hearts. A. 3 months B. 8 months C. 12 months D 18months. Data is shown as 




Figure 3.15: Recovery of function following ischaemia-reperfusion in the diabetic heart.  Percentage 
recovery of Left ventricular developed pressure (LVDP) following either Control (35 min ischaemia/60 min 
reperfusion) or IPC (3 cycles of ischaemic preconditioning prior to 35 min ischaemia/60 min reperfusion) in 
Diabetic Goto-Kakizaki rat hearts. A. 3 months B. 8 months C. 12 months D 18months. Data is shown as 
mean ﾱ S.E.M, n≥6. T-test was used for statistical analysis between the two groups. 





Figure 3.16: Recovery of function following IPC prior to ischaemia-reperfusion in the non-diabetic heart: 
Cardiac function assessment in the non-diabetic heart subjected to 3 cycles of ischaemic preconditioning 
followed by 35min ischaemia and 60 min reperfusion.  A. Rate Pressure Product (RPP) B. Left ventricular 
end diastolic pressure (LVEDP) C. Left ventricular developed pressure (LVDP) D. Coronary flow E. Heart 
Rate (HR) and F. % recovery of LVDP following 20 min ischaemia/60 min reperfusion. LVEDP. LVDP and HR 
were monitored via an inserted ventricular latex balloon, RPP was calculated as HR x LVDP as a measure of 
cardiac workload. Data is shown as mean ﾱ S.E.M, n≥6. One way ANOVA followed by a Tukey Post-Hoc 




Figure 3.17: Recovery of function following IPC prior to ischaemia-reperfusion in the diabetic heart.  
Cardiac function assessment in  the diabetic heart subjected to 3 cycles of  ischaemic  preconditioning 
followed by 35min ischaemia and 60 min reperfusion.  A. Rate Pressure Product (RPP) B. Left ventricular 
end diastolic pressure (LVEDP) C. Left ventricular developed pressure (LVDP) D. Coronary flow E. Heart 
Rate (HR) and F. % recovery of LVDP following 20 min ischaemia/60 min reperfusion. LVEDP. LVDP and HR 
were monitored via an inserted ventricular latex balloon, RPP was calculated as HR x LVDP as a measure of 
cardiac workload. Data is shown as mean ﾱ S.E.M, n≥6. Comparison between groups at multiple time-
points was analysed by two-way repeated measures (mixed model) ANOVA with a Bonferroni correction 
for multiple comparisons were used for statistical analysis between groups. 
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3.2.4.2  The diabetic heart manifests a decreased protective response to 
IPC at a younger age than non-diabetic hearts 
In hearts that were isolated from non-diabetic Wistar and diabetic GK rat hearts at 3 
and 8 months of age, the ischaemic preconditioning protocol used was successful in 
limiting the damage caused by ischaemia-reperfusion injury. IPC caused a 46% and 
38% reduction in infarct size in 3 and 8 month Wistar (non-diabetic) hearts and 55% 
and 40% reduction in  3 and 8 month GK diabetic hearts when compared with control 
groups (p<0.005 for all groups versus their respective controls).  At 12 and 18 months 
of age the non-diabetic heart was protected by IPC, albeit to a lesser extent in the 18 
month  group  (38.2%  vs.  25%  reduction  in  infarct  size,  Figure  3.18).  However,  the 
diabetic heart was not amenable to preconditioning protection in either the 12 or 18 
month groups (I/R% for 12 month group, 42.0 ± 3.9 vs. 46.9 ± 5.5 and I/R% for 18 
month group, 62.1 ± 5.9 vs. 69.1 ±4.3.  P=NS, Figure 3.19). 
 
Figure 3.18: The effectiveness of Ischaemic Preconditioning (IPC) on infarct size reduction in the setting 
of ageing in normoglycaemic Wistar hearts.  Infarct size is expressed as the ischaemic volume within the 
area at risk of the left ventricle (% I/R). Hearts were stabilized for 40 min or subjected to 3 cycles of 5 min 
ischaemia/reperfusion  then  subjected  to  35  min  of  coronary  artery  occlusion  followed  by  60  min 
reperfusion. Black bars represent control group (35 min ischemia/reperfusion) and white bars represent 
IPC group. The non-diabetic Wistar rat heart is amenable to protection by 3 cycles of IPC, though the 
effectiveness decreases with age. Data is shown as mean ﾱ S.E.M, n≥6. One way ANOVA and Tukey’s post 
hoc analysis were used for statistical analysis between all groups. 




Figure 3.19: The effectiveness of Ischaemic Preconditioning (IPC) on infarct size in the setting of ageing 
and type 2 diabetes.  Infarct size is expressed as the ischaemic volume within the area at risk of the left 
ventricle (% I/R). Hearts were stabilized for 40 min or subjected to 3 cycles of 5 min ischaemia/reperfusion 
then  subjected  to  35  min  of  coronary  artery  occlusion  followed  by  60  min  reperfusion.  Black  bars 
represent control group (35 min ischemia/reperfusion) and white bars represent IPC group. The diabetic 
GK rat heart was amenable to protection by 3 cycles of IPC at 3 and 8 months of age, however this 
effectiveness was lost with age. Data is shown as mean ﾱ S.E.M, n≥6. One way ANOVA and Tukey’s post 
hoc analysis were used for statistical analysis between all groups. 
 
3.2.5  Summary of Results 
In  summary,  the  positive  effect  of  IPC  on  functional  recovery  following 
ischaemia-reperfusion injury is lost earlier in diabetic hearts (at 12 months) compared 
to non-diabetic hearts (18 months).  Most importantly, our data confirm that 3 cycles of 
IPC are sufficient to achieve protection against lethal cell injury in young type 2 diabetic 
hearts. Furthermore, we endorse that this stimulus of IPC is adequate to protect the 
ageing,  non-diabetic  heart  as  well.  However,  the  combination  of  diabetes  with  age 
renders the heart resistant to protection elicited by 3 cycles of IPC. Interestingly, in the 
oldest diabetic group, IPC caused more damage than in the control protocol alone.   
   Ischaemia-reperfusion injury in an ageing and diabetic heart 
170 
 
3.3  Signalling defects in the ageing and diabetic heart 
3.3.1  Introduction 
The  experiments  presented  in  this  section  were  conducted  with  the  aim  of 
characterising potential changes in expression and activation of pro survival signaling 
pathways.  Based on the results presented in the previous sections that showed the 
diabetic heart was firstly more susceptible to ‘sub lethal’ ischaemia-reperfusion injury 
than the non-diabetic heart and that this effect was augmented with age and secondly, 
that the effectiveness of IPC was lost in the ageing, diabetic heart. We initiated these 
investigations starting with Akt.  
As discussed in the introduction, the role of pro-survival PI3K/Akt signaling in 
endogenous  cardioprotection  against  IRI  has  been  well  documented,  firstly,  as  an 
anti-apoptotic  kinase 
476  and  secondly,  as  a  key  element  of  the  reperfusion  injury 
salvage kinase (RISK) pathway that is initiated following ischaemic or pharmacological 
conditioning
151.  Defects in the signaling of this kinase can impair normal cell processes 
and lead to detrimental effects culminating with cell death. 
Akt, a serine/threonine kinase (also known as protein kinase B) has emerged as 
a pivotal kinase involved in molecular signal transduction pathways underlying normal 
and  pathological  conditions.  The  diverse  regulatory  functions  of  Akt  including  the 
promotion of cellular growth, survival and metabolism have led to opposing concepts in 
exploiting Akt biology to 1) treat cancer by inhibiting these functions and 2) improve the 
outcome  of  cardiovascular  diseases  by  promoting  these  actions  either  directly  or 
indirectly to limit or repair myocardial damage
139.  Existing in three distinct isoforms, 
Akt1-3 can be activated in response to numerous growth factors and hormones
139 and 
also by stress stimuli like hypoxia
477 and oxidative stress
478, 479. In the heart, Akt-1 and 
Akt-2 are most abundantly expressed and have a variety of functions.  Akt-1 has been 
related  to  cell  survival  and  growth
480,  481  whereas  Akt-2  is  involved  in  glucose 
homeostasis
482.  The importance of Akt isoforms were cemented by loss-of-function 
experiments.    Global  knock  out  of  the  Akt-1  gene  retards  growth  and  increases 
apoptosis in mice
481, 483. Whereas, Akt-2
 -/- mice develop insulin resistance and a type 2 
diabetic phenotype, moreover in response to myocardial ischaemia exhibit increased 
apoptosis
484, 485. 
Activation of Akt in response to certain physiological stimuli inhibits apoptosis 
and  promotes  cell  survival  by  phosphorylating  proapoptotic  BAX  at  the  serine  184 
residue  preventing  BAX-induced  permeablisation  of  the  mitochondrial  membrane
486; Ischaemia-reperfusion injury in an ageing and diabetic heart 
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and  also  at  the  serine  136  residue  of  proapoptotic  BAD  releasing  antiapoptotic 
BCL-XL
487.  Akt can also interact with metabolic enzymes and transcription factors such 
as members of the FOXO family
488; phosphorylation of FOXO3a promotes its cytosolic 
accumulation therefore preventing transcriptional activity of death receptor ligands and 
reduces  apoptosis
145,  Akt  can  also  directly  phosphorylate  FOXO1  and 4
139.    These 
transcription  factors  can  interact  with  numerous  downstream  targets  including 
PGC-1α
93, a master of mitochondrial biogenesis
39.  
Unsurprisingly, an innate cardioprotective role for Akt activation was suggested 
especially in the setting of IRI
134.  Gene transfer of constitutively active Akt into rats 
48 hours  prior  to  IRI,  significantly  reduced  infarct  size  and  limited  hypoxia  induced 
cardiomyocyte  dysfunction  in  vitro
489.    Acute  activation  of  Akt  via  phosphatidyl-
inositol-3-kinase (PI3K) occurs in response to IPC, protecting the heart against lethal 
reperfusion  injury.  The  resulting  downstream  signalling  following  Akt  activation  are 
thought to converge onto the mitochondria, inhibiting mPTP opening and preventing 
cell death
134.    
A hallmark of type 2 diabetes is defective insulin signalling at insulin receptors 
leading to impaired glucose uptake and utilization. The PI3K-Akt pathway is a major 
downstream  component  following  insulin  receptor  activation.  Therefore,  it  is 
unsurprising that Akt signalling becomes altered in the setting of diabetes.   Krook et al, 
1997  were  the  first  to  demonstrate  a  decrease  in  insulin-stimulated  Akt  activity  in 
soleus muscle of type 2 diabetic Goto-Kakizaki rats
490. Muscle biopsies collected from 
type-2 diabetic patients were also found to have an impaired Akt signalling axis
491. At 
the level of the heart, baseline Akt-phosphorylation in both diabetic animals 
238 and 
humans 
244 are reduced compared to non-diabetic hearts. This impairment could lead 
to a plethora of detrimental effects on the balance of anti and pro apoptotic intracellular 
signaling, potentially rendering the diabetic heart more susceptible to IRI.  
Defects  in  Akt  signalling  have  also  been  suggested  in  ageing.  An 
age-associated  reduction  in  Akt  activation  was  seen  in  both  liver  and  hepatocytes 
isolated  from  aged  rats
492.    A  decrease  in  baseline  Akt  phosphorylation  adversely 
affected cellular responses to oxidative stress in these cells.
492 An impairment of pro 
survival signaling in the ageing heart led to the development of compromised cardiac 
function; some studies suggest that a reduction in Akt activity and expression levels 
correlate with this cardiac dysfunction
493. In contrast, others suggest that chronically 
activated Akt in the ageing heart leads to pathological hypertrophy
494. 
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3.3.2  Hypothesis and aim 
Following  our  data  highlighting  the  changes  in  the  endogenous  cardioprotective 
potential with age and diabetes  we hypothesised that a possible impairment in Akt 
signaling occurs in the ageing, diabetic heart.  Furthermore, these changes may lead to 
downstream de-regulations in the levels of PGC-1α (a key transcriptional regulator) and 
catalase (an indicator of antioxidant defense), which can both be directly or indirectly 
controlled by Akt. We aimed to investigate whether Akt expression and activation could 
be affected by these comorbidities.   
3.3.3  Experimental Protocols 
3.3.3.1  Western Blot Analysis 
To assess changes in the expression or activation of proteins, Western blot analysis 
(WB) was performed in ageing and/or diabetic hearts from 3, 8, 12 and 18 month old 
Wistar and GK hearts. Hearts were collected at baseline (following 2 min perfusion on 
the Langendorff apparatus, to clear the blood which may interfere with the results).  
     To determine whether the lack of protection in the ageing, diabetic heart was 
related to changes in activation of Akt in response to IPC, GK hearts at  3 and 18 
months were collected after stabilisation or following 3 cycles of IPC.  
    At the end of the procedures, the hearts were immediately freeze-clamped in 
liquid nitrogen and frozen at -80°C.  For analysis, the heart samples were homogenized 
in PBS based buffer, the protein content was  determined using BCA protein assay 
reagent and protein levels corrected accordingly to ensure equal protein loading. Equal 
volumes of heart homogenate were added to Laemmli lysis buffer and denatured by 
heating (the method is described in detail in Chapter 2).  
    The  samples  collected  at  baseline  were  assessed  for  phosphorylated-Akt 
(Ser-473)  (Akt-P),  total-Akt  (Akt-T),  PGC-1α  and  catalase  expression  and  the  IPC 
samples and their respective controls were assessed for phosphorylated-Akt (Ser-473) 
and total-Akt using WB analysis as described in detail in Chapter 2.5.  Akt-P, Akt-T and 
catalase antibodies were purchased from Cell Signalling, UK, PGC-1α was purchased 
from Santa Cruz Biotechnology and α-tubulin (used as a loading control) purchased 
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3.3.3.2  Electron Microscopy  
For  electron  microscopy  (EM)  visualisation  of  mitochondria  in  the  ageing  and/or 
diabetic heart, myocardial tissue samples from 3 and 18 month old Wistar and GK rats 
were collected at baseline (following 2 min on the perfusion apparatus to clear blood) 
and immersed in EM-fixative (n=4 per group).  The method is detailed in Chapter 2.8.  
3.3.3.3  Measurement of Free Radicals in heart tissue 
Intracellular reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 
well  known  molecules  that  play  a  vital  role  in  disrupting  cellular  signaling  during 
oxidative  stress 
495.    Experiments  were  performed  using  the  OxiSelect  in  vitro 
ROS/RNS Assay Kit (Cell Bio Labs) to measure total free radical presence in samples 
from 3, 8, 12 and 18 month GK and Wistar rat hearts.  The assay used a specific 
fluorogenic,  ROS/RNS  probe  which  reacted  with  free  radicals  within  the  samples 
including  hydrogen  peroxide  (H2O2),  peroxyl  radical  (ROO∙),  nitric  oxide  (NO)  and 
peroxynitrite  anion  (ONOO∙).  Fluorescence  is  proportional  to  the  total  level  of 
ROS/RNS within the samples.  The method is described in detail in Chapter 2.7. 
    A scheme of collection of all samples is summarised in Figure 3.20. 
 
Figure 3.20: Scheme of collection of samples using the Langendorff apparatus.  Tissue was collected for 
examination  by  Western  Blot,  electron  microscopy  (EM),  and  reactive  oxygen  species  (ROS)/reactive 
nitrogen species (RNS) content (n=3/4 per group).  
 
3.3.3.4  Statistical Analysis 
Values are presented as mean ± standard error mean (SEM) and statistical analysis 
was performed as described in Chapter 2.9. Ischaemia-reperfusion injury in an ageing and diabetic heart 
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3.3.4  Results 
3.3.4.1  Age  alters  the  expression  and  activation  of  key  pro  survival 
signalling proteins in the diabetic heart 
Akt is essential for cardioprotection via IPC. IPC induces acute Akt phosphorylation 
151, 
therefore activation, and in this state the enzyme is cardioprotective via its multiple anti-
apoptotic 
134 and anti-necrotic effects. Surprisingly, a gradual increase in baseline Akt 
phosphorylation (Akt-P) was seen in the ageing GK rat heart, with a significant surge at 
18 months versus either 3 or 12 months (Arbitrary units (A.U.): 0.5±0.2 vs. 0.2±0.2 or 
0.1±0.05 P<0.05,  Figure  3.21). Akt-P in the ageing, non-diabetic heart appeared to 
follow a similar trend but the changes were not as pronounced or significant (Figure 
3.22).  Interestingly, in young diabetic animals the phosphorylation of Akt at baseline is 
very  low  which  supports  the  requirement  of  an  increased  IPC  stimulus  to  induce 




Figure 3.21: Phosphorylation of Akt in the diabetic heart.  Phosphorylation of Akt increased with age in 
the  diabetic  heart.    Values  determined  by  densitometry  of  Akt-phosphorylation  (Akt-P)  corrected  to 
respective α-tubulin over the relative expression of Akt-total (Akt-T) corrected to respective α-tubulin. 
Data is shown as mean ﾱ S.E.M, n=3 per group. One way ANOVA and Tukey’s post hoc analysis were used 




Figure 3.22: Phosphorylation of Akt in the non-diabetic heart. Phosphorylation of Akt trended to increase 
with age in the non-diabetic heart, however these changes did not reach significance.  Values determined 
by  densitometry  of  Akt-phosphorylation  (Akt-P)  corrected  to  respective  α-tubulin  over  the  relative 
expression of Akt-total (Akt-T) corrected to respective α-tubulin. Data is shown as mean ± S.E.M, n=3 per 
group. One way ANOVA and Tukey’s post hoc analysis were used for statistical analysis between all groups 
 
An age-related decrease was also seen in the expression of PGC-1α in the 
diabetic  heart  (Figure  3.23),  with  significant  decrease  between  the  3  and  8  month 
groups and 12 and 18 month groups: (Arbitrary units (A.U.): 1.2±0.05, 0.8±0.01 vs. 
2.9±0.3, 2.1±0.5, respectively). Interestingly, PGC-1α expression in the non-diabetic 
heart decreased with age. However, the only significant differences were noted in the 
18 month group (Figure 3.24). 




Figure 3.23: PGC-1α expression in the diabetic heart.  PGC-1α expression decreases with age in the 
diabetic heart. Values determined by densitometry of PGC-1α corrected to respective α-tubulin. Data is 
shown as mean ﾱ S.E.M, n=3 per group. One way ANOVA and Tukey’s post hoc analysis were used for 
statistical analysis between all groups. 
 
 
Figure 3.24: PGC-1α expression in the non-diabetic heart.  PGC-1α expression decreased with age in the 
non-diabetic heart.  Values determined by densitometry of PGC-1α corrected to respective α-tubulin. Data 
is shown as mean ± S.E.M, n=3 per group. One way ANOVA and Tukey’s post hoc analysis were used for 
statistical analysis between all groups. 
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3.3.4.2  Oxidative stress is increased in the aged, diabetic heart  
To further elucidate the potential mechanism that renders the aged, diabetic heart more 
susceptible  to  ischaemic  injury,  we  used  Western  Blot  analysis  to  determine  the 
expression  level  of  catalase,  an  antioxidant  enzyme  which  can  be  transcriptionally 
regulated  by  PGC-1α 
110.Catalase  expression  increased  during  the  progression  of 
diabetes,  with  the  8  and  12  month  hearts  expressing  a  higher  level  of  catalase 
compared to the 3 month group (p<0.005). However, as the diabetic heart progressed 
into  old  age  (18  months),  the  expression  of  catalase  dramatically  decreased  to  a 
significantly  lower  level  than  the  3  month  group  (p<0.05,  Figure  3.25).  Catalase 
catalyses the breakdown of H2O2 leading to less oxidative stress related molecules 
within  the  cell.  Oxidative  stress  caused  by  an  excessive  accumulation  of  reactive 
oxygen or nitrogen species (RNS) are implicated in myocardial injury 
495.  We found 
baseline levels of H2O2 and RNS were significantly increased in the 18 month diabetic 
heart compared to the 3, 8 and 12 month diabetic hearts (Figure 3.26).  Interestingly, 
no significant differences were seen in catalase expression and ROS/RNS production 
in the ageing, non-diabetic heart (Figure 3.27, Figure 3.28). 
 
Figure 3.25: Catalase expression in the diabetic GK heart.  Catalase expression decreases with age in the 
diabetic heart. Data is shown as mean ﾱ S.E.M, n=3 per group. One way ANOVA and Tukey’s post hoc 
analysis were used for statistical analysis between all groups  




Figure 3.26: Oxidative stress levels in the ageing, diabetic heart.  Basal assessment of total free radicals 
within  the  diabetic  heart  using  OxiSelect  OxiSelect  ROS/RNS  Assay  Kit  (Cell  Bio  Labs).  A.  Hydrogen 
peroxide (H2O2) and B. reactive nitrogen species (RNS) increase with age in the diabetic heart. Data is 
shown as mean ﾱ S.E.M, n=4 per group. One way ANOVA and Tukey’s post hoc analysis were used for 
statistical analysis between all groups. 
 
Figure 3.27: Catalase expression in the non-diabetic Wistar heart.  There were no significant differences 
in baseline catalase expression in the ageing, non-diabetic heart. Data is shown as mean ± S.E.M, n=3 per 
group. One way ANOVA and Tukey’s post hoc analysis were used for statistical analysis between all groups 




Figure 3.28: Oxidative stress levels in the ageing, non-diabetic heart.  Basal assessment of total free 
radicals within the diabetic heart using OxiSelect OxiSelect ROS/RNS Assay Kit (Cell Bio Labs). There were 
no significant changes in A. Hydrogen peroxide (H2O2) or B. reactive nitrogen species (RNS) in respect to 
age in the non-diabetic heart. Data is shown as mean ± S.E.M, n=4 per group. One way ANOVA and 
Tukey’s post hoc analysis were used for statistical analysis between all groups. 
 
3.3.4.3  Mitochondrial changes with age and diabetes 
The results thus far suggest impairment in basal Akt signalling in the aged, diabetic 
heart leading to decreased expression of PGC-1α. PGC-1α is a master regulator of 
mitochondrial  biogenesis
39,  therefore  we  sought  to  assess  if  these  hearts    had 
phenotypic changes in respect to mitochondrial organisation and appearance.  In-depth 
visualisation  using  electron  microscopy  showed  that  the  appearance  and  the 
organisation of mitochondria in the aged, diabetic heart are different when compared to 
the young pre-diabetic rat heart. The interfibrillar mitochondria (IFM) in the 3 month old, 
pre-diabetic heart and 3 month old, non-diabetic heart appeared organised and more 
elongated whereas in the aged, diabetic heart (18 months old) the mitochondria were 
unorganised and more spherical in shape. The IFM in the 18 month old Wistar heart 
appeared less organised than the younger age groups however, more organised than 




Figure 3.29: Mitochondrial appearance and organisation in the aged and diabetic heart.  Mitochondrial 
organisation  is  compromised  in  the  aged,  diabetic  heart.  Basal  samples  demonstrating  mitochondrial 
appearance  and  organisation  within  the  diabetic  heart  using  electron  microscopy  (EM).  To  analyse 
mitochondrial appearance the heart samples were coded and 2 ultrathin sections were prepared by a 
blinded operator. The sections were viewed with a Joel 1010 transition electron microscope (Joel Ltd, 
Warwickshire, UK.). Between 6 and 8 electron micrograph photos were taken of interfibrillar mitochondria 
(IFM) in each section. Representative pictures from A. 3 month GK heart, mitochondria appear elongated 
and organised along the interfibrillar bands of the cell B. 3 month Wistar heart C. 18 month GK heart; loss 
of mitochondrial organisation and more spherical shaped mitochondria D. 18 month Wistar heart. 
 
3.3.4.4  IPC  failed  to  increase  the  phosphorylation  of  Akt  in  the  aged, 
diabetic heart 
Lastly, baseline and IPC-induced Akt-P were assessed in young (3 months) and old 
(18 months) GK and Wistar hearts. Basal phosphorylation of Akt was significantly lower 
in young GK hearts compared to the old GK hearts (p<0.05).  3 cycles of IPC resulted 
in an increased phosphorylated state of Akt in the young hearts but no further change 
was observed in the older hearts (Figure 3.30). As expected in the young, non-diabetic 
hearts IPC elicited an increase in Akt-P. Interestingly, following the IPC stimulus in the 




Figure 3.30: Phosphorylation of Akt following IPC in young and old diabetic rat hearts.  Phosphorylation 
of Akt increases with age in the diabetic heart, with no further activation following IPC. Values determined 
by  densitometry  of  Akt-phosphorylation  (Akt-P)  corrected  to  respective  α-tubulin  over  the  relative 
expression of Akt-total (Akt-T) corrected to respective α-tubulin. Data is shown as mean ± S.E.M, n=3 per 
group. One way ANOVA and Tukey’s post hoc analysis were used for statistical analysis between all groups 
 
 
Figure  3.31:  Phosphorylation  of  Akt  following  IPC  in  young  and  old  non-diabetic  rat  hearts.  
Phosphorylation  of  Akt  increases  with  age  in  the  non-diabetic  heart,  however  phosphorylation  was 
decreased following IPC..  Values determined by densitometry of Akt-phosphorylation (Akt-P) corrected to 
respective α-tubulin over the relative expression of Akt-total (Akt-T) corrected to respective α-tubulin. 
Data is shown as mean ﾱ S.E.M, n=3 per group. One way ANOVA and Tukey’s post hoc analysis were used 
for statistical analysis between all groups. 
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3.3.5  Summary of Results 
The  data  collected  in  this  section  suggests  a  chronic  up  regulation  of  Akt 
phosphorylation, and reduced expression of the mitochondrial regulator PGC-1α and of 
antioxidant  enzymes  such  as  catalase,  potentially  due  to  the  Akt  up  regulation. 
Consequently the aged, diabetic heart exhibited less organised and more spherical 
than elongated mitochondria compared to the young, diabetic heart and enhanced level 
of  oxidative  stress.  Moreover,  IPC  failed  to  activate  Akt  above  the  already  raised 
baseline levels in the aged, diabetic heart. 
 
3.4  Discussion 
The key findings presented in this chapter are: 
-  The diabetic heart develops an increased susceptibility to shorter ischaemia 
at an earlier age than the non-diabetic heart. 
-  The extent of the injury induced by ischaemia-reperfusion increases with 
age in all hearts but this detrimental age related phenomenon seems to 
appear earlier in the diabetic heart. 
-  Three  cycles  of  IPC  previously  shown  to  protect  both  the  aged  and  the 
diabetic heart are ineffective in protecting the aged, diabetic heart. 
-  An impairment in Akt signalling, involving the chronic activation of Akt in the 
ageing, diabetic heart may contribute to these detrimental effects, possibly 
by affecting downstream targets such as PGC-1α and catalase levels and 
function. These alterations may induce an increase in oxidative stress and 
affect mitochondrial structure.  
3.4.1  Relevance of study 
Clinical data suggest that the diabetic heart is more susceptible to acute ischaemic 
damage 
167, however, the animal data has been conflicting with experimental studies 
showing more 
219, 223-225, equal 
229, 230, 240, 241 or less 
234, 235, 237-239 sensitivity to this injury 
217, 218. In the GK rat model, as in humans, diabetes develops in time, becoming further 
established with age 
496, however there has been limited investigations of ischaemia 
reperfusion injury in this setting. In parallel with the clinical setting of diabetes, our data 
demonstrates that the older diabetic hearts were more susceptible to ischaemia: infarct 
size was increased in response to a shorter ischaemic insult in diabetic adult and aged 
hearts, and the older hearts developed larger infarcts compared to the non-diabetic Ischaemia-reperfusion injury in an ageing and diabetic heart 
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hearts. Furthermore, to our knowledge, this is the first study that has shown that an 
increased stimulus of ischaemic-preconditioning previously shown to protect the young 
diabetic  and  aged  non-diabetic  heart  is  unsuccessful  in  inducing  a  cardioprotective 
effect in a model exhibiting both old age and diabetes.  
3.4.2  The activation of Akt in the myocardium – a double edged sword? 
It is largely accepted that Akt activation by phosphorylation is strongly implicated in the 
cardioprotective response to IRI 
497 and that this signalling cascade leads to inhibition 
of  mPTP  opening 
238,  reducing  the  apoptotic  and  necrotic  effects  of  reperfusion. 
However,  it  is  clear  that  the  increase  in  baseline  Akt-P  we  saw  within  the  ageing, 
diabetic  heart  did  not  serve  a  cardioprotective  role  in  this  setting.    It  is  worth 
considering that despite a crucial role for the acute activation of Akt by phosphorylation 
being implented in the survival of a stressed cell 
134, it has been shown that a chronic 
increase in basal phosphorylation of Akt may have detrimental effects. One of these 
effects was described by Hunter et al who suggested that a chronic increase in Akt 
phosphorylation  in  aged,  non-diabetic  rats  could  induce  hypertrophy 
494.  In  this 
investigation, the HW/BW % did not increase with age in the GK rat (Table 3.1, Figure 
3.3).  The GK rat exhibited an increased HW/BW% at all ages compared to the Wistar 
rat.  Hypertrophy has been suggested  to increase the susceptibility  of the heart  to 
IRI
498,  however  the  ageing  diabetic  heart  exhibits  dissimilar  responses  to  IPC  and 
shortened  ischaemia  compared  to  the  young  diabetic  heart.    All  age  groups  have 
similar  HW/BW%  suggesting  that  hypertrophy  alone  is  not  responsible  for  these 
differences in this setting. 
In accordance with this study, Nagoshi et al, 2005 suggested a detrimental role 
for chronic activation of Akt
499.  Transgenic mice with cardiac-specific overactivation of 
Akt had little functional recovery and larger infarcts following IR compared to transgenic 
mice  expressing  cardiac  specific  dominant-negative  Akt.  Biochemical  analysis 
demonstrated that chronic Akt activation induced feedback inhibition of PI3K through 
degradation and inhibition of the insulin receptor substrate (IRS)-1 and -2. Moreover, 
cardiac gene transfer of constitutively active PI3K restored the detrimental effects of 
chronic Akt activation in response to IR
499. Shiojima et  al also reported deleterious 
consequences  of  chronic  overexpression  of  Akt  in  the  heart.  Using  a  tetracycline-
regulated  Akt-1  transgenic  mouse  model,  they  demonstrated  that  long  term  Akt 
activation caused severe cardiac dysfunction
500. In contrast, modulation by exercise 
and IGF activation upstream of Akt led to chronic activation of this kinase but cardiac 
dysfunction did not occur
501, 502. Taking these studies into consideration and also that 
type 2 diabetes is related to a decrease in insulin receptor signaling
444, 503, it is possible Ischaemia-reperfusion injury in an ageing and diabetic heart 
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to  speculate  that  the  chronic  activation  of  Akt  could  be  linked  to  decreased  IRS 
signalling in the diabetic heart. The  upstream cause of chronic Akt phosphorylation 
seen in this study was not investigated. However, it appears that impairment caused by 
insulin resistance 
504 leads to detrimental outcomes, augmented in combination with old 
age. 
It  is  worth  considering  that  studies  demonstrating  chronic  activation  of  Akt 
leading  to  detrimental  outcomes  utilize  transgenic  models,  which  may  cause  non 
physiological over activation of Akt. Therefore, the finding in this study that the aged, 
diabetic  myocardium  exhibits  chronically  activated  Akt  could  provide  a  platform  for 
examining the impact of physiological Akt overactivation on the myocardium and heart 
function.  
3.4.3  Is  there  a  link  between  chronic  Akt  activation,  PGC-1α  and 
antioxidant defence?  
Profiling  of  gene  expression  in  hearts  from  transgenic  mice  with  cardiac-specific 
expression  of  activated  Akt  demonstrated  an  array  of  consequential  alterations. 
Interestingly, in these hearts, amongst other changes, Akt mediated a downregulation 
of PPARα and PGC-1α expression
505. PGC-1α is a transcriptional co-activator and a 
key regulator of energy metabolism and mitochondrial biogenesis 
506 and also regulates 
ROS detoxification systems 
110. Efficient control of these systems plays a vital role in 
increasing the tolerance of the heart to IRI; regulatory proteins such as PGC-1α allow 
the  mitochondria  to  maintain  its  energetics  and  to  reduce  oxidative  stress  when 
subjected to IRI 
507.  Pathological hypertrophy, which appears evident in the ageing 
diabetic  hearts  in  this  study,  has  also  previously  been  linked  to  decreased 
PPARα/PGC-1α  expression
508.  As  a  master  regulator  of  energy  metabolism,  a 
reduction in PGC-1α expression directs a shift from FAO to the less oxygen-consuming 
process,  glycolysis  to  maintain  ATP  production
508.  Interestingly,  physiological 
hypertrophy is associated with increased PPARα/PGC-1α
508, which could account for 
the increased heart weight noted in the ageing Wistar heart.  Schiekofer et al, 2006 
also demonstrated that Akt activation resulted in changes in gene transcription; using 
an inducible Akt transgenic mouse model they compared changes in gene expression 
following  either  acute (2  weeks)  or  chronic  (6  weeks)  activation.  They  found  acute 
activation resulted in maintained cardiac function and reversible hypertrophy classified 
as ‘physiological’ hypertrophy whereas chronic expression of activated Akt replicated 
‘pathological’  hypertrophy.  Intriguingly,  within  this  complex  study  using  microarray 
analysis, SOD was also downregulated in response to chronically activated Akt
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Interestingly,  fundamental  studies  by  Duncan  et  al,  2011  suggest  that 
alterations  in  PGC-1α  activity  in  the  setting  of  diabetes  could  have  detrimental 
consequences leading to an increased susceptibility to cardiovascular disease 
510. Our 
results showed an age-related decrease in PGC-1α expression in diabetic hearts, with 
18 month old GK rats expressing significantly less PGC-1α compared to their 3 month 
counterparts. Moreover, we saw a decreased functional capacity of the heart in the 18 
month old GK rat, a possible consequence of decreased mitochondrial energetics in 
the heart driven by decreased PGC-1α expression. Interestingly, in the non-diabetic 
heart, Akt phosphorylation and PGC-1α expression appeared to decrease with age. 
However, significant reduction was seen only in the oldest age group corresponding 
with  the  infarction  data  whereby  the  18  month  Wistar  heart  had  an  increased 
susceptibility to infarction. This may suggest that changes occur at an accelerated rate 
in the diabetic heart compared to the non-diabetic heart, therefore rendering the heart 
more vulnerable to damage at an earlier age. 
It has been demonstrated by other groups that Akt phosphorylation can reduce 
the  activation  of  PGC-1α,  directly  by  phosphorylating  PGC-1α  at  Ser570
98  and 
indirectly by inactivation of FoxO1, a stimulator of the PGC-1α promoter
93. Interestingly, 
Tonks et al demonstrated that Akt phosphorylation was impaired in insulin-resistant 
human  muscle,  and  that  hyperinsulinaemia  inactivated  FoxO1  preventing  its 
transcriptional  activity 
504.    In  addition,  Akt  has  close  regulatory  links  with  other 
members of the FoxO family such as FoxO3, which phosphorylates and inactivates its 
transcriptional activity via promoting nuclear extrusion and accumulation in its inactive 
state  in  the  cytosol  in  cardiomyocytes
145.  Olmos  et  al,  2009  showed  that  the 
transcriptional regulator Foxo3b and the co-activator PGC-1α interact directly to drive 
the  expression  of  antioxidant  genes  such  as  catalase 
511.  Therefore,  chronic  Akt 
activation  could  result  in  decreased  FOXO3  mediated  transcription  of  PGC-1α, 
supporting  the  subsequent  down  regulation  of  catalase  we  observed  in  the  aged, 
diabetic  heart.    It  is  possible  that  the  less  organised,  almost  spherical  interfibrillar 
mitochondria we saw in these hearts, is a consequence of decreased PGC-1α and 
catalase  expression.    This  thesis  provides  no  direct  linking  evidence  for  the 
transcriptional regulation of Akt on PGC-1α; attempts were made to immunoprecipitate 
out  the  PGC-1α  protein  from  the  aged  diabetic  heart  to  assess  post  translational 
modifications  such  as  phosphorylation  status;  however  this  proved  problematic  and 
may have been caused by the use of frozen not fresh heart tissue.  
A  main  process  that  contributes  to  the  damage  caused  by  IRI  is  the  rapid 
production of reactive oxygen species (ROS) upon reperfusion of the myocardium 
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The availability of endogenous antioxidants, such as catalase, to counterbalance this 
release  of  ROS,  is  crucial  to  reduce  the  myocardial  damage 
513.  Diabetes  is 
accompanied by an increased production of intracellular ROS 
193, and a compensatory 
increase in catalase 
514. However, it is suggested that the increase in the level of the 
antioxidant  enzymes  is  likely  to  be  insufficient  to  completely  counteract  ROS 
overproduction 
514.  Interestingly, our results support this and suggest that in young 
diabetic hearts, where diabetes is not fully established the level of H2O2 and RNS are 
low,  therefore  low  levels  of  catalase  are  required  to  counteract  oxidative  stress. 
However, it appears that as the diabetic ages into 8 and 12 months, oxidative stress 
remains low possibly by a concurrent increase in catalase expression.  Interestingly, 
this antioxidant defence is lost with age, with a reduction in catalase expression and a 
subsequent increase in oxidative stress within the heart. These changes in regulation 
of oxidative stress production may possibly due to the down regulation of catalase via 
high Akt-P and low PGC-1α levels in the diabetic heart.  
Interestingly, catalase expression and H2O2 and RNS levels did not significantly 
change in the ageing, non-diabetic heart.  Therefore, the increased phosphorylation of 
Akt  in  the  aged,  non-diabetic  heart  may  not  be  associated  with  changes  in  these 
downstream pathways in the non-diabetic heart.  This suggests the aforementioned 
alterations in signalling may be a diabetes-associated phenomenon. 
3.4.4  Is IPC possible in the aged, diabetic heart? 
Having found that the diabetic heart is more susceptible to infarction we moved on to 
investigate if the endogenous cardioprotective potential is also affected by age in the 
diabetic heart. Previously it was demonstrated that the young, diabetic heart is still 
amenable to ischaemic preconditioning protection but the threshold is raised, therefore 
an  increased  stimulus  is  required
245.  Yellon  and  colleagues,  2005  found  that  this 
increased  IPC  stimulus  was  required  to  achieve  an  essential  level  of  Akt 
phosphorylation  necessary  to  mediate  cardioprotection 
238.  Similar  to  the  studies 
examining cardioprotection in diabetes, conditioning the aged heart has also remained 
a controversial issue.  Yellon and colleagues showed in 2001 that the Sprague-Dawley 
ageing heart required an increased IPC stimulus to elicit cardioprotection 
401. However, 
to  our  knowledge  no  investigations  have  combined  the  two  comorbidities,  age  and 
diabetes.  Therefore  we  investigated  whether  the  aged,  diabetic  heart  could  be 
protected against lethal IRI by 3 cycles of IPC.  Our data shows that IPC protection 
cannot be achieved in older diabetic animals. One could argue that an even higher IPC 
stimulus is required for protection to be elicited in these aged diabetic hearts. However, 
our  data  showed  that  the  18  month  diabetic  hearts  undergoing  3  cycles  of  IPC Ischaemia-reperfusion injury in an ageing and diabetic heart 
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exhibited more damage following ischaemia than their respective control; therefore it is 
unlikely that an increased stimulus would be effective. In aged, non-diabetic hearts this 
protocol was successful in limiting IR damage, however to a lesser extent than the 
younger  non-diabetic  hearts.  It  seems  that  the  initial  increased  threshold  for 
cardioprotection  observed  in  young  diabetic  hearts  evolves  with  age  towards  the 
complete  loss  of  this  ability.    We  found  that  the  basal  level  of  phosphorylated  – 
therefore activated, Akt was increased with age and no further increment was observed 
following  a  preconditioning  protocol  in  aged  diabetic  hearts.  Interestingly,  a  similar 
increase in phosphorylated-Akt, had been linked to the aged heart 
515.  Kunuthur et al, 
2012 demonstrated that young Akt2
-/- mice exhibiting a diabetic phenotype were not 
amenable to protection by 1 cycle of IPC, however increasing the stimulus to 3 cycles 
restored protection. Interestingly, diabetic status determined by HbA1c levels in aged 
Akt2
-/- mice was enhanced; however whether an increased stimulus of IPC would have 
an infarct limiting effect in these mice was not investigated. Furthermore, Akt1
-/- mice 
were  not  amenable  to  protection  by  either  stimulus  suggesting  a  vital  role  for  this 
isoform in IPC
516.  
3.5  Conclusion 
There are many possible mechanisms responsible for the loss of cardioprotection in 
the  ageing 
384,  as  well  as  in  the  diabetic  myocardium 
517.  From  the  network  of 
intracellular  signalling  pathways  which  could  affect  the  myocardial  susceptibility  to 
infarction this investigation was focussed on Akt which is a key regulator of survival in 
general  and  of  myocardial  preservation  following  ischaemia-reperfusion  injury,  in 
particular. In conclusion, this section of my thesis suggests increased susceptibility of 
the aged, diabetic rat heart to ischaemia-reperfusion injury and the inability of these 
hearts  to  be  preconditioned  against  this  insult.    One  of  the  major  causes  of  these 
negative outcomes could be the chronically augmented phosphorylation of Akt in the 
aged, diabetic myocardium which may lead to detrimental downstream effects such as 
the down regulation of PGC-1α and catalase, leading to compromised defense against 
oxidative stress. Moreover, there is no biochemical reserve for sufficient additional Akt 
phosphorylation  to  be  activated  by  preconditioning  and  hence  this  form  of 
cardioprotection is lost. It is noticeable, based on this study, that old age and diabetes 
associate to impact on signalling pathways that mediate IPC (summarised in Figure 
3.32).  Further exploration of signalling deficits in the aged, diabetic heart using suitable 
animal models could prove crucial in successful translation of conditioning strategies 





Figure 3.32: Possible consequences of the chronically activated RISK kinase Akt, in the aged, diabetic 
heart. 
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Novel  cardioprotective  strategies  are  required  in  order  to  reduce  the  increased 
cardiovascular  risk  in  diabetic  patients.  The  hyperglycaemic  profile  and  associated 
microvascular consequences of diabetes have been suggested to play an important 
role in increasing patient’s susceptibility to infarction 
518. As mentioned, the heart can 
be conditioned by pharmacological agents; interestingly anti-diabetic drugs have been 
linked  to  improved  cardiovascular  outcomes  and  protection  against 
ischaemia-reperfusion injury. Some may argue that sufficient glycaemic control by oral 
anti-diabetic agents have proved vital in reducing cardiovascular risk, however whether 
these  agents  have  independent  protective  mechanisms  distinct  from  their 
glucose-lowering  properties  is  still  unclear.    From  these  anti-diabetic  drugs  with 
cardioprotective properties we were interested in the biguanide drug, metformin and 
the dipeptidylpeptidase-4 (DPP-4) inhibitor, sitagliptin. 
This chapter is structured into 3 main sections and a final discussion: 
1.  The  effect  of  chronic  metformin  treatment  in  12  month  old  diabetic  and 
non-diabetic  rats  on  myocardial  infarction  in  response  to  acute 
ischaemia-reperfusion injury and whether this treatment modulates prosurvival 
kinases.  
2.  The  investigations  regarding  metformin’s  cardioprotective  mechanisms  when 
given chronically using a cardiac cell line and isolated cardiomyocytes. 
3.  The effect of chronic sitagliptin treatment in diabetic and non-diabetic rats on 
myocardial infarction in response to acute ischaemia-reperfusion injury. 
4.1  The effect of chronic metformin treatment in aged, diabetic 
rats. 
4.1.1  Background 
Metformin, an oral anti-diabetic drug from the biguanide, insulin sensitizing class, has 
been suggested as potential cardioprotective agent 
259 following the UKPDS (United 
Kingdom Prospective Diabetes Study) observation that there is a significantly lower 
incidence  of  cardiovascular  events  in  patients  receiving  this  drug
260.  Numerous 
mechanisms  have  been  attributed  to  the  successful  glucose  lowering  effects  of 
metformin including inhibition of complex I of the mitochondrial respiratory chain 
261, 
decreasing  hepatic  glucose  production 
262,  increasing  glucose  uptake 
263  and 
stimulation  of  adenosine  monophosphate-activated  protein  kinase  (AMPK) 
264. 
However,  experimental  myocardial  ischaemia-reperfusion  injury  performed  in 
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infarct volumes without any change in blood glucose levels 
265. This suggested that the 
cardioprotective effect exerted by metformin could be independent of its hypoglycaemic 
actions.  
Alongside its insulin-sensitizing effects 
519, metformin has been shown to have 
direct beneficial control on cellular mechanisms by up regulating kinases such as Akt
281 
and AMPK 
264, implicated in cell survival and metabolism, respectively. 
Akt is an important pro survival kinase and its role in cardioprotection has been 
discussed in detail in Chapter 1.4).  In experimental models of ischaemia-reperfusion 
injury, acute administration of metformin phosphorylated and activated Akt leading to 
closure  of  the  mitochondrial  permeability  transition  pore  (mPTP)  and  subsequent 
protection against myocardial infarction
281.  
  AMPK,  a  serine-threonine  kinase  that  can  sense  and  restore  energy 
homeostasis when a cell becomes deprived of energy, is an important component in 
the pathway by which metformin produces its glucose lowering affects 
264. Alongside 
this action, recent investigations have also implicated this kinase cardioprotection 
284.  
For instance the AMPK activator, A-2769662, was shown to successfully reduce infarct 
size in both diabetic and non-diabetic isolated rat hearts 
520.  
Metformin pre-treatment reduced infarct size in both diabetic and non-diabetic 
animal  models.  This  protection  was  associated  with  the  activation  of  pro  survival 
kinases including AMPK via phosphorylation 
284 and components of the reperfusion 
injury salvage kinase (RISK) pathway such as the PI3K-Akt axis 
281. Metformin given 
during reperfusion following an ischaemic insult in a rat model of ischaemia reperfusion 
injury (IRI) can also reduce infarct size 
284 indicating a potential use for this agent in 
setting of acute myocardial infarction.  
In comparison, there has been little experimental work investigating  chronic 
effects of metformin, a scenario that may be a better reflection of patients on metformin 
treatment in the clinic.  
It is important to note that the mechanisms underlying cardioprotection following 
an  acute  treatment  with  an  agent  can  be  very  different  when  the  same  agent  is 
administered chronically. For example, it has been shown that acute treatment with 
atorvastatin for 1-3 days in rats decreased infarct size via Akt-PI3K activation, however 
when given chronically for a 2 week period the cardioprotective effect was lost 
521. This 




522. These observations were confirmed with a different statin, lovastatin 
in a cell-based model 
523.  This does not come as a surprise as chronic Akt activation 
can  promote  unwanted  cellular  and  tissue  growth,  therefore  negative  feedback 
mechanisms  will  be  up  regulated.  Therefore,  we  investigated  possible  downstream 
mechanisms of chronic metformin treatment, which may play a role in cardioprotection.  
  Metformin is a pleotropic drug that can control numerous factors involved in 
cellular survival; amongst them is Peroxisome Proliferator-Activated Receptor Gamma 
Coactivator-1α (PGC-1α) 
524, a tissue-specific transcriptional co-activator which plays a 
key role in regulating energy metabolism 
525. PGC-1α is predominantly expressed in 
mitochondrial-rich  tissues  such  as  brown  adipose  tissue,  skeletal  muscle  and  the 
heart
525. As PGC-1α plays a vital role in energy metabolism 
525, it is suggested that this 
coactivator can interact with mitochondrial regulatory pathways 
526 and possible with 
factors involved in mitochondrial dynamics such as mitofusin-2 (Mfn-2) 
526. 
  Interestingly, the diabetic status has been associated with a reduced level of 
PGC-1α 
203, 204, while metformin has been shown to increase the expression of PGC-1α 
in skeletal muscle possibly via AMPK activation 
524. Gundewar et al, 2009 showed that 
chronic low dose (125µg/kg) metformin administered after irreversible LAD ligation in 
mice,  exerts  beneficial  effects  on  cardiac  function  and  survival  in  this  heart  failure 
model via an increase in AMPK activation and an increase in PGC-1α expression 
287. 
However, there is limited information regarding these effects in the diabetic heart and 
their role in the protection against IRI. In addition to diabetes, age can also contribute 
to the IRI damage 
527. Interestingly, Reznick et al, 2007 compared AMPK activity in 
young  (3  months)  and  old  (28  months)  rats  and  demonstrated  an  age-associated 
decrease in AMPK activation and mitochondrial biogenesis following AICAR treatment 
528. Age related changes in metabolism and mitochondrial biogenesis, suggest PGC-1α 
as a potential target for anti-ageing strategies 
529, 530.    
4.1.2  Hypothesis 
We hypothesized that chronic metformin treatment could possibly activate AMPK and 
restore PGC-1α expression in diabetic hearts. Furthermore, this restoration of PGC-1α 
could  lead  to  improved  mitochondrial  biogenesis  in  these  hearts  and  hence  could 
provide an enhanced capacity for the heart to be protected against an ischaemic insult. 
The  aim  of  this  chapter  was  to  investigate  in  aged,  rat  hearts,  whether  chronic 
metformin treatment reduces myocardial infarct size through a mechanism independent 
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4.1.3  Experimental Protocols 
4.1.3.1  Animals 
Male  Goto-Kakizaki  (GK)  rats  (a  mild,  non-obese  diabetic  model 
427  obtained  from 
Taconic (Denmark), were bred in UCL facilities and kept in house until they reached 12 
months of age; they received humane care in accordance with the United Kingdom 
Animal (Scientific Procedures) Act of 1986. Male Wistar rats (normoglycaemic) were 
obtained from Charles River UK Limited (Margate, UK) and kept in house until they 
also reached 12 months of age. 
4.1.3.2  Treatments 
Rats  were  singly  housed  and  randomly  assigned  to  receive  either  300mg/kg/day 
metformin (Sigma, UK) sweetened with a non-caloric sweetener in drinking water, or 
sweetener alone in drinking water for 4 weeks. The metformin was sweetened to mask 
its metallic taste 
531 otherwise animals tended to have a reduced water intake. A pilot 
study was performed on 6 animals, whereby the drinking rate was monitored for 7 days 
in order to estimate the water consumption. Throughout the treatment the drinking rate 
was monitored every 2 days and then the amount of powdered metformin was adjusted 
to ensure each rat received a dose of 300mg/kg/day. Biological parameters including 
body  weight,  HbA1c  (A1C  now+  test  kit,  Bayer,  UK)  and  overnight  fasting  blood 
glucose (Accu-chek system, Roche) were collected prior, at 2 weeks and at 4 weeks 
after treatment 
The animals were randomly selected for IRI followed by infarct measurements 
or  for  Western  blot  analysis  and  electron  microscopy  studies.  There  were  4 
experimental groups: Wistar and Goto Kakizaki control groups which received only the 
sweetener in the drinking water and Wistar and Goto Kakizaki treated groups which 
received metformin added with the sweetener in the drinking water.  
4.1.3.3  Ex vivo Langendorff isolated heart experiments 
For determination of infarct size, GK and Wistar rats were anesthetized with sodium 
pentobarbital (55 mg/kg I.P.) and heparin (300 IU). The hearts were rapidly excised 
and  quickly  mounted  onto  a  Langendorff  constant  pressure  perfusion  system 
(ADInstruments, Chalgrove, UK), hearts were subjected to the ischaemia-reperfusion 
protocol as presented in (Figure 4.1). Experiments were performed as described in the 
previous chapter, including the monitoring of cardiac function and assessment of infarct 




Figure 4.1: Experimental groups and Langendorff experimental protocol.  Rats were randomly assigned 
into 4 treatment  groups; Group 1 Wistar (non-diabetic) control and Group 2  Goto-Kakizaki (diabetic) 
control which received 4 weeks of water control artificially sweetened. Group 3 Wistar (non-diabetic) 
treated and Group 4 Goto-Kakizaki (diabetic) treated received 300mg/kg/day metformin in sweetened 
drinking water for 4 weeks.  
 
4.1.3.4  Western Blot and electron microscopy sampling 
For these investigations, three groups of animals, all 12 months of age, were used: 
group  1  (non-treated  Wistar  rats),  group  2  (control  GK  rats  receiving  only  the 
sweetener)  and  group  3  (treated  GK  rats  which  received  metformin)  (n=4  in  each 
group). The animals were anesthetized with sodium pentobarbital (55 mg/kg I.P.) and 
heparin (300 IU). Hearts were harvested and perfused with Krebs buffer for 2 min to 
ensure the heart was cleared of blood. A small section of tissue from the left ventricle 
was collected in the electron microscopy fixative buffer and the remaining tissue was 
snap frozen in liquid nitrogen for Western blot analysis.  
4.1.3.5  Electron microscopy 
Electron  microscopy  (EM)  visualisation  of  mitochondria  was  performed  in  diabetic 
metformin  treated,  diabetic  non-treated  hearts  and  non-diabetic  non-treated  hearts. 
The method is detailed in Chapter 2.8.  
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4.1.3.6  Western Blot Analysis of heart samples 
Western  Blot  analysis  was  performed  as  described  in  the  previous  chapter; 
membranes were probed for phospho-α-AMPK (Thr 172), total α-AMPK, phospho-Akt 
(Ser  473),  total  Akt,  PGC-1α  and mitofusin-2 (Mfn-2).    For  detection of  PGC-1α  in 
different  sub  cellular  compartments,  nuclear  and  cytoplasmic  extracts from  GK  and 
metformin treated GK rat hearts were prepared using a nuclear/cytosol fractionation kit 
(Qiagen-Qproteome nuclear protein kit) according to the manufacturer’s instructions. 
Equal amounts of nuclear or cytoplasmic protein were subjected to western blotting of 
PGC-1α, and the fractions verified using nuclear TATA binding protein and cytosolic 
α-tubulin. 
4.1.3.7  ATP assay 
Heart samples collected for Western Blot analysis of protein expression were also used 
to investigate the basal levels of adenosine triphosphate (ATP) in hearts from groups 
1-3. We sought to assess whether levels of ATP were affected in the diabetic versus 
non-diabetic heart and whether metformin had any effect on these levels. ATP is a 
fundamental  player  in  many  cellular  processes  including  energetics,  signalling  and 
metabolism and its production can be regulated by AMPK.  ATP concentration was 
determined using ATP-bioluminescent assay kit (FL-AA, Sigma, UK) and the protocol is 
described in details in general methods chapter 2.7.1. 
4.1.3.8  Metformin treatment in HL-1 cell line 
Next, we utilized a cardiac cell line HL-1 to further explore the relationship between 
chronic  metformin  treatment,  AMPK  and  PGC-1α.  We  hypothesised  that  the 
metformin-dependent  phosphorylation  of  AMPK  was  required  for  the  metformin 
dependent effects on PGC-1α.   
The HL-1 cardiac cell line (derived from murine atrial cardiomyocytes) which 
contracts and maintains the characteristics of the adult cardiomyocyte
532, were grown 
in  Claycomb  media  supplemented  with  Noradrenaline,  FBS,  Penstrep  and 
L-Glutamine.  Cells were grown in T-25 flasks coated with Fibronectin and gelatin until 
confluent when they were split using 0.25% trypsin.  For experiments, cells were plated 
at 200,000 per well.   
Firstly,  we  wished  to  characterise  the  concentration  of  AMPK  inhibitor, 
Compound C (Sigma, UK) required to abolish metformin induced phosphorylation of 
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containing: (1) Compound C only (0-40µM) (2) AICAR (AMPK activator, Millipore) + 
Compound  C  (0-40µM)  and  (3)  Metformin  +  Compound  C  (0-40µM)  for  16  hours, 
summarised in Figure 4.2 or Figure 4.3.  Following treatment, HL-1 cells were collected 
by gently washing with warm PBS and removed from the plates by suspension in 100µl 
of Lamelli lysis buffer containing 5% β-mercaptoethanol by a cell scraping technique. 
Samples were then heated to 80-90°C for 10 minutes to ensure protein denaturation. 
Finally, samples were centrifuged at 8000 rpm for 5 minutes, and kept on ice. Samples 
were  assessed  for  protein  activation  and  expression  using  Western  Blot  analysis 
already described in this chapter.  
 
Figure  4.2:  Treatment  scheme  for  HL-1  cells.  The  HL-1  cells  were  plated  at  200,000  per  well.  For 
experiments  cells  were  incubated  for  16  hours  with  A.  Increasing  concentrations  of  AMPK  inhibitor 
Compound C. B. Metformin (1mM) in additions to increasing concentrations of Compound C. and C. AICAR 




Figure 4.3: Treatment scheme for HL-1 cells.  The HL-1 cells were incubated for 16 hours with (1-3) 1mM 
Metformin or (4-6) 1mM Metformin and 20µM AMPK inhibitor Compound C. Metformin treatment in 
aged, diabetic isolated cardiomyocytes 
 
4.1.3.9  Metformin treatment in isolated cardiomyocytes 
Adult  ventricular  cardiomyocytes  were  isolated  from  12  month  rat  diabetic  GK  rat 
hearts as described in chapter 2.4.3. Isolated cardiomyocytes were resuspended in 
M199 medium with added penicillin (100 IU/ml), streptomycin (100 IU/ml), L-carnitine 
(2 mM), creatine (5 mM), taurine (5 mM) and BSA (2g/L) (Medium 199, Sigma, UK ) 
and transferred onto laminin-coated 6 wells plates. Following 2 hours of plating, the 
media was gently removed leaving only attached, viable cardiomyocytes in the wells.  
For  experiments  1ml  of  fresh  media  was  added  to  each  well  containing:  (1)  No 
treatment (2) Compound C (20µM) (3) Compound C (40µM) (4) Metformin (1mM) (5) 
Metformin + Compound C (20µM) (6) Metformin (1mM) + Compound C (40µM) for 16 
hours,  summarised  in  Figure  4.4.  Subsequently,  cardiomyocytes  were  collected  by 
gently washing with warm PBS and removed from the plates by suspension in 100µl of 
Lamelli  lysis  buffer  containing  5%  β-mercaptoethanol  by  a  cell  scraping  technique. 
Samples were then heated to 80-90°C for 10 minutes to ensure protein denaturation. 
Finally, samples were centrifuged at 8000 rpm for 5 minutes, and kept on ice. Samples 
were  assessed  for  protein  activation  and  expression  using  Western  Blot  analysis 
already described.  




Figure 4.4: Treatment organisation for isolated cardiomyocytes.  For experiments cardiomyocytes were 
incubated for 16 hours with 1) Media alone (no treatment) 2) 20µM AMPK inhibitor Compound C 3) 40µM 
AMPK  inhibitor  Compound  C  4)  1mM  Metformin  5)  1mM  Metformin  and  20µM  AMPK  inhibitor 
Compound C and 6) 1mM Metformin and 40µM AMPK inhibitor. 
 
4.1.3.10  Statistical Analysis  
Data  were  analysed  by  either  one-way  ANOVA  followed  by  Bonferroni’s  multiple 
comparison test, students t-test or repeated measures ANOVA using GraphPad Prism 
5.0 (GraphPad Software Inc, San Diego, California, USA). The choice of test is noted in 
the figure legend.  A p-value <0.05 was considered to be statistically significant. Values 
are presented as means ± standard error mean (SEM). 
4.1.4  Results 
4.1.4.1  The  effect  of  chronic  metformin  treatment  on  physiological 
parameters 
Due to the insulin-sensitizing effects and hence blood glucose lowering potential of 
metformin, diabetic status was monitored throughout the 4 week study. Blood glucose 
and body mass were measured prior to the study, then at 2 weeks and at 4 weeks, 
whereas  glycated  haemoglobin  (HbA1c)  was  measured  prior  to  and  at  4  weeks.  
Metformin  reduced  blood  glucose  and  HbA1c  by  33.4%  and  23.8%  (p<0.005), 
respectively following 4 weeks of treatment in GK rats, however, no change was seen 
in  normoglycaemic  Wistar  rats  (p=ns).  As  expected,  as  a  side  effect  of  metformin 
treatment, GK  rats receiving  the  drug  showed  a  7.4% (P<0.005)  decrease  in  body 
weight.  No  significant  changes  were  recorded  for  any  parameters  in  groups  that Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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received sweetened water control. Data is summarised in Table 4.1 and Table 4.2.  
Mean plasma insulin levels were not assessed in this study, however in accordance 
with Portha et  al, 1991, the glycaemic status we report is consistent with impaired 
insulin secretion and resistance previously reported in the GK model of type 2 diabetes 
443.  
 
  Goto Kakizaki - Control  Goto Kakizaki -Metformin 
















(g)  -  -  2.77 ± 
















3.3  -  61.4 ± 
3.7 
58.2 ± 
5.2  -  44.3 ± 
3.4* 
Table 4.1: Summary of metformin treatment in Goto-Kakizaki rats.   Summary of parameters measured 
before,  during  and  at  the  end  of  the  treatment  with  either  water  +non-caloric  sweetener  or 
300mg/kg/day metformin in water + non-caloric sweetener in 12 month diabetic GK rats. Body mass, 
blood glucose and HbA1c were measured initially, at 2 weeks and at 4 weeks prior to excision of the heart 
for experimentation. Heart mass was measured following isolated Langendorff heart preparation. Data is 
represented as mean ﾱ S.E.M, n≥6. *P<0.05 versus initial reading within group. **P<0.005 versus initial 
reading within group. Repeated measures ANOVA was used to determine statistical significance. 
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  Wistar - Control  Wistar -Metformin 
















(g)  -  -  1.85 ± 









0.6  -  25.7 ± 1.6  27.9 ± 
1.2  -  24.3 ± 
0.7 
Table 4.2: Summary of metformin treatment in Goto-Kakizaki rats.  Summary of parameters measured 
before,  during  and  at  the  end  of  the  treatment  with  either  water  +non-caloric  sweetener  or 
300mg/kg/day metformin in water + non-caloric sweetener in 12 month non-diabetic Wistar rats. Body 
mass, blood glucose and HbA1c were measured initially, at 2 weeks and at 4 weeks prior to excision of the 
heart for experimentation. Heart mass was measured following isolated Langendorff heart preparation. 
Data is represented as mean ﾱ S.E.M, n≥6.. Repeated measures ANOVA was used to determine statistical 
significance. 
4.1.4.2  Chronic  metformin  treatment  reduces  infarct  size  in  a  glucose-
independent manner 
Oral metformin treatment given chronically for 4 weeks at 300mg/kg/day significantly 
reduced infarct size in both non-diabetic and diabetic rat hearts. In the diabetic group, 
infarct  size  was  reduced  by  65.4%  compared  to  non-treated  GK  rats  (I/R  %; 
16.6%± 2.0  vs.  47.8  ±  2.0,  p<0.001,Figure  4.5).  This  reduction  in  infarct  size  was 
greater  than  the  protection  afforded  by  metformin  in  the  non-diabetic  group.  In the 
normoglycaemic Wistar rat hearts, metformin reduced infarct size by 31.1% with no 
effect  on  blood  glucose  (I/R  %;  40.8  ±  4.5  vs.  58.9 ± 3.5,  P<0.005,  Figure  4.5).  
However,  one  of  the  most  interesting  observations  is  the  correlation  between 
metformin’s  protection,  blood  glucose  level  and  diabetic  status.  While  metformin 
protects both diabetic and non-diabetic hearts, the degree of protection is higher in the 
diabetic heart in which metformin induces a significant decrease in blood glucose. 
In  this  model  metformin  had  no  significant  effect  on  any  of  the  functional 
parameters  monitored  by  the  intra-ventricular  balloon  in  either  the  non-diabetic  or 




Figure 4.5: The effect of chronic metformin treatment on infarct size in the Wistar and GK rat.  Infarct 
size is expressed as the infarcted volume within the area at risk of the left ventricle (% I/R) in hearts either 
treated with metformin for 4 weeks or control hearts. Chronic metformin significantly reduced the infarct 
size compared to the control group in both the non-diabetic and diabetic heart. Data is shown as mean ± 
S.E.M, n≥6. ** p<0.005, ***p<0.001 versus respective control. One way ANOVA followed by a Tukey Post-
Hoc analysis were used for statistical analysis between groups. 





Figure 4.6: Cardiac function assessment following chronic metformin treatment in the Wistar (non-
diabetic)  and  Goto-Kakizaki  (GK,  diabetic)  heart.  Function  was  monitored  throughout  the  entire 
protocol.  A.  Rate  Pressure  Product  (RPP)  B.  Left  ventricular  end  diastolic  pressure  (LVEDP)  C.  Left 
ventricular developed pressure (LVDP) D. Coronary flow E. Heart Rate (HR) and F. % recovery of LVDP 
following 35 min ischaemia/60 min reperfusion. LVEDP. LVDP and HR were monitored via an inserted 
ventricular latex balloon, RPP was calculated as HR x LVDP as a measure of cardiac workload. Data is 
shown as mean ﾱ S.E.M, n≥6. Comparison between groups at multiple time-points was analysed by two-
way repeated measures (mixed model) ANOVA with a Bonferroni correction for multiple comparisons 
were used for statistical analysis between groups. 
   Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
203 
 
4.1.4.3  The effect of chronic metformin treatment on pro-survival kinases 
in the diabetic heart 
To examine the potential mechanism that could be responsible for the cardioprotective 
effect of chronic metformin treatment in the diabetic heart, we assessed the expression 
and activation of pro-survival kinases Akt and AMPK. The reduction in infarct size was 
mirrored by a significant increase in the phosphorylation of AMPK at baseline (1.4±0.1 
vs 0.9±0.1 a.u., P<0.05, Figure 4.7) with no change noted in total AMPK protein levels. 
In  contrast,  phosphorylated  Akt  was  unchanged  following  4  weeks  of  metformin 
treatment (3.9 ± 0.4 vs 4.0 ± 0.2 a.u. p= ns, Figure 4.8). 
 
Figure  4.7:  The  effect  of  chronic  metformin  treatment  on  AMPK  expression  and  phosphorylation.  
Metformin increases AMPK phosphorylation but has no effect on AMPK’s total levels in Goto Kakizaki (GK) 
rat hearts. AMPK-P/T molecular weight 62 kDa.  Data is shown as mean ± S.E.M, n=4 per group. *P<0.05 
versus non-treated GK. One-way ANOVA followed by Bonferroni’s multiple comparison test were used to 




Figure  4.8:  The  effect  of  chronic  metformin  treatment  on  Akt  expression  and  phosphorylation.  
Metformin has no effect on Akt expression or baseline activation in Goto Kakizaki (GK) rat hearts. Akt-P/T 
molecular weight is approximately 60 kDa.  Data is shown as mean ± S.E.M, n=4 per group.  One-way 
ANOVA followed by Bonferroni’s multiple comparison test were used to determine statistical significance. 
 
4.1.4.4  Mitochondrial  regulators  are  enhanced  following  chronic 
metformin treatment in the diabetic heart 
Recent  advances  in  the  literature  suggest  that  AMPK  can  interact  and  modulate 
mitochondrial  regulators  such  as  PGC-1α.  Following  the  confirmation  that  AMPK 
phosphorylation  was  enhanced  subsequent  to  chronic  metformin  treatment  in  the 
diabetic  heart,  we  assessed  whether  the  expression  of  PGC-1α  is  also  effected. 
Interestingly, previous studies showed that PGC-1α’s expression was down regulated 
in type 2 diabetes 
203, 204 and that metformin can increase the expression of PGC-1α in 
skeletal  muscle 
524.    In  accordance  with  these  previous  findings,  we  observed  a 
diabetes-associated down regulation of PGC-1α expression in the diabetic heart (0.38 
±  0.1  vs  0.54  ±  0.1,  p<0.001,  Figure  4.9)  and  a  significant  restoration  of  PGC-1α 




Figure 4.9: The effect of chronic metformin treatment on PGC-1α expression in the diabetic heart.  A 
diabetes-related decrease in PGC-1α expression was observed in the GK rat heart. Chronic metformin 
treatments (4 weeks) enhanced PGC-1α expression in Goto Kakizaki (GK) rat hearts.  PGC-1α molecular 
weight is approximately  92/112 kDa. Data is shown as mean ± S.E.M, n=4 per group.  One-way ANOVA 
followed by Bonferroni’s multiple comparison test were used to determine statistical significance. 
As a regulator of mitochondrial biogenesis, changes in PGC-1α expression will 
impact on the structure, organisation and function of the mitochondria.  Alongside its 
predominant role in mitochondrial energy metabolism, PGC-1α has also been shown to 
influence the morphology of mitochondria
39; a subject that has attracted much interest 
in the setting of ischaemia reperfusion injury. We therefore assessed whether chronic 
metformin treatment effected the expression of the mitofusin protein Mfn-2 and used 
electron  microscopy  images  to  highlight  any  structural  and  organisational  changes 
within the mitochondria. Diabetic status had no significant effect on the levels of Mfn-2 
at  baseline  (2.6  ±  0.2,  Wistar  vs  2.3  ±  0.2,  GK  a.u.  p=ns);  however,  metformin 
treatment significantly increased the expression of Mfn-2 in diabetic hearts to a level 
greater than that seen in the normoglycaemic Wistar hearts (2.6 ± 0.2 vs 3.3±0.1 a.u., 
p<0.005, Figure 4.10). Mfn-2 promotes fusion of mitochondria, thereby creating an inter 
connecting  network  of  highly  functional  organelles.  Electron  microscopy  images 
demonstrate that mitochondria in the untreated hyperglycaemic GK hearts appeared 
unorganised and more spherical in shape. Interestingly, following metformin treatment, Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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the mitochondria seem more organised and elongated, resembling those in the Wistar 
normoglycaemic heart (Figure 4.11). 
 
 
Figure  4.10: The effect of chronic metformin treatment on Mfn-2 expression in the diabetic heart.  
Chronic metformin treatments (4 weeks) enhanced Mfn-2 expression in Goto Kakizaki (GK) rat hearts. No 
significant difference was seen in Mfn-2 expression between the non-diabetic and diabetic heart. Mfn-2 
molecular weight 82 kDa. Data is shown as mean ± S.E.M, n=4 per group.  One-way ANOVA followed by 
Bonferroni’s multiple comparison test were used to determine statistical significance. 




Figure 4.11: The effect of metformin treatment on mitochondrial appearance in the diabetic heart.   
Chronic metformin treatment correlates with changes in mitochondrial appearance in the diabetic heart. 
A. Non treated 12 month old Goto-Kakizaki diabetic heart. B. Metformin treated (4 weeks 300mg/kg/day) 
Goto-Kakizaki diabetic heart. C.. 12 month old Wistar normoglycaemic heart. (Representative electron 
micrograph photos). 
PGC-1α  is  a  dynamic  molecule  that  is  known  to  migrate  between  different 
subcellular compartments of the cell to exert different effects 
100; therefore we sought to 
investigate if metformin treatment had an impact on this process. Following subcellular 
fractionation  we  found  that  the  nuclear  PGC-1α  expression  decreased  following 
metformin  treatment  compared  to  untreated  GK  hearts.  Surprisingly,  the  cytosolic 
fraction showed no difference in PGC-1α expression. Moreover, the cytosolic fractions 
appear as a single band compared to the double band seen in the total cell extract and 
in the nuclear fraction (Figure 4.12). 
ATP  is  produced  via  numerous  mechanisms  including  glycolysis  and 
mitochondrial  fatty  acid  oxidation  in  the  heart,  depending  on  the  availability  of 
substrates and the oxygen supply. As the energy powerhouses of the cell, functional 
mitochondria are essential for efficient energy production. PGC-1α can influence the 
shift between metabolic pathways that provide ATP; therefore we sought to assess the 
level of ATP in the diabetic and non-diabetic heart, and whether chronic metformin Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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treatment had any influence on ATP levels in diabetic hearts.  Intriguingly, we found 
that basal ATP levels in the 12 month GK heart were significantly higher than levels 
found in the 12 month Wistar heart. Moreover, chronic metformin treatment diminished 
the elevated levels of ATP in the diabetic heart (Figure 4.13).  
 
 
Figure  4.12: The effect of metformin treatment on the subcellular  localisation  of PGC-1α.  Chronic 
metformin  treatment  leads  to  decreased  nuclear  accumulation  of  PGC-1α.  Following  metformin 
treatment, PGC-1α expression in the nuclear fragment decreased compared to that of the non-treated 
Goto-Kakizaki. Data is shown as mean ± S.E.M, n=4 per group, **p<0.005. PGC-1α expression is calculated 
by measuring both bands in the nuclear fraction and single band in the cytosolic fraction and corrected to 
an appropriate loading control. Student’s t-test was used for statistical analysis. 




Figure 4.13: The effect of chronic metformin treatment on basal ATP levels in the diabetic Goto-Kakizaki 
(GK) rat heart.  Basal ATP levels were significantly higher in the diabetic GK heart compared to the non-
diabetic Wistar heart, metformin treatment (4 weeks) reduced the basal increase in ATP production. Data 
is shown as mean ± S.E.M, n=4 per group.  One-way ANOVA followed by Bonferroni’s multiple comparison 
test were used to determine statistical significance. 
 
4.1.4.5  The  up  regulation  of  PGC-1α  expression  following  chronic 
metformin treatment may require AMPK phosphorylation  
To further elucidate the mechanism by which metformin restores the expression levels 
of PGC-1α, HL-1 cells were treated with metformin and a known activator of AMPK, 
AICAR, in the presence of increasing concentrations of the AMPK inhibitor Compound 
C. Activation of AMPK and ACC by phosphorylation was assessed using Western Blot 
analysis.  Metformin  increased  the  phosphorylation  of  both  AMPK  and  ACC;  in 
metformin treated cells, this increase was inhibited by 20µM and 40µM compound C 
however  in  AICAR  treated  cells  levels  were  undetectable  (Figure  4.14  and  Figure 
4.15).  
Following  these  findings,  HL-1  cells  were  treated  with  metformin  in  the 
presence and absence of 20µM Compound C, subsequently AMPK-P, PGC-1α and 
Mfn-2 expression were assessed. Analysis showed 20µM Compound C significantly 
reduced  AMPK-P  (Figure  4.16);  furthermore  metformin  associated  increase  in 
expression of PGC-1α was prevented in presence of the inhibitor compound (Figure 
4.17). This concentration of Compound C did not significantly prevent the metformin-
associated increase in Mfn-2 expression (Figure 4.18).  
Next,  we  assessed  protein  expression  and  activation  following  metformin 
treatment in the presence and absence of 20µM or 40µM Compound C in 12month, Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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diabetic  GK  isolated  cardiomyocytes  (Figure  4.19).  In  the  previous  study  20  µM 
Compound  C  did  not  alter  the  Mfn-2  levels;  we  hypothesised  that  a  higher 
concentration of the inhibitor may be required to elicit a significant effect therefore in 
these  studies  we  also  used  40µM  Compound  C.    We  found  metformin  increased 
AMPK-P and both concentrations of Compound C inhibited this increase (Figure 4.20). 
PGC-1α  expression  was  also  increased  following  metformin  treatment,  20  μM  of 
Compound  C  decreased  PGC-1α  expression  but  this  reduction  did  not  reach 
significance. 40μM of Compound C significantly prevented the metformin associated 
increase in PGC-1α expression, however, Compound C alone also decreased PGC-1α 
expression at this concentration (Figure 4.21). Mfn-2 expression was not significantly 
affected by metformin and/or  AMPK-P inhibition; however  a similar  trend was seen 
(Figure 4.22).  
 
Figure 4.14: Characterisation of the effectiveness of Compound C in blocking the action of metformin on 
AMPK  activation  in  HL-1  cells.  HL-1  cells  were  treated  with  either  increasing  concentrations  of 
Compound C only (μM: 0,5,10,20,40), treated with 1mM Metformin in the presence of Compound C or 
treated with 1mM AICAR + Compound C for 16 hours before protein assessment using Western Blot. Total 
levels of AMPK and phosphorylation at Thr172 were assessed. 
 
 
Figure 4.15: Characterisation of the effectiveness of Compound C in blocking the action of metformin on 
ACC activation in HL-1 cells.  HL-1 cells were treated with either increasing concentrations of Compound C 
only (μM: 0,5,10,20,40), treated with 1mM Metformin in the presence of Compound C or treated with 
1mM AICAR + Compound C for 16 hours before protein assessment using Western Blot. Total levels of 




Figure 4.16: AMPK activation following 16 hours metformin treatment in HL-1 cells.: HL-1 cells were 
treated for 16 hours with 1mM metformin in the presence or absence of 20μM Compound C.  AMPK 
phosphorylation was assessed using Western Blot analysis, n=3 per group, student’s t test was used to 




Figure 4.17: PGC-1α expression following 16 hours metformin treatment in HL-1 cells.  HL-1 cells were 
treated for 16 hours with 1mM metformin in the presence or absence of 20μM Compound C.  PGC-1α 
expression  was  assessed  using  Western  Blot  analysis,  n=3  per  group,  student’s  t  test  was  used  to 
determine statistical significance. 




Figure 4.18: Mfn-2 expression following 16 hours metformin treatment in HL-1 cells.  HL-1 cells were 
treated for 16 hours with 1mM metformin in the presence or absence of 20μM Compound C.  Mfn-2 
expression  was  assessed  using  Western  Blot  analysis,  n=3  per  group,  student’s  t  test  was  used  to 
determine statistical significance. 
 
 
Figure 4.19: Plating of isolated cardiomyocytes.  Representative pictures of isolated cardiomyocytes from 
12 month GK rat hearts. Cardiomyocytes were isolated and plated for 2 hours (Day 0) and 24 hours (Day 




Figure 4.20: AMPK activation  following 16 hours metformin treatment in isolated cardiomyocytes from 
the  12  month  diabetic  GK  hearts.  Following  isolation,  cells  were  treated  for  16  hours  with  1)  no 
treatment  2)  20μM  Compound  C  (CC)  only  3)  40μM  Compound  C  (CC)  4)  1mM  metformin  5)  1mM 
metformin + 20μM Compound C 6) 1mM metformin + 40μM Compound C . AMPK phosphorylation was 
assessed using Western Blot analysis, n=3 per group, One-way ANOVA followed by Bonferroni’s multiple 
comparison test was used to determine statistical significance. 




Figure 4.21: PGC-1α expression following 16 hours metformin treatment in isolated cardiomyocytes 
from the 12 month diabetic GK hearts.  Following isolation, cells were treated for 16 hours with 1) no 
treatment  2)  20μM  Compound  C  (CC)  only  3)  40μM  Compound  C  (CC)  4)  1mM  metformin  5)  1mM 
metformin + 20μM Compound C 6) 1mM metformin + 40μM Compound C . AMPK phosphorylation was 
assessed using Western Blot analysis, n=3 per group, One-way ANOVA followed by Bonferroni’s multiple 
comparison test was used to determine statistical significance. 




Figure 4.22: Assessment of Mfn-2 expression following 16 hours metformin treatment in isolated 12 
month diabetic GK  cardiomyocytes.  Following isolation, cells  were treated for 16 hours with 1) no 
treatment  2)  20μM  Compound  C  (CC)  only  3)  40μM  Compound  C  (CC)  4)  1mM  metformin  5)  1mM 
metformin  +  20μM  Compound  C  6)  1mM  metformin  +  40μM  Compound  C  .  Mfn-2  expression  was 
assessed using Western Blot analysis, n=3 per group, One-way ANOVA followed by Bonferroni’s multiple 
comparison test was used to determine statistical significance. 
 
4.1.5  Summary and Discussion 
The key findings presented in this section of the chapter are: 
-  Chronic metformin treatment lowered blood glucose only in the GK rats but 
elicits a cardioprotective effect against ischaemia-reperfusion injury in both the 
diabetic and non-diabetic ageing heart.  
-  Intriguingly, this protection is more effective in the diabetic heart. 
-  The ageing diabetic heart has a decreased expression of PGC-1α compared to 
the non-diabetic heart. 
-  Chronic metformin treatment is associated with an increased level of 
phosphorylated AMPK and increased expression of PGC-1α and Mfn-2. 
4.1.5.1  Chronic  Metformin  treatment  protects  the  diabetic  and 
non-diabetic heart against ischaemia-reperfusion injury 
Type 2 diabetic patients taking metformin have a reduced incidence of cardiovascular 
events
260,  moreover,  experimentally  this  agent  is  proven  to  be  cardioprotective  in 
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different animal models of ischaemia-reperfusion injury. Patients presenting with type 2 
diabetes are often middle to old aged, however the majority of experimental information 
collected have used young, diabetic or non-diabetic animal models. Therefore using a 
model which corroborates 2 co-morbidities (diabetes and age) will provide insightful 
information regarding metformin-related cardioprotection.  
The majority of experimental studies have been performed in an acute setting, 
either  administrating  metformin  for  a  short  period  before  an  ischaemic  insult 
284  or 
following ischaemia 
281 in a postconditioning fashion. However, if a long term treatment 
can  potentially  lower  the  incidence  of  cardiovascular  events,  prevention  is  often 
preferable to cure. Therefore experimental investigations assessing whether long term 
treatment with metformin proves beneficial is essential and may aid interpretation of 
clinical outcome studies. 
The  data  presented  in  this  section  demonstrated  that  chronic  metformin 
treatment reduced infarct size in both aged diabetic and non-diabetic rat hearts, albeit 
to a lesser extent in the latter group. The fact that metformin could reduce infarct size in 
the  non-diabetic  group  led  us  to  question  whether  cardioprotection  elicited  by 
metformin  in  the  diabetic  heart  is  entirely  based  on  a  simple  reduction  of 
hyperglycaemia.  Interestingly,  in  this  model,  metformin  did  not  appear  to  have  a 
significant effect on cardiac function; however the intra-ventricular balloon used in this 
mode of the Langendorff preparation may not be sensitive enough to register small but 
significant changes.  
4.1.5.2  Chronic Metformin treatment enhances phosphorylation of AMPK 
not Akt in the ageing, diabetic heart 
The molecular mechanisms underlying metformin associated protection are complex 
and not fully understood yet. The majority of experimental evidence in the acute setting 
thus far shows a strong involvement via AMPK 
266, 283 and Akt 
281 activation.  
AMPK is a dynamic kinase molecule that acts as the major regulator of energy 
balance  within  the  cell 
533.  This  study  shows  that  chronic  metformin treatment  also 
causes an increased basal activation of AMPK by phosphorylation. Other studies also 
demonstrate this; Musi et al, 2002 
268 revealed that AMPK is still activated in skeletal 
muscle following 10 weeks of oral metformin treatment in type 2 diabetic patients 
268. 
However,  in  contrast,  no  enhancement  of  AMPK  phosphorylation  was  seen  in 
normoglycaemic  rat  hearts  from  rats  treated  with  metformin  for  2  weeks 
534.  




534, suggesting that perhaps the cardioprotective benefits of metformin are time 
and/or dose-dependent 
535.  In contrast, some studies oppose the necessity for AMPK 
activation to elicit the positive effects of metformin 
536. For instance, Foretz et al, 2010 
showed  that  metformin  administration  in  mice  produced  a  reduction  in  hepatic 
gluconeogenesis and that this decrease did not require AMPK activation and instead 
directly decreased hepatic energy state 
271. This variability in results may be caused by 
the diverse effects of metformin in different organs or tissues and also potentially by the 
use of different experimental models. Metformin treatment has been assessed in both 
non-diabetic animals and diabetic animals, the latter consisting of genetically modified, 
chemically induced or sporadic models which all have differences in basal signalling. In 
this  respect,  the  12  month  old  Goto  Kakizaki  rat  model  is  an  important  tool  to 
investigate  the  chronic effect  of  metformin,  as it  more  closely  reflects a  non-obese 
middle aged diabetic patient.  
  Apart  from  activation  of  AMPK,  previous  studies  have  shown  that  acute 
metformin treatment given at the time of reperfusion can activate the RISK pathway 
281. 
Bhamra et al, 2008 demonstrated that diabetic GK and non-diabetic Wistar isolated rat 
hearts  could  be  protected  against  IRI  by  administering  metformin  during  the  first 
15minutes  of  reperfusion.  Acute  metformin  applied  in  this  setting  activated  Akt  by 
phosphorylation; moreover simultaneous administration of a PI3K inhibitor, LY294002, 
prevented this increase in phosphorylation and subsequently protection was lost.  The 
authors  further  characterised  this  finding  by  assessing  mPTP  opening  in  isolated 
cardiomyocytes and demonstrated metformin induced activation of PI3K/Akt pathway 
led to inhibition of the mitochondrial permeability transition pore (mPTP) and therefore 
reduced infarct size in this model of IRI 
281. Akt phosphorylation was also assessed in 
this study; however, chronic treatment with metformin did not  appear  to chronically 
activate this kinase.  It is likely that chronic administration of drugs may not manifest 
the same outcomes as acute drug administration due to the existence  of inhibitory 
feedback regulation mechanisms 
521. 
4.1.5.3  Chronic  metformin  treatment  can  restore  reduced  PGC-1α 
expression  and increase  mitochondrial  regulation in  the  ageing, 
diabetic heart 
A decreased expression of PGC-1α has been previously shown in diabetic skeletal 
muscle 
524. In this study, we showed that PGC-1α protein expression is down-regulated 
in aged, diabetic rat myocardial tissue compared to the non-diabetic rat heart, a finding 
not  yet  to  be  reported  elsewhere.  Moreover,  electron  microscopy  images  suggest 
mitochondria  to  be  more  organised  and  in  their  favoured  elongated  appearance  in Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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metformin-treated  GK  rat  hearts;  possibly  as  a  consequence  of  enhanced  PGC-1α 
expression.    PGC-1α,  a  key  regulator  of  energy  metabolism  has  been  extensively 
studied 
525, with its expression finely regulated to meet the energy demands of cellular 
systems 
506.  Interestingly,  investigations  in  skeletal  muscle  suggest  that  increasing 
activation  of  AMPK  by  pharmacological  activation,  either  by 
5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside  (AICAR) 
271  or  metformin 
524 
enhanced PGC-1α expression resulting in increased mitochondrial biogenesis.  Yet, 
the  mechanisms  by  which  increasing  AMPK  activity  can  subsequently  lead  to 
increased PGC-1α expression are still not completely understood. This study suggests 
similarities  to  this  scenario:  following  administration  of  metformin  for  4  weeks  we 
recorded  an  increase  in  activation  of  AMPK  and  a  subsequent  increase  in  the 
expression levels of PGC-1α in the heart, an effect similar to that previously seen in 
skeletal muscle.  
Intriguingly,  basal  ATP  levels  in  the  aged,  diabetic  heart  were  surprisingly 
significantly greater than in the age matched Wistar hearts and metformin treatment 
decreased basal levels of ATP. ATP levels are tightly regulated in the heart by both 
AMPK and PGC-1α
94, and normal cardiac function is dependent on a constant supply 
and demand of ATP. In the young insulin resistant heart, it has been suggested that 
PGC-1α  expression  is  increased  in  accordance  with  a  metabolic  shift
206  and 
dependency on fatty acid oxidation in response to a decreased availability of glucose 
uptake available for glycolysis
537.  
As  the  diabetic  heart  ages,  PGC-1α  expression  appears  to  decrease  (as 
reported  in chapter 3), therefore it could be suggested that fatty acid oxidation which is 
responsible for 60-90% of ATP synthesis could become inappropriately regulated and 
therefore  production  of  ATP  by  the  respiratory  chain  is  inadequately  controlled. 
Excessive concentrations of long-chain fatty acids including acyl CoA ester are present 
in the diabetic heart
538, which may lead to overproduction of ATP and favour activation 
of cell membrane KATP channels and a subsequent change in Ca
2+ handling
210. This 
was  shown  to  occur  in  type  2  diabetic  db/db  mice  which  exhibit  impaired  cardiac 
contractility
539.  Metformin may enhance AMPK activation therefore restoring the control 
of AMP:ATP ratio and alongside PGC-1α ensures normal ATP regulation. However, the 
lipid profile of ageing GK hearts were not assessed in this investigation and some may 
argue that an increased level of ATP would in fact be beneficial in IRI
248.  
Recent advances suggest that proteins involved in the control of mitochondrial 
dynamics namely Mfn-2, can also regulate mitochondrial metabolism 
526. Mfn-2 has Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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pleiotropic roles within the cellular system, moreover, it has emerged as a key target of 
the PGC-1α regulatory pathway 
540. In support of a PGC-1α/Mfn-2 interaction, Soriano 
et al, 2006 showed that overexpression of PGC-1α in cultured muscle cells induced 
both Mfn-2 mRNA and protein expression above the levels of other genes typically 
enhanced by PGC-1α. They also found that PGC-1α stimulates the expression of Mfn-
2 through its transcriptional properties 
541. Additionally, a decreased expression of Mfn-
2 has been demonstrated in skeletal muscle of type 2 diabetes patients 
542.  
Based on these findings reported in the literature and our data showing that 
chronic  metformin  administration  can  increase  PGC-1α  expression,  and  improve 
mitochondrial  organisation  and  appearance  in  GK  rat  hearts,  we  hypothesised  that 
Mfn-2 expression may be implemented in this pathway. We did not see a significant 
reduction in Mfn-2 levels in the diabetic heart compared to the non-diabetic heart, yet 
metformin treatment enhanced Mfn-2 expression. Mfn-2 could potentially play a role in 
metformin  induced  protection  in  this  set  up.  Although  we  do  not  show  any  direct 
evidence,  it  is  possible  that  metformin  through  phosphorylation  of  AMPK  can  up-
regulate  and  provide  an  increased  platform  for  activation  of  PGC-1α  via  either 
phosphorylation or deacetylation 
39.  This increase in activity may then act downstream 
on the mitofusin protein Mfn-2 which contributes to improved mitochondrial biogenesis 
and renders the diabetic heart less prone to damage by IRI. 
4.1.5.4  Up regulation of PGC-1α expression may require phosphorylation 
and activation of AMPK 
In an attempt to establish whether a direct link exists between metformin associated 
phosphorylation of AMPK and PGC-1α expression; HL-1 cells and isolated 12 month 
diabetic cardiomyocytes were incubated with metformin with or without the presence of 
AMPK  inhibitor  compound  C  and  protein  expression  and  activation  assessed. 
Characterisation  studies  using  the  HL-1  cell  line  demonstrated  that  metformin 
treatment enhanced AMPK phosphorylation and PGC-1α expression and that these 
changes  were  reduced  when  AMPK  activation  was  inhibited.  Furthermore,  this 
outcome  was  repeated  in  aged,  diabetic  cardiomyocytes.  Interestingly,  inhibition  of 
AMPK phosphorylation did not significantly affect metformin associated influence on 
mfn-2 expression, which may suggest that an alternative pathway other than AMPK-
phosphorylation  could  contribute to metformin-related  changes  in  Mfn-2  expression. 
Whether  metformin  associated  up  regulation  of  PGC-1α  expression  in  the  diabetic 
heart absolutely requires AMPK phosphorylation is unclear. Inhibition of AMPK using 
20µM  of  Compound  C  did  not  significantly  reduce  the  enhancement  of  PGC-1α 
expression  due  to  the  variability  in  the  data.  The  reduction  in  expression  reached Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
220 
 
significance when using 40µM of the inhibitor compound, however, this concentration 
of  Compound  C  also  decreased  the  expression  of  PGC-1α  without  prior  metformin 
administration. Therefore, one cannot exclude the possibility that Compound C has a 
direct inhibitory effect on PGC-1α expression or that perhaps the higher concentration 
produced toxic effects on the cells. 
It has been demonstrated previously that there is a strong overlap in the target 
genes of AMPK and PGC-1α especially in those involving mitochondrial function
543. 
The findings in this investigation and the potential importance of AMPK activation on 
subsequent PGC-1α transcription are supported by numerous studies. These include 
studies  demonstrating  that  AMPK  over-activation  by  mutational  changes  increase 
mitochondrial content in vivo
544 and that AMPK can directly influence PGC-1α activity 
through  direct  interaction  by  phosphorylation
90.    Whether  AMPK  phosphorylates 
PGC-1α  in  the  heart  is  yet  to  be  determined  and  would  provide  significant 
understanding  into  how  chronic  metformin  treatment  may  lead  to  an  improved 
mitochondrial  function  in  the  heart.  To  answer  whether  AMPK  can  directly 
phosphorylate PGC-1α in the heart, we attempted to immunoprecipitate (IP) out the 
PGC-1α  protein  from  aged,  diabetic  heart  tissue  and  to  assess  whether  metformin 
phosphorylated  PGC-1α.  Unfortunately,  this  proved  problematic  and  we  were 
unsuccessful in isolating PGC-1α protein from our heart samples.  
4.1.5.5  Metformin may alter the subcellular location of PGC-1α  
The up regulation of PGC-1α expression following metformin treatment may provide a 
platform for post translational modifications to occur. A dynamic shift in localisation can 
take place in response to a change in the energy status of the cell, with the main pool 
localised  in  the  cytoplasm  rapidly  modified  by  phosphorylation,  de/acetylation, 
ubiquination,  methylation  or  GlcNacylation
506.    Subsequently  PGC-1α  can  be  both 
activated and transported into a different cellular location, for example into the nucleus 
to co activate transcription factors for target genes, or remains in an inactive form in the 
cytoplasm, all depending on the cellular demands 
100.  
Interestingly, in the whole cell, we found that the PGC-1α protein appeared as a 
double  band;  the  lower  band  was  uniform  and  the  upper  band  more  differential  in 
expression  levels.    This  led  to  an  overall  decreased  expression  in  diabetes,  which 
increased  in  metformin  treated  hearts.  Following  subcellular  fractionation,  the 
cytoplasmic fraction displayed no difference in PGC-1α expression following metformin 
treatment and appeared as a single band. Intriguingly, this band was seen in the same 
molecular weight range as the lower band seen in the whole cell experiment. In the Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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nuclear extract, PGC-1α appeared once again as a double band; however the results 
were opposite to that seen in the whole cell investigation.  PGC-1α expression was 
decreased in the nuclear extract following metformin treatment in the diabetic heart. 
Interestingly, Holloway et al, 2010 demonstrate an increased accumulation of nuclear 
PGC-1α expression in diabetic hearts isolated from Zucker diabetic fatty (ZDF) rats, an 
alternative model of type 2 diabetes 
545.  However, other authors suggest that PGC-1α 
is  active  when  transported  into  the  nucleus 
100,  therefore  creating  a  puzzling 
conclusion.  
It could be suggested that the double banding that was used to calculate total 
PGC-1α  expression  levels  are  in  fact  a  representation  of  activity  and  expression, 
Aquilano et al, 2010 suggesting that the two bands could be representative of a post-
translational process
546. Based on this, one interpretation of our results could be that 
the upper band, which had a reduced expression in the nuclear fraction, could be a 
representation of a post-translational modification.  One possible modification could be 
acetylation, which would translate that the diabetic hearts have more PGC-1α in the 
acetylated (inactive) form, therefore prevented it from performing its co-transcriptional 
activity. The results are intriguing and difficult to interpret, but they definitely indicate 
trafficking of PGC-1α between the cell compartments. Experiments investigating the 
functional  state  of  PGC-1α  in  different  cellular  compartments  could  provide  crucial 
information on the acetylation and/or phosphorylation of the protein.  Recent evidence 
also  suggests  mitochondrial  localisation  of  PGC-1α 
546  and  upon  activation  target 
genes can be directly stimulated within the mitochondria, thereby reinforcing a possible 
direct  link  to  mitochondrial  biogenesis.  Interestingly,  metformin  induced 
phosphorylation  of  AMPK  in  skeletal  muscle  improved  mitochondrial  biogenesis  by 
stimulating  PGC-1α  transcription 
524,  or  by  direct  activation  of  PGC-1α  via 
phosphorylation 
90, suggesting a dual effector system following metformin treatment.  
4.1.6  Conclusion 
Chronic administration of metformin is cardioprotective against ischaemia-reperfusion 
injury  in  both  non-diabetic  and type  2  diabetic rat  hearts.  A  possible  dual  effect of 
metformin  is  seen  in  the  setting  of  type  2  diabetes  and  cardioprotection,  whereby 
glucose  is  lowered  alongside  the  initiation  of  prosurvival  signalling  pathways.  This 
results  in  an  enhanced  protection  against  ischaemia-reperfusion  injury.  The 
mechanism  of  protection  elicited  by  metformin  appears  to  be  dependent  on  the 
duration of the treatment. Previous studies have demonstrated that acute metformin 
treatment  activates  Akt and  AMPK  leading  to  the  acute  closure  of  the  mPTP.  The Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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protection associated with chronic metformin treatment appears to be independent of 
acute Akt and AMPK activation. The chronic activation of AMPK by metformin may 
promote  changes  at  the  transcriptional  level  in  the  cardiomyocyte,  resulting  in  an 
increased expression of PGC-1α and improved mitochondrial biogenesis in the diabetic 
heart (Figure 4.23).  
 
Figure 4.23: The effect of chronic metformin treatment in type 2 diabetic rats.:  
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4.2  Sitagliptin and cardioprotection 
4.2.1  Background 
Glucagon  like  peptide-1  (GLP-1)  is  an  incretin  hormone,  secreted  postprandially 
following an increase in blood glucose. It binds to G-protein coupled receptors in the 
pancreas and stimulates a G protein receptor pathway involving adenylyl cyclase and 
cAMP,  which  results  in  increased  insulin  secretion  from  the  pancreatic  β-cells  and 
decreased glucagon release from α-cells
295. Circulating GLP-1 is rapidly broken down 
into its inactive metabolite GLP-1(9-36) amide by DPP-4; therefore there is an interest 
in finding ways to prolong active GLP-1 in the blood stream. In this respect, two groups 
of drugs have emerged: GLP-1 receptor agonists, that mimic the action of GLP-1 but 
are  resistant  to  DPP-4  degradation  (exenatide,  liraglutide)  and  drugs  which  inhibit 
DPP-4 itself (gliptins such as sitagliptin, vildagliptin, saxagliptin) 
295. 
 Alongside  the  direct  benefit  of  GLP-1  and  its  breakdown  products  on 
myocardial metabolism
547,  548, emerging evidence suggests GLP-1, GLP-1(7-36) and 
GLP-1(9-36) all have the ability to protect against acute IRI
302, 304, 549.  
Based  on  this  evidence,  the  Yellon  lab  hypothesised  that  treatment  with  a 
DPP-4 inhibitor; Sitagliptin may also confer cardioprotection against IRI. Unpublished 
studies  demonstrated  that  2  weeks  oral  pre-treatment  with  Sitagliptin,  significantly 
reduced  myocardial  infarct  size  in  the  non-diabetic  isolated  perfused  rat  heart. 
Interestingly,  it  appeared  that  the  infarct-limiting  effects  of  2  weeks  Sitagliptin  pre-
treatment  were  glucose-sensitive.  In  this  respect,  cardioprotection  was  noted  when 
hearts were perfused with 11mmol/L glucose but not 5mmol/L glucose. In addition this 
protection was abolished in the presence of GLP-1 receptor antagonist exendin (Figure 
4.24).  Similarly,  cardioprotection  elicited  by  GLP-1  treatment  was  also  glucose-
sensitive with infarct reduction observed at glucose levels of 7, 9 and 11 mmol/L but 
not at 5 mmol/L (Figure 4.25). Importantly, in this model, the infarct size developed in 
the control hearts which were perfused with different concentrations of glucose in the 
buffer (5, 7, 9, 11 mmol/L) but without the drug was not affected (Figure 4.26).  




Figure 4.24: The influence of glucose levels on sitagliptin induced cardioprotection in the isolated heart.  
Pre-treatment for 2 weeks with Sitagliptin reduced the myocardial infarct to area at risk ratio (I/R %) in 
isolated rat hearts perfused with buffer containing 11 but not 5 mmol/L glucose. This infarct-limiting 
effect  was  abolished  in  hearts  Langendorff-perfused  with  Exendin  9-39  (Exendin),  a  GLP-1  receptor 
antagonist. One-way ANOVA followed by Bonferroni’s multiple comparison test was used to determine 
statistical significance (n≥6/group).  Data produced by Miss Abigail Wynne. 
 
 
Figure 4.25: The influence of glucose levels on GLP-1 induced cardioprotection in the isolated heart..:. 
The effect of different concentrations of glucose on GLP-1 induced reduction in infarct size. Non-diabetic 
Sprague-dawley rat hearts were isolated and perfused according to Langendorff isolated heart perfusion. 
Perfusion of isolated rat hearts with buffer containing GLP-1 reduced myocardial infarct to area at risk 
ratio (I/R %) in hearts perfused with buffer containing glucose at 7, 9, or 11 mmol/L but not at 5 mmol/L. 
One-way ANOVA followed by Bonferroni’s multiple comparison test was used to determine statistical 
significance (n≥6/group).  Data produced by Dr Shah Begum/Miss Abigail Wynne. 




Figure 4.26: The effect of different concentrations of glucose on infarct size.  Non-diabetic Sprague-
dawley rat hearts were isolated and perfused according to Langendorff isolated heart perfusion, There 
was  no  difference  in  myocardial  infarct  to  area  at  risk  ratio  (I/R  %)  in  hearts  perfused  with  buffer 
containing glucose at either 5, 7, 9, or 11 mmol/L. One-way ANOVA followed by Bonferroni’s multiple 
comparison test was used to determine statistical significance (n≥6/group).  Data produced by Dr Shah 
Begum/Miss Abigail Wynne. 
 
4.2.2  Hypothesis 
Using the aforementioned unpublished data from the Yellon lab, we hypothesised 2 
weeks pre-treatment with DPP-4 inhibitor Sitagliptin may reduce infarct size in vivo in a 
glucose dependent manner. To assess this hypothesis, diabetic and non-diabetic rat 
models  exhibiting  different  basal  blood  glucose  levels  were  treated  with  or  without 
sitagliptin for 2 weeks and infarct size examined in vivo. 
4.2.3  Experimental Protocols 
4.2.3.1  Animals 
Male  Goto-Kakizaki  (GK)  rats  (a  mild,  non-obese  diabetic  model 
427  obtained  from 
Taconic (Denmark), were kept in house until they reached 7-8 months of age; they 
received  humane  care  in  accordance  with  the  United  Kingdom  Animal  (Scientific 
Procedures)  Act  of  1986.  Male  Wistar  rats  (normoglycaemic)  were  obtained  from 
Charles River UK Limited (Margate, UK) and kept in house until they reached 3-4 or 
7-8 months of age. 
4.2.3.2  Treatments 
Rats were randomly assigned to receive 100mg/kg/day Sitagliptin (Sigma, UK) or water 
control orally by gavage for 2 weeks. Physiological parameters including body weight Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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and overnight fasting blood glucose (Accu-chek system, Roche) were collected prior to 
and at 10 days into treatment. 
4.2.3.3  In vivo rat model of ischaemia-reperfusion injury 
Left  anterior  descending  coronary  artery  (LAD)  occlusion  and  reperfusion  were 
performed  in  vivo  as  described  in  detail  in  the  chapter  2.2.2.  Briefly,  rats  were 
anesthetised  with  sodium  pentobarbital  (20mg/kg  intraperitoneally)  and  heparin 
(300IU). The rats were intubated and ventilated with a Harvard ventilator (room air, 70 
strokes/min, tidal volume: 8-9ml/kg). Body temperature was maintained at 37.4±1°C by 
means  of  a  rectal  probe  thermometer  attached  to  a  temperature  control  system 
(CMA450).  A  lateral  thoracotomy  was  performed  to  expose  the  heart and  a  suture 
placed around the LAD. The suture was tightened using a loop system to create LAD 
ligation  and  regional  ischaemia  which  was  confirmed  by  a  change  in  ECG  profile. 
Following 30 minutes of ischaemia, the vessel was reperfused for 120 minutes (as 
described in chapter 2.2.2). At the end of reperfusion, the heart was removed from the 
chest, the LAD permanently occluded and the heart perfused with 0.5% Evans blue in 
saline  to  delineate  the  area  at  risk.  Hearts  were frozen  at  -20°C for  several  hours 
before infarct size determination using TTC staining, as described in chapter 2.2.4). 
4.2.4  Results 
4.2.4.1  Sitagliptin pre-treatment reduced myocardial infarct size in vivo in 
a glucose-dependent manner 
Physiological parameters were recorded prior to and 10 days into control or sitagliptin 
treatment. In the young Wistar group, body weight increased after 10 days, however 
this is likely to be due to the general weight gain seen in Wistar rats over time. From 
the start, the middle-aged Wistars were significantly bigger than both other groups. 
Sitagliptin treatment was weight neutral in both middle-aged groups (Table 4.3). Blood 
glucose levels were in the normoglycaemic range in young (3-4 month) Wistar rats, 
however as Wistar rats aged to 7-8 months, their blood glucose levels significantly 
increased (mmol/L: 5.6±0.2 vs 7.5±0.3, p<0.001, Figure 4.27).  Middle aged diabetic 
GK rats demonstrated a significantly greater  blood glucose level than  either Wistar 
group  (9.3±1.5,  p<0.001  vs  both  groups,  Figure  4.27).  Interestingly,  sitagliptin  pre-
treatment did not reduce blood glucose levels in any of the groups, Figure 4.28.  




Control  Sitagliptin 
Baseline  10days  Baseline  10days 
Young Wistars  305.7±12.4  355.5±9.7*  309.5±14.4  370.9±8.7* 
Middle aged 
Wistars  557.6±9.3*  548.3±12.0  570.0±20.1*  562.4±19.7 
Middle aged GKs  409.8±5.0  400±3.7  393.5±10.4  384±12.1 
Table 4.3: The effect of sitagliptin treatment on body weight.  Summary of body weight before and 
10days into Sitagliptin or control treatment. Young (3-4 months) Wistars, middle-aged (7-8month) Wistars 
and  middle-aged  (7-8month)  GKs  were  weighed  before  and  10days  into  100mg/kg/day  sitagliptin  or 
control (water) treatment. Young Wistars had a significantly greater body weight 10days into treatment 
and middle-aged Wistars were significantly heavier than both other groups. One-way ANOVA followed by 
Bonferroni’s multiple comparison test was used to determine statistical significance.  
 
 
Figure 4.27: Basal blood glucose levels in non-diabetic and diabetic rats.  Blood Glucose levels. Fasting 
blood glucose was measured before treatment in all 3 groups; young (3-4 month) Wistars, middle-aged (7-
8month) Wistars and middle-aged (7-8month) GKs. Blood glucose was measured via collection of blood 
from the tail vein and assessed using the Accu-chek system, Roche. Data is shown as mean ± S.E.M, n≥6 
per group. One-way ANOVA followed by Bonferroni’s multiple comparison test was used to determine 




Figure  4.28:  Summary  of  blood  glucose  measured  before  and  after  administration  of  sitagliptin  or 
control.  Fasting blood glucose was measured initially and at 10days into treatment in young (3-4 month) 
Wistar rats, middle-aged (7-8 month) Wistar rats and middle-aged (7-8 months) Goto-Kakizaki (GK) rats.  
100mg/kg/day sitagliptin treatment for 2 weeks did not reduce blood glucose in any of the groups.  Data 
is represented as mean ﾱ S.E.M, n≥6.  Repeated measures ANOVA was used to determine any statistical 
significance. 
 
    In vivo LAD occlusion/reperfusion studies showed sitagliptin pre-treatment was 
successful in reducing myocardial infarct size in both middle aged Wistar and GK rats 
(15.4±2.4% with Sitagliptin vs. 44.8±4.0% with control in Wistars; and 29.10±5.3% with 
Sitagliptin  vs.  60.9±5.5%  with  control  in  GKs.  P<0.05:N≥6/group).  However,  in  the 
young Wistar group there was no difference in infarct size (34.5±5.9% with Sitagliptin 
vs. 33.8±3.1% with control). Moreover, young Wistars developed smaller infarcts in the 




Figure 4.29: The effect of Sitagliptin treatment on infarct size in the young Wistar, and middle-aged 
Wistar and GK rats.  Infarct size is expressed as the infarcted volume within the area at risk of the left 
ventricle  (%  I/R)  in  hearts  either  treated  with  sitagliptin  for  2  weeks  or  control  hearts.  Sitagliptin 
treatment significantly reduced the infarct size compared to the control group in both the middle-aged 
Wistar and GK rat but not the young Wistar group. Data is shown as mean ﾱ S.E.M, n≥6. ***p<0.001 
versus respective control. One way ANOVA followed by a Tukey Post-Hoc analysis were used for statistical 
analysis between groups. 
 
4.2.5  Summary and Discussion 
The key findings presented in this section of the chapter are: 
-  Chronic sitagliptin treatment reduced infarct size in vivo in both middle-aged 
diabetic GK rats and middle-aged non-diabetic Wistar rats. 
-  However, this treatment is not effective in reducing this injury in the young non-
diabetic Wistar rats. 
-  Interesingly, the blood glucose levels in the young Wistar groups were 
significantly lower than in the other two groups. 
-  This suggests a glucose-dependency of sitagliptin induced cardioprotection in 
vivo. 
4.2.5.1  The  cardioprotective  effect  of  Sitagliptin  is  dependent  on  blood 
glucose levels 
The cardioprotective effects of exogenous GLP-1, GLP-1 agonists and DPP-4 inhibitors 
have  been  well  documented 
549.    However,  no  investigations  are  yet  to  report  a 
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and in vivo models that the non-diabetic rat heart could be protected against IRI using 
exogenous GLP-1. In this study they included valine pyrrolidide (VP), a DPP-4 inhibitor 
that prevents the breakdown of exogenous GLP-1; however, the inhibitor alone did not 
reduce infarct size. Inhibition of cAMP, PI3K and p44/42 MAPK by specific inhibitors all 
abolished infarct-limiting effect of GLP-1
304.   Blood glucose levels were not assessed 
in  the  in  vivo  investigations,  however,  the  data  collected  using  the  standard 
Langendorff isolated heart model used 11mmol/L glucose in the perfusion buffer
304, 
therefore reflects the outcome of the preliminary data from the Yellon lab (Figure 4.25).  
Following  these  initial  studies  with  exogenous  GLP-1,  Ye  et  al,  2010 
demonstrated that DPP-4 inhibitors could also protect the heart against IRI
322. 3 days 
oral  pre-treatment  with  Sitagliptin  successfully  reduced  infarct  size  in  vivo  in  mice 
subjected  to  IR.  Sitagliptin  treatment  increased  myocardial  levels  of  cAMP  and 
subsequent  PKA  activity  and  inhibition  of  PKA  by  H-89  completely  abolished  this 
protection.  Further  studies  in  vitro,  suggested  a  similar  mode  of  action  to  that  of 
exogenous  GLP-1;  p44/42  MAPK  was  also  essential  for  the  protective  effect  of 
sitagliptin
322. In comparison to the previously mentioned study, the DPP-4 inhibitor was 
given orally for 3 day prior to IR as a pre-treatment, which could suggest short term 
administration of DPP-4 inhibitors, such as VP used in the previous study, is not a 
sufficient amount of time to stimulate cardioprotective pathways. 
In accordance with the study by Ye et al, 2010
322; our data demonstrated that 
chronic, 2 week sitagliptin treatment also protected the heart against IRI; moreover this 
protection was only seen in the middle-aged Wistar and middle-aged GK groups which 
exhibited  blood  glucose  levels  greater  than  7  mmol/L.  Interestingly,  in  the  study 
performed by Ye et al, the blood glucose levels were on average 7.5 mmol/L, which in 
fact corresponds to the levels of glucose in which cardioprotection was observed in our 
study.  This  apparent  glucose-dependency  was  also  observed  in  preliminary  data 
obtained with GLP-1, whereby GLP-1 mediated cardioprotection with infarct-limitation 
being observed at glucose levels of 7, 9, and 11 mmol/L but not at 5 mmol/L (Figure 
4.25).  
In  contrast,  Sauve  and  co-workers
324  could  not  demonstrate  any  significant 
infarct limitation with genetic DPP-4 knockout mice. However, it is worth noting that 
these  results  were  obtained  following  permanent  LAD  ligation  not 
ischaemia-reperfusion  injury.  Furthermore,  8  weeks  Sitagliptin  treatment 
(250mg/kg/day)  prior  to  permanent  LAD  ligation  failed  to  protect  STZ-diabetic  mice 




324.  Interestingly, the mice used in this latter study were fed a high-fat diet (HFD) 
which  caused  basal  blood  glucose  levels  to  be  10mmol/L;  following  induction  of 
diabetes using STZ, mice became severely hyperglycaemic with blood glucose levels 
of 20-30 mmol/L.  Sitagliptin treatment in HFD-STZ mice significantly reduced blood 
glucose levels but only to approximately 15mmol/L. In treated animals, HbA1c levels 
were  in  fact  dramatically  reduced  from  70-80mmol/mol  to  approximately 
30-35mmol/mol, which is in within the ‘non-diabetic’ threshold
550. Interpretation of these 
results is difficult, and may suggest an ideal window of blood glucose is needed for 
sitagliptin to produce its cardioprotective effect.   
4.2.5.2  Possible  mechanisms  for  glucose  dependency  of 
cardioprotection? 
The  mechanisms  that  contribute  to  the  postulated  glucose-dependency  of  the 
cardioprotective effect of sitagliptin were not investigated in this study. Previous studies 
suggesting that GLP-1/PKA activation occurs during sitagliptin induced protection
322, 
corroborated  with  studies  that  report  glucose-dependent  changes  in  intracellular 
calcium and GLP-1 receptor-PKA signalling suggest that this signalling pathway could 
be  distinctly  altered  in  response  to  high  blood  glucose  levels
551.    An  alternative 
possibility is that the GLP-1 receptor could be differentially regulated in response to 
differing  circulating  blood  glucose  levels.  Poornima  et  al,  2008  saw  a  significant 
activation  of  Akt  and  subsequent  cardioprotection  in  GLP-1  treated  Spontaneously 
Hypertensive Heart Failure (SHHF) rats. Interestingly, these rats had blood glucose 
levels  of  greater  than  12  mmol/L.  In  the  presence  of  high  glucose,  GLP-1  could 
possibly  activate  a  G-protein  coupled  receptor  signalling  pathway  involving  the  Akt 
component of the RISK pathway leading to cardioprotection, perhaps in conditions of 
low blood glucose this cardioprotective pathway is not activated. However this pathway 
is yet to be investigated in rats exhibiting low blood glucose levels 
548.  Interestingly, 
Chai  et  al,  recently  showed  that  the  administration  of  GLP-1  increased  Akt-
phosphorylation  and  PKA  activity;  leading  to  subsequent  phosphorylation  and 
activation  of  eNOS  in  bovine  aortic  endothelial  cells
552.  Interestingly,  the  eNOS/NO 
pathway is implicated in cardioprotection against IRI
134. In contrast, Ye and colleagues 
did not see a change in Akt-phosphorylation following sitagliptin treatment in mice 
322. 
The  link  between  GLP-1,  high  glucose  and  Akt  phosphorylation  is  yet  to  be  fully 
investigated. Pharmacological cardioprotection against ischaemia-reperfusion injury in ageing and diabetes 
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4.2.5.3  GLP-1 independent effects of sitagliptin on cardioprotection? 
The data discussed so far involving GLP-1 and DPP-4 inhibitor compounds postulate a 
strong involvement of elevated GLP-1 levels and PKA signalling in cardioprotection. 
However,  DPP-4  inhibition  can  lead  to  a  plethora  of  downstream  signalling  effects, 
including modulation of other gastrointestinal hormones, neuropeptides, cytokines, and 
chemokines
553.  Therefore  it  was  not  completely  surprising  when  Ku  et  al,  2011 
demonstrated  that  DPP-4  deficiency  protected  the  heart  against  IRI.  However, 
administration of exendin(9-39), GLP-1 receptor antagonist did not fully abolish this 
protective  effect,  suggesting  a  possible  GLP-1  independent  mechanism  of 
protection
554.  Zaruba  et  al,  2009  demonstrated  that  pharmacological  and  genetic 
inhibition  of  DPP-4  induced  cardioprotective  effects  including  reduced  cardiac 
remodelling  and  improved  function  and  survival  in  mice.  This  protective  effect  was 
attributed  to  stabilisation  of  active  SDF-1α  in  heart  lysates  and  preservation  of  the 
cardiac SDF-1-CXCR4 homing axis, a chemokine which is another known substrate of 
DPP-4
555. In support of this, an active SDF-1α-CXCR4 axis was proven essential for 
protecting the myocardium from apoptotic cell death following myocardial infarction
556.  
4.3  Conclusion 
The  signalling  mechanisms  by  which  chronic  DPP-4  inhibition  can  result  in 
cardioprotection against ischaemia-reperfusion injury are still unclear. The suggestion 
that  DPP-4  inhibition  can  produce  beneficial  effects  independent  of  GLP-1  activity 
raises the question whether cardioprotection is also independent of the modulation of 
this  incretin  hormone.  The  observation  that  blood  glucose  levels  influence  the 
cardioprotective potential of the DPP-4 inhibitors and GLP-1 therapies is an intriguing 
prospect. Further studies are required to delineate the importance of blood glucose 
levels  on  the  cardioprotective  effect  of  anti-diabetic  agents,  particularly  DPP-4 
inhibitors.   
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5.1  General conclusions 
Specific conclusions have been presented in detail at the end of each results chapter 
and only an overview of the most significant findings will be presented here.  
In essence, one of the main novelties of the studies presented in this thesis 
consists in the investigation of cardioprotective strategies in more appropriate animal 
models.  The  majority  of  laboratory  studies  have  used  young,  healthy  animals  to 
investigate the detrimental effects of myocardial ischaemia-reperfusion injury and the 
signalling pathways involved to elicit protection against this lethal insult
7, 410. However, 
in clinical settings the patients that develop cardiovascular disease are usually at least 
middle  aged,  and  also  manifest  a  number  of  co-morbidities  such  as  hypertension, 
hyperlipidaemia and diabetes
557, 558.  
The overall aim of this thesis has been to assess the influence of two interacting 
co-morbidities,  old  age and  type  2  diabetes  on:  (1)  the  susceptibility  to  myocardial 
ischaemia-reperfusion  injury,  (2)  the  ability  of  ischaemic  preconditioning  to  protect 
against  myocardial  ischaemia-reperfusion  injury  and  (3)  the  effificacy  of  potential 
cardioprotective anti-diabetic agents when administered chronically in the presence of 
these aggravating factors.  In addition, investigations have been made in the attempt to 
elucidate the mechanisms responsible for the observed changes in the cardioprotective 
potential of the aged, diabetic heart. 
Our data showed that: 
(1) During  ageing,  the  diabetic  heart  develops  an  increased  susceptibility  to 
ischaemia at an earlier age than the non-diabetic heart. 
(2) The extent of the injury induced by ischaemia-reperfusion increases with age in 
all hearts but this detrimental age related phenomenon seems to appear earlier 
in the diabetic heart. 
(3) The  aged,  diabetic  heart  is  less  amenable  to  cardioprotective  manoeuvres 
(such as ischaemic preconditioning). 
(4) There is an increased baseline activation of the prosurvival kinase Akt in the 
ageing, diabetic heart.  Moreover, acute activation of Akt following IPC is not 
achievable, which may explain why this manoeuvre is not cardiorprotective in 
the aged, diabetic heart. 
(5) We noticed that the expression of PGC-1α and catalase change with age and 
diabetes.  It  is  possible  that  these  alterations  may  be  a  consequence  of  the 
chronic  activation  of  Akt.  These  modifications  may  explain  the  increase  in Overall discussions 
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oxidative stress and the change in mitochondrial structure, which we report here 
as well. These changes may be responsible for the increased susceptibility to 
IRI.  
(6) Chronic metformin treatment is cardioprotective against ischaemia-reperfusion 
injury in both the diabetic and non-diabetic ageing heart. However, the 
protection was more pronounced in the diabetic animals in which metformin had 
also a significant glucose lowering effect. 
(7) Chronic metformin treatment is associated with mitochondrial improvements, an 
increased level of phosphorylated AMPK and an enhanced expression of 
PGC-1α and Mfn-2. 
(8) Preliminary data seem to indicate that sitagliptin treatment was cardioprotective 
against myocardial infarction in a glucose dependent manner. 
We  conclude  that  ageing  in  combination  with  type  2  diabetes  renders  the 
diabetic heart more susceptible to ischaemia-reperfusion injury and less amenable to 
protection by IPC at an earlier age than in the ageing, non-diabetic heart. Therefore, 
we suggest that the diabetic heart may age quicker than the non-diabetic heart and this 
consequently could translate into an increased vulnerability to cardiovascular events at 
a younger age in type 2 diabetic patients.  
The paradox of Akt upregulation at baseline but reduced cardioprotection in the 
aged, diabetic heart is intriguing and potentially extremely important when considering 
the translational application of conditioning strategies that target the reperfusion injury 
salvage  kinase  (RISK)  pathway  to  elicit  protection  against  IRI.  Furthermore,  the 
changes in the prosurvival signalling in the aged, diabetic heart may also have an 
effect  on  pharmacological  protection.  Chronic  treatment  with  the  oral  anti-diabetic 
metformin  elicits  cardioprotection  via  a  mechanism  distinct  from  those  previously 
defined following the acute application of this agent. Lastly, a different oral anti-diabetic 
agent sitagliptin protects the heart against infarction in a glucose-dependent manner. 
However, we did not investigate the influence of old age on the cardioprotective effect 
of this drug.  
5.2  Limitations 
The studies performed in this thesis had some limitations that should be considered 
and discussed when interpreting the findings and when planning future investigations. 
  In spite of the fact that the Langendorff perfused heart preparation is universally 
used  and  accepted  as  a  means  to  investigate  heart  physiology  and  pathology, Overall discussions 
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including the susceptibility to ischaemia-reperfusion injury, however it has a number of 
limitations. Firstly, it is an ex vivo preparation in which the heart is perfused with a 
crystalloid buffer and is independent of the neural and endocrine regulatory influences. 
In  addition,  the  crystalloid  buffer  we  used  contains  only  glucose  as  a  metabolic 
substrate whereas metabolism in the adult and diabetic heart is very complex.  The 
adult, non-diabetic heart relies predominantly on fatty acids as an energy substrate for 
ATP production but can also utilize glucose especially in times of oxygen deprivation 
such  as  ischaemia. Whereas,  as  diabetes  progresses,  the  heart  has  an  increased 
reliance  on  fatty  acids.  Due  to  technical  limitations  regarding  the  Langendorff 
apparatus, fatty acids were not included in the perfusate. Furthermore, both type 2 
diabetes  and  old  age  cause  global  molecular  and  cellular  changes  throughout  the 
entire body including the vasculature not just within the heart. Therefore, an in vivo 
model  of  ischaemia-reperfusion  injury  was  used  to  assess  the  susceptibility  to 
infarction. This model would have provided additional physiological information of the 
how the aged and diabetic heart responds to myocardial infarction. 
We find an increased basal activation of Akt in the aged, diabetic heart and 
downstream changes in protective signalling pathways. However, we do not show any 
direct  linking  evidence  between  elevated  Akt-phosphorylation  and  these  effects. 
Therefore,  how  chronic  Akt  phosphorylation  directly  impacts  on  PGC-1α  and 
subsequently how PGC-1α influences catalase levels in the myocardium need to be 
further explored. This could be investigated using isolated ventricular cardiomyocytes 
from young and old diabetic and non-diabetic rat hearts and suitable inhibitors.  More 
importantly,  time  limitations  did  not  allow  for  further  investigations  to  examine  the 
possible  upstream  causes  of  chronic  Akt-phosphorylation  in  age  and  diabetes. We 
would have liked to have started this with the exploration of insulin receptor signalling 
in the aged, diabetic myocardium. 
Metformin  was  administered  in  vivo  for  4  weeks  before  infarct  size 
measurement using the Langendorff isolated heart preparation. Firstly, metformin has 
an  effect  on  energy  metabolism  through  modulating  AMPK  activity,  therefore  by 
removing  the  heart from  the  whole  body  these  effects  may  be  masked  due  to  the 
reasons described above regarding the use of glucose as the only metabolic substrate 
in this model. However, by using the isolated heart, our data revealed a direct effect of 
metformin on the cardiac tissue, excluding the influence of the whole body system. 
Depending on the aim and desired end point of this investigation, this approach may be 
either  crucial  for  providing  information  regarding  the  myocardial  cell  but  criticisable 
when assessing whole body physiology.   Overall discussions 
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Our  molecular  investigations  used  whole  heart  tissue  and  also  isolated 
cardiomyocytes.  The  use  of  AMPK  inhibitor  Compound  C  appeared  to  produce 
non-specific effects on PGC-1α expression. Therefore, for definite clarification of the 
relationship  between  AMPK  and  PGC-1α  expression  and  activity  in  the  heart,  the 
studies should use cell systems in which genetic silencing or genetic ablation of AMPK 
had been previously induced. 
Unfortunately, time constraints and animal limitations did not allow us to assess 
the effect of chronic metformin treatment on myocardial ischaemia-reperfusion injury in 
young diabetic and non-diabetic animals.  
Chronic  administration  of  sitagliptin  prior  to  in  vivo  coronary  artery  ligation 
provided  a  more  translational  model  to  investigate  cardioprotection  in  diabetes. 
However, this study is in the early stages and did not examine the possible signalling 
mechanisms  behind  the  apparent  glucose-dependency  of  cardioprotection  with  this 
agent.    However,  glucose-clamping  experiments  would  determine  the  absolute 
requirement of hyperglycaemia for the protective effects of sitagliptin.  
Another approach which can circumvent the rapid metabolism of drugs by the 
rodent liver, and therefore reducing the absolute effect of the treatment, could be the 
use  of  implanted  osmotic  pumps  when  investigating  chronic  treatments  with 
pharmacological agents.  
5.3  Future directions 
In addition to the possible additional work discussed in the limitations section, which 
will confirm and improve the data already reported, there are some possible crucial 
further directions which emerged from these studies.  It would be important to examine 
whether  the  findings  are  reproducible  in  an  in  vivo  left  coronary  artery 
occlusion-reperfusion model. To additionally explore the detrimental effects of chronic 
Akt phosphorylation in respect to IRI, mitochondrial permeability transition pore (mPTP) 
opening  in  aged,  diabetic  cardiomyocytes  needs  to  be  investigated.  Furthermore, 
immunoprecipitation  experiments  could  investigate  whether  the  PGC-1α  protein  is 
modified  at  the  post-translational  level  in  the  aged,  diabetic  heart  and  the  use  of 
pharmacological agents or genetic manipulations could determine the importance of 
Akt-phosphorylation in these processes.  
  Of upmost interest is the investigation of the upstream cause of chronic Akt 
phosphorylation  in  the  aged,  diabetic  myocardium  and  whether  reducing  this Overall discussions 
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phosphorylation  by  pharmacological  inhibition  would  reduce  the  susceptibility  to 
infarction  and  also  restore  the  ability  to  condition  the  heart  with  ischaemic 
preconditioning. More importantly, human heart tissue from cardiac surgery should be 
assessed to verify if chronic Akt phosphorylation is also present in the human aged, 
diabetic myocardium 
  To assess whether the chronic protective effects of metformin treatment exist in 
the young diabetic and non-diabetic rats would also enhance this area of research. 
Furthermore,  to  evaluate  whether  the  basal  changes  in  PGC-1α  expression  are 
associated  to  age  and/or  diabetes  as  early  stages  of  diabetes  are  associated  with 
increased PGC-1α expression.  To further elucidate the importance of PGC-1α in the 
cardioprotective  benefits  of  metformin  treatment,  it  would  be  interesting  to  treat 
PGC-1α  deficient  mice  with  metformin  and  determine  their  susceptibility  to 
ischaemia-reperfusion injury.  
  The  findings  of  the  chronic  sitagliptin  study  are  preliminary  but  suggest  a 
potentially translational important finding. An interesting study would be to treat long 
term  with  this  agent  to  normalise  blood  glucose  levels  and  to  then  determine  the 
susceptibility to IRI. Alternatively, using glucose clamps alongside the addition of DPP-
4 inhibitors and other known targets of DPP-4 degradation will help to tease out the 
mechanisms behind the apparent glucose dependency of this agent.  
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